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SUMMARY
The aim of this study was to conduct a detailed examination of 
hormone concentrations in the plasma of subjects with breast 
disease. In particular, women with breast cancer were investigated, 
and men with gynaecomastia.
Plasma oestradiol-17B, testosterone, luteinizing hormone, follicular 
stimulating hormone and prolactin levels were studied in women with 
breast cancer. All plasma hormone concentrations were within the 
normal range although plasma testosterone levels were higher in 
women with breast cancer than in normal women matched for age, 
parity and menstrual status.
Pituitary releasing hormones were used to induce a rise in the 
levels of plasma LH, FSH, growth hormone (GH), thyroid stimulating 
hormone (TSH) and prolactin concentrations in patients with breast 
cancer and the various pituitary function tests were compared. It 
was shown that luteinizing hormone releasing hormone (LHRH) induced 
a rise in the levels of plasma LH and FSH and thyrotrophic releasing 
hormone (TRH), a rise in plasma TSH and prolactin. The addition of 
TRH to LHRH did not affect the levels of plasma LH and FSH above 
that produced by LHRH alone. TRH led to a higher elevation of 
plasma prolactin levels than chiorpromazine. A test consisting of 
the administration of LHRH, TRH and insulin by infusion was found to 
be the most suitable for studying pituitary function in women with 
breast cancer undergoing yttrium implantation of the pituitary.
This test was then used to assess the pituitary function after 
yttrium implant. Response of each hormone to its own releasing 
hormone was used to assess the degree of pituitary ablation obtained 
which, in turn, was correlated with clinical response. The results 
showed that the more complete the ablation, the more likely there 
was to be a clinical response. This test of pituitary function was 
also used to assess the effect of quadruple chemotherapy on 
pituitary function. The results showed that in women with advanced 
breast cancer chemotherapy did not have a demonstrable effect on 
pituitary function.
The effect of administration of the hormonal drugs - an 
antioestrogen (tamoxifen) and a synthetic oestrogen (stilboestrol) 
on plasma FSH, oestradiol-17B, testosterone and prolactin levels 
were examined. Both drugs depressed plasma FSH levels, stilboestrol 
having a greater effect than tamoxifen. Stilboestrol also induced 
elevation of plasma prolactin concentrations. The effect of these 
drugs on the concentrations of plasma hormones was, however, not 
related to the clinical response of the disease.
These studies showed a pulsatile pattern of concentrations of plasma 
luteinizing hormone (LH) in normal young men, which was absent in 
both young and old men with gynaecomastia and in normal old men. In 
comparison to normal young men, young men with gynaecomastia had a 
lower plasma LH level and consequently a lowered ratio of LH to 
follicle stimulating hormone (FSH) LH/FSH ratio, while in comparison 
with normal old men older men with gynaecomastia had a normal LH/FSH
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ratio, but raised values of LH and FSH. This group of older men 
with gynaecomastia also had higher plasma oestradiol-17B (E2) levels 
and a raised oestradiol-17B testosterone ratio, when compared with 
normal men of a similar age.
From these results, it would seem that the causes of breast disease 
are multifactorial which will be solved only after many related 
aspects have been considered and discussed and further research 
carried out. This thesis seeks no more than to make a contribution 
to this discussion; nevertheless it is felt that certain aspects of 
breast disease have been clarified and that sampling methods have 
been identified to give a more accurate and realistic indication of 
plasma hormone levels.
Nothing discovered in the course of this work or in the study of the 
literature, discounts a hormonal contribution to the cause of breast 
cancer. It is believed that in the further refinement and 
investigation of the full role of these plasma hormones in male and 
female breast disease, will the cause of breast cancer be eventually 
clarified.
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I INTRODUCTION
Any individual woman stands a 1:14 chance of developing breast 
cancer during her life. It ranks as the commonest cause of death in 
women in the 35-40 age group and every year 12,000 women die of
breast cancer in the United Kingdom. Any part of the breast may be
affected by cancer but it most frequently commences in the upper 
outer quadrant of the breast. Spread of the disease can be local, 
lymphatic or blood borne.
Conventionally, cancer of the breast is graded according to 
severity. The method used to stage breast cancer is the Union 
Internationale Contre le Cancer (UICC) T.N.M. system in which 
tumour, nodes and metastases are each classified. From these 
"stages" of severity are constructed: stage I - growth confined to 
breast; stage II - breast plus affected mobile lymph nodes in 
axilla; stage III - tumours more than 5 cms in size, or tumours of
any size with direct extension to chest wall or skin, or any tumour
associated with fixed axillary lymph nodes, or supra or infra 
clavicular lymph nodes thought to be invaded; stage IV - as above 
plus distant metastases. An example of an advanced case (stage IV) 
of breast cancer with skull secondaries is seen in Figures 1 and 2.
Histologically, the commonest type of breast cancer is an invasive 
duct carcinoma. Various histological types are described of which a 
non-descript pattern is the most common (90$); histological 
appearance of the type is seen in Figure 3.
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Fig. 1
Photograph of a patient with advanced cancer of the breast.
Fig. 2
Photograph of an X-ray of skull secondaries in the patient 
in Fig. 1.
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Fig. 3
Photomicrograph showing an invasive ductal carcinoma of breast. 
(H § E Magnification x 150)
The results of treatment of breast cancer are poor and after 5 years 
(from all types of treatment) only 68$ with stage I are alive, *10$ 
of stage II and 15$ of stage III and 2$ of stage IV are still alive.
It is a disease which disseminates early but recurs late. Recent 
evidence suggests that even 30 years after the initial treatment of 
early cancer, women still have an excess mortality from metastatic 
disease. "Statistical" cure has not been demonstrated. However, 
some 26$ of women have personal cure* in that they die from some 
other cause before their metastatic disease becomes evident 
(Brinkley & Haybittle, 198*0. If the disease is to be cured, there 
must be an understanding of the basic mechanism causing the cancer.
NORMAL BREAST DEVELOPMENT
The breast is a hormone target organ.
Studies in endocrine ablated rats indicate that oestrogen and 
progesterone are required for ductal development, the added effect 
of prolactin for alveolar formation and for full breast development 
(comparable to that found in late pregnancy), four hormones are 
necessary:oestrogen, progesterone, prolactin and growth hormone 
(Lyons et al 1955, Cowie & Folley, 1958). Evidence that these same 
hormones are necessary for the development of the human breast is 
less direct. However, the coincidence of breast development with 
the start of ovarian function during puberty, the effect of 
oestrogenic hormones on male breast development (Fitzsimmons, 1 9 W ,
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the great hypertrophy of the breast during pregnancy and the atrophy 
of the female breast which occurs after the menopause or in 
hypopituitary states (Sheehan & Sommers, 1949) suggest that similar 
mechanisms may apply in the human breast.
Breast Cancer
There is considerable experimental evidence that the hormones which 
are so intimately concerned with the normal growth and function of 
the female breast may also affect the development and progression of 
mammary carcinoma. The most striking evidence that hormones are 
involved in the occurrence of breast cancer in humans was 
demonstrated by a Glasgow surgeon, George Beatson. In 1896, he 
demonstrated a case of a 33 year old woman who had local recurrence 
of tumour in her mastectomy scar which healed when the ovaries had 
been removed. With the discovery of cortisone, Charles Huggins in 
Chicago, in 1952, reported that a similar effect in postmenopausal 
women could be achieved by adrenalectomy. Evidence that the effect 
of castration on human breast cancer was due to deprivation of 
oestrogens was first reported by Pearson and his colleagues. They 
measured urinary calcium in women with metastatic bone disease 
during several menstrual cycles, following oophorectomy and after 
administration of oestradiol and demonstrated a cyclical pattern of 
urinary calcium during the menstrual cycle which was abolished by 
oophorectomy (Pearson et al, 1954). The dramatic fall in the level 
of urinary calcium following oophorectomy was believed to be due to 
reversal of bone breakdown as a result of removal of oestrogen
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stimulation, a belief strengthened by reversal of this effect by the 
administration of ethinyl oestradiol. Further evidence for the 
involvement of oestrogen in the growth of human breast cancer was 
provided by the demonstration by Jensen and his colleagues (1971) 
that the cytosol of 70% of breast cancers contained the same high 
affinity binding protein for oestrogens as did other oestrogen 
sensitive tissue. Initially believed to reside in the cytoplasm, it 
is now suggested that oestrogen binding protein normally is situated 
in the nucleus. The complex formed by oestrogen and its receptor 
acts on the genome to stimulate cell growth and division and other 
events. Breast cancers which do not possess this oestrogen 
mechanism are insensitive to the action of the hormone.
A model for the study of hormonal effects on breast cancer is 
provided by the MCF-7 cell line which was originally cultured from 
ascitic breast cells. This is sensitive to oestrogenic stimulation 
and in the absence of the hormone, or following the addition of an 
anti-oestrogen (tamoxifen) to the culture medium, growth is 
suppressed. Similar effects have also been demonstrated in 
transplants of human breast cancer into immune deprived (nude) mice 
(Shafie, 1980, Seibert et al, 1983)*
Similar evidence to implicate other hormones, eg progesterone, 
testosterone, growth hormone and prolactin in the growth of human 
breast cancer is less convincing.
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Source of Oestrogens
In women the two major oestrogens secreted from the ovary are 
oestrone and oestradiol 17B. In premenopausal women the majority of 
the oestrogens are secreted, ie from the ovaries, the cyclical 
secretion from them produces high circulating levels of oestrone and 
oestradiol 17B at various periods during the menstrual cycle. After 
the menopause the circulating levels of oestrogens are much 
diminished and are only present in small amounts. Most of the 
oestrone and oestradiol 17B is not derived from ovary or adrenal but 
indirectly by their synthesis at peripheral sites (liver, muscle and 
fat) from aromatization of the androgen C19 steroids 
androstenedione and dehydroepiandrosterone (Nimrod & Ryan, 1975).
There is also evidence that tumours possess several enzymes and can 
convert C19 steroids into active oestrogens (Miller et al, 1982). 
Studies show that there are a lot of C19 steroids available in the 
breast which contains high concentrations of dehydroepiandrosterone 
sulphate and other androgen conjugates and can produce oestrogenic 
hormones.
Risk of Breast Cancer
If the causes of breast cancer were fully understood then the risk 
factors could be identified and preventative treatment of the women 
at risk carried out. Hormones may also influence the risk of the 
development of breast cancer.
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Dominant risk factors can be considered in two groups. (1) 
geographical variations of the incidence of the disease and (2) risk 
factors which occur within a given population. There are striking 
differences in the incidence of breast cancer and its natural 
history in different geographical areas. Most marked is the 
difference in the incidence of breast cancer in Europe and the USA 
and Japan, in which the incidence is eight times lower (Wynder et 
al, 1963). There is now evidence that this incidence is rising, an 
effect also seen in Japanese who migrate to the West, which suggests 
the importance of environmental factors (Stocks, 1957* MacMahon, 
1970). It is suggested that hormonal effects may explain these 
differences, possibly by the effect of diet on the synthesis of 
metabolism of oestrogens. Interest has, therefore, been expressed 
in studies of the hormonal background of such women.
Estimations of urinary steroids were reported in populations of 
normal women known to have a high or low risk of breast cancer. 
Young Japanese women (low risk group) excreted a lower level of 
urinary 11-deoxy-17-oxo-steroids than young British women (high risk 
group) while in the older age group the reverse was true (Bulbrook 
et al, 1964; 1967).
In a study of the normal women from Guernsey, Wang and his 
colleagues (1976) measured plasma dehydroepiandrosterone sulphate, 
androsterone sulphate and A 4 androstenedione levels in these normal 
British (high risk group) and Japanese women (low risk group) and 
found that plasma dehydroepiandrosterone sulphate and A 4
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androstenedione concentration was lower in the Japanese than the 
British women. Plasma androsterone sulphate levels were lower in 
all groups of Japanese women but not significantly so. These 
results were contrary to expectation.
A study of the plasma oestrogen concentration was also carried out 
in normal British and Japanese postmenopausal women (Bulbrook et al, 
1976). These workers found that the concentrations of plasma 
oestrogens in these two races were not significantly different 
except in an adolescent group. They concluded that the difference 
in the incidence rates in breast cancer in Britain and Japan did not 
appear to be related to difference in plasma oestradiol-17B or 
oestrone levels.
Within the population of women, whether at low risk or high risk of 
developing breast cancer, women who have their first child at a 
younger age are less susceptible to the risk of developing breast 
cancer than those whose first full time pregnancy occurs later 
(MacMahon, 1970). Thus, women who have borne their first child 
before the age of 25 have about half the risk of developing breast 
cancer compared to women who have their first child over the age of 
30. Nulliparous women also are more at risk but less so than women 
who have their first pregnancy after the age of 35 (MacMahon, 1970, 
1973)* It has been suggested that the number of menstrual cycles 
which occur before the first full time pregnancy is the important 
determinant of risk so that pregnancy with full stimulation of 
breast development early in reproductive life is protective. In
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other words, it is confinements during the first ten years of 
reproductive life which protect against the late development of 
breast cancer (Smithers et al, 1952).
Attempts to define whether the hormone environment predisposes to 
the development of breast cancer has been studied on the Island of 
Guernsey (Bulbrook and Hayward, 1967;Bulbrook et al, 1969; Bulbrook 
et al, 19T1 )• Twenty four hour samples of urine were collected from 
five thousand women over five and a half years and stored. As 
patients with breast cancer emerged in the population their urine 
was matched by those of ten to twelve controls and all were then 
fully analysed. In the first report of women studied, twenty-seven 
women had developed breast cancer and the mean excretion of 
aetiocholanolone and androsterone in these women were then compared 
with that in one hundred and eighty-seven matched controls and in 
one thousand five hundred and six women in the population who had 
not developed breast cancer. A group of these Guernsey women in the 
high risk category - (old at menarche, old at first child, family 
history of breast cancer and a low urinary aetiocholanolone level) 
were later studied further (Wang et al, 1979). Plasma samples were 
taken five years after the urine samples from three hundred and 
eighty-six of these normal high risk women (aged 30-69).
The levels of plasma androgens were found to correlate with the 
excretion of urinary aetiocholanolone and the levels were at the 
lower end of the normal range in this group, indicating that the low 
level of urinary aetiocholanolone five years before was not an
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indicator of transient androgen production.
Other risk factors within a population include a family history of 
breast cancer. A woman with a first degree relative who has 
developed carcinoma of the breast is herself at greater risk than a 
woman with no family history of breast cancer (Anderson, 1971) and 
such families provide suitable groups for hormone studies (Wang et 
al, 1979). It is also relevant that the administration of 
oestrogens given for hormone replacement is associated with an 
increased risk of breast cancer (Hoover et al, 1976). Furthermore, 
women who are deprived of ovarian function early in life have a 
lower incidence of breast cancer (Herrel, 1937» Smithers et al, 
1952).
In view of these facts it is not surprising that much work has 
concentrated on the hormonal background of patients with established 
breast disease, the effect of endocrine therapy on hormone levels 
and hormonal changes which may increase risk. Such studies 
initially depended on urinary estimates but with the availability of 
new immune assay methods of greater sensitivity, plasma estimations 
became available. These have now been applied and in this thesis 
three studies, using immunoassay methods of estimating hormones in 
circulating body fluids are described.
These are:
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1) Detailed studies of plasma hormone levels in women with 
established breast cancer, sampled consecutively and compared with 
carefully matched controls.
2) Studies of the effect of anti-oestrogen therapy, hypophysectomy 
and chemotherapy on hormonal levels in patients with advanced breast 
cancer.
3) Comparison of plasma hormone levels in men with gynaecomastia and 
normal hormonal subjects.
Each study is described following a review of the relevant 
literature, but this has been confined to the time at which the 
study was performed. Published reports which have appeared in later 
years have been included in the discussion section which concludes 
each study.
The methods of hormone assay which have been used in the separate 
sections are all similar. These are described in a general methods 
section which precedes the description of the three individual 
studies.
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II
GENERAL METHODS
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GENERAL METHODS OF STUDIES OF PATIENTS
1. Plasma Collections
The protocol for plasma collections was similar in all subjects with 
minor variations according to the study. Three types of plasma 
sampling were adopted.
a. Single blood samples at a fixed time each day.
b. Multiple blood samples at various intervals during the day.
c. Frequent multiple sampling in pituitary function tests.
a. Single Plasma Sampling
A single sample of blood was removed from an arm vein using an 18G 
needle. The blood was then heparinised and centrifuged at 2,500 
rpm for 10 minutes at -4°C. Plasma was pipetted off, subsequently 
frozen and stored at -20°C. If follow up samples from an 
individual were required, ^ these samples were taken at the same time 
of day as the first sample and all the plasmas from a single patient 
were then measured in one batch in the same assay.
b. Multiple Plasma Sampling
In certain studies blood was withdrawn at frequent intervals 
throughout the day. The patients investigated were allowed to walk 
around freely and to eat meals. An 18G teflon cannula with 
stilette was inserted into an arm vein through which blood was 
withdrawn. Plasma was prepared and stored as described 
previously. Fig. *1 shows a patient undergoing this procedure.
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Photograph of a patient with breast cancer undergoing a multiple 
plasma hormone study - note the cannula in situ in the right wrist.
c. Details of the sampling methods used in pituitary function 
studies are described in Study 3.
2. Hormone Assay Methods
For technical reasons it has been necessary to have some assays of 
the same hormone carried out in two different laboratories. The 
laboratories involved were the Tenovus Institute, Cardiff and the 
Immunoassay Section, Department of Clinical Chemistry, Royal 
Infirmary, Edinburgh.
Because of the differences in technique between the assays in the 
two laboratories, it should not be assumed that the numerical 
results obtained are strictly comparable or have the same normal 
range. Within any one study, however, control and other group 
values will have been obtained from the same laboratory by the same 
method and are therefore comparable.
As the determinations of plasma hormone levels constitute the major 
measurements within this project, it is pertinent to examine the 
reliability of these measurements. This can be assessed under four 
main headings (Borth, 1952). For an assay to be considered 
reliable each of these criteria should be fulfilled.
a. Reproducibility
b. Specificity
c. Accuracy
d. Sensitivity
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a) Reproducibility
Reproducibility is the precision of an analytical measurement. It 
is usually assessed as the coefficient of variation of the analysis.
Coeff. of variation = SD/x X 100$ 
where SD is the standard deviation.
X is the mean measurement.
The standard deviation may be assessed either from the variance of 
many measurements about the mean from one sample or from the 
difference between duplicate estimations on many samples. In 
routine clinical chemistry, for example, the coefficient of 
variation normally runs between approximately 1-7$.
b) Specificity
The specificity of a method reflects the extent to which only the 
compound to be analysed contributes to the signal generated by the 
detector used. Specificity may be examined by various methods 
including
1) Analysis of fluids likely to be free from the hormone to be 
measured eg. water or plasma from a subject who has had surgical 
ablation of endocrine (hormone secreting) organs.
2) Comparison of the apparent concentrations of a hormone in 
plasma before and after the addition of such compounds as might 
interfere with the assay.
3) Comparison of the apparent hormone concentrations found on 
analysis of different sizes of plasma samples.
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4) Examination of the apparent hormone concentration of plasma 
found after purification of the sample to varying degrees.
c) Accuracy
Accuracy is an assessment of the proximity of the measurement to the 
true value (e.g. as measured by an ideal method). The accuracy of 
an analytical method can be determined by measuring the percentage 
recovery of known amounts of a pure compound added to the sample 
before analysis (theoretically, after correction for any losses, 
accuracy should be 100$).
d) Sensitivity
The sensitivity of a method for the determination of a substance may 
be defined as the smallest mass of that substance which can be 
distinguished with a given degree of certainty from zero. 
Sensitivity is, therefore, particularly important when dealing with 
measurements at low levels. It is frequently calculated from the 
formula ts.<[rT" where t=student*s t value for p<0.01, s = standard 
deviation at low levels, n = no. of measurements. Under certain 
circumstances, sensitivity can be shown to be numerically equal to 
approximately twice the standard deviation of the method blank. 
Sensitivity may also be influenced by other factors in addition to 
the precision of the blank such as the size of the sample analysed, 
the manipulative loss incurred prior to detection and the fraction 
of the sample submitted for detection.
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In the sections which follow, the assays were carried out by two 
different laboratories each of which have examined the reliability 
criteria for their own assay(s); where possible, these data have 
been included.
i. Plasma Gonadotrophins - LH and FSH 
Females (Tenovus Institute, Cardiff)
The assay methods for LH and FSH were those described by Groom et al 
(1977). The anti-sera for LH (F87) and FSH (M-93) were gifts from 
Professor W. R. Butt, Birmingham Hospital for Women, the purified LH 
for labelling (IRC-2) was from Dr. A Stockell Hartree, University of 
Cambridge and the purified FSH for labelling (CPDS-13) from 
Professor Butt. The non-radioactive LH standard was 63/15 while 
the FSH standard was 2nd IRP HMG. All incubations were carried out 
at 4°C.
Briefly, hormone standards and samples were pipetted in 100 ul 
solution with 200 ul water and 200 ul of first antibody solution 
(diluted 1:2*10,000 for LH and 1:500,000 for FSH) on Day 1. The 
tubes were mixed and left overnight at 4°C. The following day, the 
125i labelled hormone (approx 1ng/ml) was added in 100 ul solution 
and the tubes were re-incubated overnight. On the third day, the 
second antibody was added in 200 ul solution and then left to 
precipitate the double antibody complex overnight at 4°C. On Day 
4, the precipitate was collected by centrifugation, the tubes were 
decanted and drained and the precipitate was counted in a gamma 
counter. The specificity of these assays has been examined by
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assay of standard pituitary preparations supplied by the Medical 
Research Council: reasonable agreement was found between the
nominal and determined values for LH and FSH (Groom et al, 1971)» 
and discrepancies could be accounted for by known contamination of 
the standard used. The within assay CV for each gonadotrophin 
assay was less that 10$ at the levels under study and all samples 
assayed in any one study were analysed within a single assay. The 
lowest detectable level for LH was 0.5 u/1 and that for FSH was 1 
u/1. The range of values found in normal subjects were 0.5 - 80 
u/1 in pre-menopausal women, rising to 200 u/1 in postmenopausal 
women.
Males (Immunoassay Section, Dept, of Clinical Chemistry, Royal 
Infirmary, Edinburgh)
LH and FSH were measured by radioimmunoassay (Hunter et al, 197*0 by 
methods similar to those described above. The assay for plasma LH 
employed anti-sera (raised in guinea pigs) to the LH preparation 
DEAE 2 obtained from Dr. A Stockell Hartree, University of 
Cambridge, and the assay for FSH employed anti-sera to the crude FSH 
containing fraction CM-1 obtained from Professor ¥ R Butt, 
Birmingham Hospital for Women. LH for iodination was fraction IRC- 
2 (Hartree) distributed as preparation 71/53 from MRC National 
Institute for Biological Standards and Control (NIBSC). FSH for 
iodination was fraction CPD 5/6 from Dr. Butt. The non-radioactive 
standards used were for the LH assay preparation 68/40, and for FSH 
68/39 both from NIBSC. Separation of bound from free peptides was 
by double antibody technique using goat or rabbit anti-guinea pig
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gamma-globulin from Burroughs Wellcome.
The specificity of these assays has been considered in detail by 
Hunter and Bennie (1975) who showed that there was little 
interference by LH in the FSH assay (<0.035$) and FSH in the LH 
assay (0.54$). Similarly there was little interference by TSH, as 
shown by the fact that LH and FSH levels measured by these assays, 
were unchanged when TSH had changed markedly in vivo. However, 
some samples supposedly devoid of human gonadotrophins did yield 
slight responses in these assays due to matrix effects caused by 
substances of high molecular weight (Hunter et al, 1973).
The within-batch precision of assays, assessed from duplicate 
determinations was 11.8$ for FSH and 15.4$ for LH (n = 48 plasmas) 
whilst between assay CV's were 10.2$ and 11.5$ for FSH and LH 
respectively (n = 8 assays). The lowest detectable level of LH was
0.5 u/1 and of FSH was 0.3 u/1.
The mean and range (±£SD) values for men with sperm counts of >60 x 
106/ml were 5.50 (2.24-12.76) u/1 for LH and 2.94 (1.29-6.70) u/1 
for FSH, (n = 111 for both hormones), (Hunter et al, 1974).
ii. Testosterone
Males and Females (Tenovus Institute, Cardiff)
The method used was a rapid procedure for the specific determination 
of testosterone as described by Joyce et al (1975). The assay 
entailed extraction of plasma (0.25 ml or 0.05 ml in men, 0.5 ml in
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women) with 10 volumes of ethyl ether. The extract was then 
evaporated to dryness and a simple biphasic solvent partition 
between cyclohexane (4ml) and aqueous ethanol (2ml) was used to 
remove cross-reacting steroids (11-oxo-C19 steroids). Quantitation 
of testosterone was by saturation analysis (over the mass range
0.069 pmol-0.694 pmol) using an anti-serum raised in a rabbit 
against testosterone 11 cC-hemi-succinyl-bovine serum albumin at a 
dilution of 1:6000. Separation of free and bound steroid was 
achieved by using charcoal absorption.
The reproducibility of the assay was assessed from a series of 
duplicate measurements. At the levels encountered in females, S.D. 
was 1.35ng which it can be calculated is equivalent to approximately
0.10nmol/l, leading to a C.V. of 10$ or less. Accuracy, 
established by the addition of known amounts of testosterone (0-0.63 
pmol) to plasma from an ovariectomised, adrenalectomised female, 
ranged from 98.2-107.5$. The sensitivity of this assay was 0.076 
nmol/1. The specificity of this method was confirmed by showing 
that, firstly, similar values were obtained using an alternative 
purification procedure, secondly less than 1$ cross-reaction was 
observed with 11B-hydroxytestosterone and other steroids tested with 
the exception of dihydrotestosterone (11$), and thirdly, that levels 
were undetectable in the plasma from an adrenalectomised, 
ovariectomised subject.
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iii. 0estradiol-17B
Males (Immunoassay Section, Dept, of Clinical Chemistry, Royal 
Infirmary, Edinburgh)
Females (Tenovus Institute, Cardiff)
0estradiol-17B was measured by radioimmunoassay after extraction of 
plasma with diethyl ether, using a specific antibody generated 
against oestradiol-17B - 6—(0 - carboxymethyl) oxime-bovine serum 
albumin. For samples from males, plasma (0.5 ml) was extracted 
with 5 ml diethyl ether by vortexing for 2 mins., and the ether 
extract was evaporated to dryness (Bolton and Rutherford, 1976)* 
The residue was re-dissolved in 0.5 ml carbon tetrachloride and 
back-washed with 0.5 ml 50 mmol/1 sodium hydroxide solution. An 
aliquot (0.2 ml) of the aqueous phase was used for radioimmunoassay. 
To 0.2 ml of standards (containing 2-100 pg oestradiol in 0.2 ml of 
NaOH) or samples 18.4 pmol (2.5 pg) [2,4,6,7^H] oestradiol-17B was 
added a suspension of antibody coupled to a solid phase at a 
dilution sufficient to bind about 70$ of the added tracer in a final 
volume of 0.5 ml. After overnight incubation, bound and free 
steroid were separated by dilution and centrifugation. The mass of 
oestradiol-17B present was determined from a semi-logarithmic plot 
of the standard curve. The precision of the assay was estimated 
from the values obtained for the same sample in 11 consecutive 
assays. The inter-assay CV was found to be 20$. From the values 
obtained from the same sample measured repeatedly in a single assay 
the intra-assay CV was 7.7$. Accuracy, established by measuring 
the recovery of 0.073-0.368 pmol of unlabelled steroid added perml 
plasma, was found to be 91.1 ±.7.0$ (mean + SD, n=11). The working
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range of the assay was 7.5 - 370 pmol/1.
Specificity was achieved by using an antiserum selected with minimal 
cross-reactions with the potentially interfering oestrogens. The 
apparent concentration of oestradiol-17B was not significantly 
different when samples were assayed before and after chromatography 
on Sephadex LH-20 to remove interfering steroids, indicating that, 
in practice, the assay was highly specific.
Similarly, for samples from females, plasma (1 ml) was extracted and 
the dried residue from ether extraction was used for 
radioimmunoassay.
The assay was essentially as described above with the omission of 
the back extraction into alkaline carbon tetrachloride. The 
precision of the assay was assessed from replicate analysis of 0.2 
ml samples for a plasma pool and was found to be 5*1% at a mean 
level of 1190 pmol/1. Even at lower levels, within-assay precision 
was less than 10/S. The accuracy of this method, assessed from a 
series of quadruplicate determinations of the recovery of unlabelled 
oestradiol-17B from a pool of plasma was greater than 90$ over the 
physiological range. The specificity of the method relies upon the 
use of the specific anti-E2-17B-6-BSA and less than 1$ cross 
reaction was observed with other steroids with the exception of 
oestriol (3$) and oestrone (7$). Sensitivity of the assay was 30 
pmol/1.
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iv. Prolactin
Males and Females (Tenovus Institute, Cardiff).
All the plasma samples were analysed using the method of Cole & 
Boyns (1973) modified by Cole et al (1976) and described more fully 
by Groom (1977). This employed a rabbit antiserum raised against 
an extract of amniotic fluid (antiserum R47) capable of binding 
human prolactin (HPr). Purified human pituitary prolactin used for 
labelling was provided by Dr. U J Lewis, and the unlabelled standard 
was 71/222 from NIBSC. All incubations were carried out at 4°C.
In brief, plasma (100 ul) was dispensed with 200 ul water and 
incubated with 200 ul first antibody (rabbit antiserum R47 final 
dilution 1 :1200). A series of unlabelled standards (71/222) were 
similarly mixed with water and antibody. After overnight 
incubation at 4°C, 100 ul ^25i_iabe;Lie(j prolactin (human pituitary) 
was added and the incubation was continued overnight. On the third 
day, 200 ul of the second antibody (sheep antirabbit) was added and 
the tube was left till the following day. On Day 4, the 
precipitate was collected by centrifugation, the tubes were decanted 
and drained, and the precipitate was counted.
The precision within an assay, assessed from analysis of multiple 
plasma samples was less than 10$. All samples from one study were 
analysed within the same assay. The specificity was established by 
demonstrating parallelism between the displacements of radioactively 
labelled prolactin by samples of plasma and standards of human 
pituitary prolactin. Although some cross-reaction occurred with
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human LH, FSH and TSH, this was eliminated by prior absorption of 
the antiserum with human chorionic gonadotrophin (HCG). Cross­
reactions with human GH or human placental lactogen were 
insignificant. The sensitivity of the assay was approximately 20 
mU/1.
v. Growth Hormone (Tenovus Institute, Cardiff)
GH was assayed by a method similar to that used for plasma LH, FSH 
and prolactin. This employed a rabbit antiserum obtained from 
Burroughs Wellcome Ltd., Beckenham, Kent (RD16, final dilution 
1:300,000). Purified growth hormone for labelling (69/46) was 
donated by the National Institute for Medical Research, London while 
the unlabelled standard was the 1st IRP (international reference 
preparation) - human growth hormone (HGH) obtained from NIBSC.
In brief, plasma (100 ul) was dispensed with 200 ul water and
incubated with 200 ul first antibody (RD16, final dilution
1:300,000). A series of unlabelled standards (1st IRP-HGH) were 
similarly mixed with water and antibody. After overnight
incubation at 4°C, 100 ul 12  ^I-labelled GH (MRC 69/46) was added
and the incubation was continued overnight. On the third day, 200 
ul of the second antibody (sheep antirabbit) was added and the tube 
was left till the following day. On Day 4, the precipitate was 
collected by centrifugation, the tube was decanted and drained and 
the precipitate was counted.
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The precision within an assay, assessed from analysis of multiple 
plasma samples, was less than 10$. All samples from one study were 
analysed within the same assay. Less than 1$ cross-reaction was 
observed with highly purified preparations of LH, FSH, TSH and 
prolactin.
vi. TSH
(Tenovus Institute, Cardiff)
TSH was assayed using an antiserum (68/58) from the Medical Research 
Council (MRC) and the material for labelling (DE-32-3) was obtained 
from Dr. A Stockell Hartree. The unlabelled standard was MRC 
standard A.
In brief, plasma (100 ul) was dispensed with 200 ul water and 
incubated with 200 ul first antibody (68/58, final dilution 
1:240,000). A series of unlabelled standards (MRC standard A) was 
similarly mixed with water and antibody. After overnight 
incubation at 4°C, 100 ul 1-labelled TSH (DE-32-3) was added
and the incubation was continued overnight. On the third day, 200 
ul of the second antibody (sheep antirabbit) was added and the tubes 
were left till the following day. All incubations were at 4°C. On 
Day 4, the precipitate was collected by centrifugation and the tube 
was decanted and drained and the precipitate was counted.
The precision within an assay, assessed from analysis of multiple 
plasma samples, was less than 10$. All samples from one study were 
analysed within the same assay. After absorption of the antisera
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with HCG, less than \ % reaction was observed with highly purified 
preparations of LH, FSH, GH and prolactin.
vii. Cortisol
(Tenovus Institute, Cardiff)
Cortisol was determined by the method of Fahmy et al (1975). One 
hundred microlitre portions of plasma were diluted with 500 ul 
ethanol, mixed and centrifuged. The supernatant extract was 
decanted, dried under nitrogen and 100 ul antiserum (raised in 
rabbits against cortisol-3-(0-carboxymethyl) oximo-bovine serum 
albumen) was added to these tubes, and also to standard tubes 
containing 0.14-2.20 p mols unlabelled cortisol. After mixing and 
incubation for 30 min. at room temperature, [3h] cortisol solution 
(100 ul containing 37>000 dpm) was added and incubation was carried 
out for 1 hour at 30°C. After cooling in ice for 15 min., bound 
and free hormone were separated by the addition of 5 ml dextran- 
charcoal suspension, cooled on ice for 15 min. and centrifuged. An 
aliquot of the supernatant, bound fraction (0.5 ml) was used for 
counting.
The reproducibility of the assay was calculated from a series of 
duplicate estimations. The standard deviation was calculated for 
each of three different concentration ranges leading to intra-assay 
precisions at the mid-point for each range of 15.3$ (0-165 nmol/1, 
n=10), 5.9$ (165-550 nmol/1, n=31) and 3.5$ (550-1102 nmol/1, n=31).
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The inter-assay precision was calculated from values recorded from 
three individual plasma samples which were processed in five 
successive assays. The CV was 11.6$ at a level of 380 nmol/1 ±.44 
S.D., 2.3$ at 650 nmol/1 ±  15 S.D. and 10$ at 1350 nmol/1 ±.143 S.D. 
The accuracy was assessed by determining the recovery of samples of 
increasing masses of cortisol added to plasma which had been 
obtained from a patient with Addisonfs disease and was known to be 
of low cortisol titre. The recovery of added standard varied from 
94.4$ to 110.4$ over the range of concentrations produced (0-1322 
nmol/1).
The assay, using anti cortisol-3-bovine-serum-albumin was highly 
specific. This anti-serum cross-reacted only at levels of 7.1$ and 
4$ respectively with 11-deoxy-cortisol and corticosterone and none 
of the other naturally-occurring steroids which were examined cross­
reacted at levels greater than 0.7$. The sensitivity of the assay 
(derived from estimates of the standard deviation at low 
concentrations) was 23 nmol/1.
3. Statistical Methods
Non-parametric statistical tests were used in most cases except for 
the larger groups of men where parametric methods were used.
In the male patients the distribution of plasma LH and FSH values 
were skewed both within individuals and for the distribution of 
patient means (Fig. 5). The skewness was reduced by using
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Plasma LH and FSH concentrations in patients with gynaecomastia 
and normal controls - note the skewness.
logarithms (Fig. 6). Thus for analyses the natural logarithms of 
LH and FSH were used. Natural logarithms have the advantage that 
their standard deviation is approximately the numerical equivalent 
of the coefficient of variation of the sample value (Wide et al, 
1973; Hunter et al 197*0* In all other cases the raw values were 
used. The parametric methods used were t tests, Hotelling’s T 
test of which assume normal distribution.
To test whether the levels of the hormones tended to vary together, 
Kendal’s rank correlation (t) was used. The value T can vary from 
+ 1 (when the values are completely correlated ) to -1. All other 
cases give a value of between +1 and -1 (Kendal 1973).
Test for a. pulsatile pattern of plasma LH and FSH
Several studies have shown that gonadotrophin levels particularly LH 
vary in a pulsatile pattern both in males and females (Nanken and 
Troen, 1971; Yen et al, 1972; Santen & Barden, 1973).
To examine for this possibility in the present date, a test by Moore 
and Wallis (19*13) was used and which is as follows:- 
For a given series of hormone levels, the total number of steps is 
the number of adjacent points with distinct hormone levels (ignore 
any where there is no measured change). These steps are then 
classed as upward or downward and the number of upward steps 
compared with that which we would expect in a random series. (Fig. 
7).
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Plasma LH and FSH concentrations in patients with gynaecomastia 
and normal controls expressed in logarithms - note the skewness 
is now reduced.
No. of distinct 
steps = 13
ignore ignore No. upward = 9
In calculating number of upward and downward steps ignore the steps 
where the levels remain the same.
The validity of this test is not affected by the variability of the 
assay, although its power may be. The only property of the assay 
which might affect it, is any drift effect, and quality control.samples 
were included throughout the assay to check for this.
Fig. 7
The diagram is an example of the Moore and Wallis test.
Although this test will give a significant result for various other 
types of departure from randomness (e.g. a constant trend), a 
smaller number of upward steps than expected from a random series is 
at least a necessary condition for this type of pulsatile pattern. 
This test was used in both the male patients with gynaecomastia and 
the normal control subjects and in the women with breast cancer and 
their controls where samples were taken every 15 minutes for 8 
hours.
In comparing the two groups of women a similar statistical test to 
the Moore and Wallis test was also used, namely Kendal's test which 
was based on a comparison of the observed number of turning points 
(rather than upward steps) to be expected if the sequence was random 
with the observed number. Kendal's rank correlation coefficient is 
represented by the Greek letter T. Like in a correlation 
coefficient, it varies from +1 for complete positive correlation 
through 0 for no correlation to -1 for complete negative correlation 
(Swinscow, 1976). Both these tests should give a null result if 
there is a completely random series. Kendalfs test is better for 
detecting cyclical variation while Moore and Wallis is better for 
pulsatile pattern.
In calculating number of upward and downward steps ignore the steps 
where the levels remain the same.
The validity of this test is not affected by the variability of the 
assay, although its power may be. The only property of the assay
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which might affect it, is any drift effect, and quality control 
samples were included throughout the assay to check for this.
Test for *Plasma Hormone Increments1 in pituitary function tests 
fHormone increment1 was the average of the hormone concentrations at 
specified times after injection in a stimulation test (Tablel), 
minus the basal concentrations. Times were chosen after examining 
plots of all the patients* data so as to cover the time span over 
which any apparent response was evident.
Wilooxon Signed Rank Test
Wilcoxon signed rank test is used on paired data and is the non- 
parametric test equivalent to the parametric 1 paired t* test. The 
test is better than a paired t test when the numbers involved are 
small, while the t test is better if larger numbers are involved 
(Swinscow, 1976).
This test was used to compare the *hormone increments* before and 
after pituitary ablations. Wilcoxon*s signed rank test was also 
used to compare the values in the six women with breast cancer and 
their six matched controls as the numbers involved in this study 
were small.
Mann Whitnev Test
The Mann Whitney test is a very similar test to the Wilcoxon two 
sample test. It is a non-parametric test equivalent to the para­
metric, unpaired t test (Swinscow, 1976). It was used to compare
TABLE I
Hormone Time in Minutes
GH/insulin 60, 90, 120
LH/LHRH 30, 60
FSH/LHRH 30, 60
TSH/TRH 20, 30
Prolactin/TRH 10, 20, 30
Prolactin/Chlorpromazine 60, 90, 120
Times used to calculate increments of the 
various plasma hormone concentrations after 
releasing hormones.
the hormone values in the patients with breast cancer who did not 
have pituitary function tests both before and after pituitary 
ablation and the values were therefore unpaired.
Hotellinss Jj2- test
Hotellings T2 test is a parametric test and is the equivalent of a 
simple t test when there is more than one measurement for each 
patient. It is used to compare simultaneously levels of two cor­
related hormones between two groups and the results are different 
from individual t tests as the measurements are correlated within 
each group. It was used to compare the levels of oestradiol-17B 
and testosterone levels in the older men with gynaecomastia with the 
older controls and also to compare the values of LH and FSH in the 
young men with gynaecomastic and younger controls and the older men 
with gynaecomastia and the older controls. Because changes in the 
levels of plsam LH and FSH or in testosterone and oestradiol-17B can 
be shown to be correlated in each group, Hotellings T2 test was 
therefore used, which compared the difference between the means of 
the two groups of hormones simultaneously.
This test is illustrated in Fig 8. In diagram (a) group I and 
group II are each well separated on the LH and FSH plot, although LH 
and FSH individually would show considerable overlap. In diagram 
(b) there is no correlation within either group, and an ordinary t 
test would be adequate in this situation.
Hotellings test - used to compare correlated plasma hormone levels.
a) In this example LH and FSH are correlated. Group I and Group II 
are each separated on the LH and FSH plot although individually 
LH and FSH would show considerable overlap.
b) In this example there is no correlation within either group and 
an ordinary t test would be adequate.
Ill
HORMONAL PROFILES IN BREAST DISEASE
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Study JL - Plasma Hormonal Profiles in Women with Breast Cancer
1. Literature review
Considerable research has been performed in women with breast cancer 
to determine whether circulating levels of hormone are of prognostic 
value and to elucidate the effects of endocrine ablative and 
additive procedures on plasma hormone levels.
In the late 1950's and early 1960's the techniques then available 
for assays of hormones were mainly bioassays and chemicals methods 
and there were mainly, if not solely, applicable to urine. Twenty 
four hour urine samples did have an advantage in that they 
represented what was happening during a day, but it was difficult to 
collect good urine samples, and storage of assays was a problem. 
The recent development of precise assays by radio-immune methods has 
allowed the estimation of concentrations of hormones in circulating 
body fluids.
i. Oestrogens and breast cancer
In women, the two major oestrogens secreted from the ovary and 
adrenal are oestrone and oestradiol-17B, whose formulae are shown in 
Table II. In the pre-menopausal woman, the majority of the
oestrogens is secreted from the ovary, while in the post-menopausal 
woman, most of the oestrone and oestradiol-17B is derived, not from 
a direct secretion from adrenal, which is small, but indirectly by 
their synthesis at peripheral sites (liver, muscle, fat) from 
a n d r o g e n s  C-19 s t e r o i d s  A 11 a n d r o s t e ne d i o n e and
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TABLE II
HO
1. Oestrone
OH
2. Oestradiol 17£
Main oestrogens secreted in the human.
dehydroepiandrosterone.
Oestrogens are metabolised or conjugated prior to excretion 
primarily in the liver the principle ones being oestriol and 
oestrone sulphate. The conjugate oestrone sulphate is stongly 
bound to albumen in the plasma and is excreted slowly by the kidney. 
By contrast, oestriol, in the form of glucuronide is rapidly 
excreted. Oestrone sulphate thus is the major circulating 
oestrogen (Purdy, 1961); oestriol glucuronide probably the major 
urinary oestrogen (Brown, 1955).
Biologically, the most important naturally occurring oestrogen is 
oestradiol-17B but both oestrone and oestriol have biological 
activity. Oestrone sulphate acts only after hydrolysis, to yield 
oestrone, but the hydrolysing enzyme is present in many tissues. 
The carcinogenic potential of these three free oestrogens differs. 
Oestrone and oestradiol17B have repeatedly been shown to produce 
tumours in rats (Geschickler et al, 1942; Dunning et al, 1953; 
Mackenzie, 1955; Cutts et al, 1964); oestriol, which has not been 
as fully evaluated, has been found to be carcinogenic in mice 
(Rudali et al, 1975). It has also been reported that oestriol can 
stimulate macromolecular synthesis in human breast cancer cells to 
the same extent as oestrone and oestradiol-17B, can bind to 
oestrogen receptor and can stimulate protein synthesis (thymidine 
incorporation) of breast cancer in 'tissue culture (Lippman et al, 
1977).
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a) Urinary oestrogens
Oestrogens are present in the urine mainly in the form of 
glucuronides and sulphates but small quantities of free oestrogen 
are also present. In 1955-56, both Brown (1955) and Bauld (1956) 
developed chemical methods for the accurate chemical estimation of 
small amounts of oestrone, oestradiol-17B and oestriol in human 
urine. These were by hydrolysis of the urine extraction of the 
oestrogens by chromatography on alumino columns and determination of 
their concentrations by the Kober colour reaction.
Oestrogens in the intact female
Although these original methods were moderately precise and 
sensitive, no convincing association between urinary oestrogen 
levels and breast cancer could be demonstrated. Never the less, it 
was reported by Brown (1958) that postmenopausal women with breast 
cancer excreted higher amounts of oestriol than normal controls; 
Marmorston (1965) also reported abnormalities of oestrogen excretion 
in women with breast disease. In this study premenopausal women 
with breast cancer and benign breast disease excreted a 
significantly lower percentage of total oestrogen as oestrone and a 
significantly higher percentage of total oestrogen as oestriol than 
did normal, sick (emphysema) and well controls; postmenopausal 
women with breast cancer excreted significantly higher levels of 
oestriol than similar controls. These findings have not been 
confirmed. The results of early work on urinary oestrogens were 
conflicting and confusing (Irvine et al, 1961; Jull et al, 1963; 
Marmorston et al, 1965; Lemon et al, 1966; Schweppe et al, 1967;
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Arguelles, 1973)*
Oestrogens in endocrine ablated females
Several groups of workers measured urinary oestrogens (using Brown1 s 
method) after oophorectomy alone in premenopausal women and after 
oophorectomy and adrenalectomy in both pre and post menopausal 
women, and reported that while residual excretion of oestrogens in 
the urine might continue following these operations (Strong et al, 
1956; Bulbrook and Greenwood, 1957; Birke et al, 1958) the 
presence of urinary oestrogen did not appear to jeopardise the 
clinical response to treatment. Continued excretion of oestrogens 
was also found after hypophysectomy (Greenwood and Bulbrook, 1957); 
there was no correlation between the oestrogen levels following this 
operation and the clinical course (Scowen, 1958). The source of 
oestrogens in patients whose ovaries, adrenals or pituitaries have 
been removed remains obscure. Dietary factors have been 
implicated.
However, the methods used for estimating urinary oestrogens were not 
sufficiently sensitive at low values, to measure precisely the 
amounts remaining in the urine in postoperative patients of this 
type, and it became generally accepted that the measurement of 
urinary oestrogens was of limited value in predicting response to 
endocrine ablation. These criticisms also apply to urinary 
oestrogens in intact women. In premenopausal women cyclical 
variation is known to occur and for meaningful assessment daily 24 
hour collections throughout one or even two menstrual cycles are
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required. In the postmenopausal woman, urinary oestrogen levels 
are very low and accurate chemical measurements are difficult.
Conclusion
Despite the amount of work put into measuring urinary oestrogens, 
little has come out of it and it does not seem too productive to 
consider further studies of this type. At the same time urinary 
oestrogens did give some indication that one can not explain the 
behaviour of breast cancer to endocrine treatment by changes in 
urinary oestrogens.
b) Plasma Oestrogens
The introduction of radioimmuoassay methods in the late 1960's 
(Abraham, 1969) for the measurement of plasma oestrogens both in pre 
and postmenopausal women led to the reevaluation of the role of 
oestrogens in breast cancer. The two oestrogens, oestrone and oest- 
radiol-17B in normal pre and postmenopausal women have been assayed 
by several workers (Baird, 1968; Abraham, 1969; Baird and Guevara, 
1969; Korenman, 1969). Reported normal values are shown in Tables 
III and IV. Two very good studies in pre and postmenopausal women 
have been described by England et al (1974 a & b). These workers 
showed that the pattern of oestradiol-17B secretion throughout the 
menstrual cycle in the normal premenstrual woman was constant from 
decade to decade but that concentrations varied with age. The 
average concentrations for any given day of the cycle were reported 
to be higher in women in the 4th decade of life than either younger 
or older women. In normal postmenopausal women, oestradioll7B
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levels were very low, while oestrone levels were slightly higher. 
Day to day variation was slight. The concentrations of plasma 
oestradiol17B was oestrone in pre and postmenopausal women with 
early breast cancer or with advanced breast cancer have been 
compared with those in normal, healthy women by Wang and Swain 
(1974). No significant difference in plasma oestradiol-17B or 
oestrone concentrations was found in either group of patients, 
compared to controls; however, there was a trend in four, of higher 
plasma oestradiol-17B levels in premenopausal women with advanced 
breast cancer compared to the control group.
In 1974, England and his colleagues reported extension of their 
earlier work in normal females to women with breast cancer. They 
studied the plasma oestradiol-17B levels throughout one complete 
menstrual cycle in thirty-one pre-menopausal women with benign 
breast disease, and in ten pre-menopausal women with cancer of the 
breast - aged 40-49 years. They also studied twenty-five 
postmenopausal women with cancer of the breast, comparison of all 
groups was with those in thirty-two normal premenopausal and twenty- 
five normal postmenopausal females reported earlier. In the 
premenopausal women with breast cancer, the mean oestradiol-17B 
concentration was slightly but significantly greater than in the 
normal women. In the postmenopausal women, the concentration of 
oestradiol-17B was near the lower limit of the sensitivity of the 
assay in both normal and cancer groups. There was no difference 
between the values for the two groups. The authors suggested, that 
studies in postmenopausal women might be more rewarding were
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oestrone to be assayed rather that oestradioll7B as the former is 
present at rather higher levels. j
More recently it has been reported by Siiteri et al (1982) that the 
percentage of free oestradiol 17B is important. The percentage of 
free oestradiol 17B was estimated by these workers in a group of 
seventeen women with breast cancer and in controls matched for 
weight and menopausal status. The mean value of free oestradiol 17B 
in the women with breast cancer was significantly higher than in the 
control group but neither the body weight or serum hormone binding 
globulin (SHBG) was different. It was concluded that the elevation 
of free oestradiol 17B was due to other factors than a fall in SHBG, 
either due to competition by steroids or other substances for 
oestradiol 17B binding to SHBG or an abnormal steroid binding site.
Conclusion
There appears to be no concensus of opinion that either urinary or 
plasma oestradiol-17B concentrations are different between normal 
women and women with breast cancer.
ii Androgens and Breast Cancer
In the early 1960fs a great deal of interest was also taken in the 
excretion of androgenic hormones in women with breast cancer. These 
estimations were carried out originally in urine but, as with other 
hormones, more sensitive radioimmunoassays were developed and deter­
minations in plasma became possible.
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(a) Urine
Quantitatively the main androgens excreted in female urine are the 
11-deoxy-17-oxosteroids (previously termed 17-ketosteroids). These 
comprise aetiocholanolone, androsterone, dehydroepiandrosterone and 
their conjugates. Their chemical structure is shown in Table V.
Interest in androgen excretion in women with advanced breast cancer 
was aroused when Bulbrook et al (1960) showed that the pre-operative 
levels of aetiocholanolone, especially when combined as a function 
of the levels of hydroxycorticosteroids (17-OHCS) formed a 
Miscriminant function1 which might predict the subsequent clinical 
response of the patient to adrenalectomy or hypophysectomy. The 
function was (80-80( 17-OHCS mg/2^f hours) + aetiocholanolone ug/2^ 
hours). If this discriminant was positive, the likelihood of a 
clinical response to hormone manipulation was greater than if it had 
a negative value.
It was also suggested by Bulbrook et al, (1962), that the urinary 
levels of aetiocholanolone were lower in women with early breast 
cancer than normal controls but this was not confirmed by subsequent 
workers in a number of centres, e.g. Ahlquist et al (1968); Wade et 
al (1969); Cameron et al (1970); Miller et al (1975) who failed to 
find differences. It is relevant that studies of profiles of 
urinary androgen excretion in patients with lung disease and lung 
cancer have revealed differences similar to these described by 
Bulbrook in women with breast cancer, but reflect the degree of 
illness in patients with terminal disease (Marmorston, 1966; Rao,
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TABLE V
0
1. Aetiocholanolone
0
2. Androsterone
HO''
3. Dehydroepiandros terone
The main 11-deoxy 17-oxosteroid androgens (unconjugated forms) 
excreted in female urine.
1970).
Estimations of urinary aetiocholanolone were also measured in four 
hundred and seventeen women, with either benign or malignant breast 
disease or with no breast disorder, the ages were between 20 and 70 
years and the women came from South East Scotland and South 
Wales (Miller et al, 1975). No significant differences in urinary 
levels were detected between patients with breast disease, whether 
benign or malignant or control patients. It was also noted that 
the prognostic values of pre-operative aetiocholanolone measurements 
was limited in patients with early breast cancer. Low levels of 
aetiocholanolone were associated with post-menopausal patients, a 
group in which, the prognosis is generally poorer than that in 
premenopausal women.
In another study (Grattarola, 1973) urinary testosterone was 
measured in nineteen patients with breast cancer, clinically cured 
5-15 years after mastectomy, and twenty-two breast cancer patients 
who had developed lung and/or bone metastases during the same 
period. All patients were between 50 and 65 years of age. 
Thirty-five postmenopausal women (age range 52-65 years) without 
breast cancer were taken as control subjects. Urinary testosterone 
was also measured in another group of postmenopausal women (age 
range 58 to 68) who had developed lung and/or bone metastases from 
other types of malignancies which had never been treated. It was 
found that the mean value of the urinary testosterone level of the 
normal control group did not differ significantly from that of the
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clinically cured breast cancer patients or from that of the patients 
who developed lung or bone metastases from other malignancies. The 
urinary testosterone was found to be significantly above normal in 
the breast cancer patients, who developed recurrences 5-15 years 
after mastectomy for breast carcinoma. The conclusion was that 
increased andogenic activity was the hormonal factor in the 
development of breast cancer and that it can affect the course of 
this disease in the years following treatment of the primary tumour.
(b) Plasma Androgens
Whilst the urinary excretion of androgens in women with breast 
cancer has been studied fairly extensively, far less work has been 
done on the measurement of these hormones in the blood. The main 
androgens which have been found in plasma in females are 
dehydroepiandrosterone, androsterone and their sulphates, 
testosterone and A  4 androstenedione. The chemical formulae for 
these substances are shown in Table VI. These androgens are the 
parent compounds of those which appear in the urine. Compounds 
found in the urine are derived by reduction and conjugation 
principally by the liver. The plasma compounds, being 
unmetabolised material, may represent a more direct estimation of 
androgen function.
It has been reported that plasma levels of 17-oxosteroids are raised 
in women with breast cancer compared with controls (Benard et al, 
1962).
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TABLE VI
1. testosterone
OH
2. A 4 androstenedione
o
o
.3. dehydroepiandrosterone sulphate (DHAS)
0
4. androsterone sulphate
0 '
The main plasma androgens found in normal women
A subsequent study, however, by Deshpande (1965) of normal women and 
patients with early and advanced breast cancer showed that levels of 
plasma 17-oxosteroids in cancer patients did not differ from those 
of the normal women. Plasma 17-OHCS level was normal in the early 
disease, but raised in advanced cases. In 1964, Deshpande and 
Bulbrooke showed that the total 17-oxosteroids in the plasma are 
mainly represented by dehydroepiandrosterone sulphate and andro- 
sterone sulphate and subsequent studies in breast cancer have 
concentrated on individual 17-oxosteroids.
It was reported that the concentrations of plasma dehydroepiandro­
sterone sulphate were lower in a group of patients with advanced 
breast disease than in a group of patients with benign breast 
disease (Brownsey et al, 1972). These findings agree with the work 
of Wang et al (1973) who reported that plasma dehydroepiandrosterone 
sulphate (DHAS) concentrations in women with early or advanced 
breast cancer was subnormal compared to the levels found in normal 
women. A further study was carried out by Wang in two hundred and 
eleven normal women, two hundred and two women with early breast 
cancer before and after mastectomy and ninety women with advanced 
breast cancer. Dehydroepiandrosterone sulphate sulphate and 
androsterone sulphate were significantly subnormal after mastectomy 
as they also were subnormal in women with advanced breast cancer. 
However, there was no difference in the mean levels of plasma 
dehydroepiandrosterone sulphate and androsterone sulphate in normal 
women compared with women with early breast cancer before mastectomy 
(Wang et al, 1974).
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In the Guernsey population, studied by Bulbrook and his colleagues, 
Wang et al (1975) reported that these women with a family history of 
breast cancer had levels of plasma C-19 steroids lower than those 
who had no such association. The age adjusted geometric mean level 
of plasma dehydroepiandrosterone sulphate and androsterone sulphate 
were significantly lower in young sisters, (but not daughters) of 
women with breast cancer than in controls. The greatest difference 
was found in the younger age group.
It was reported by Thomas et al (1976) who used the Guernsey 
population as controls that plasma dehydroepiandrosterone levels in 
women with both early and advanced breast cancer were lower than in 
normal women. They were also lower in young women aged 20-29 with 
benign breast disease.
Studies have also been carried out to determine the concentrations 
of A  4 androstenedione in normal women and in women with early and 
advanced breast cancer (Wang et al, 1977). No significant difference 
was found between the mean levels of plasma A  4 androstenedione in 
normal women and those with early breast cancer assayed before 
mastectomy. However plasma A ^  androstenedione was subnormal in 
patients with early breast cancer after mastectomy and in patients 
with advanced breast cancer. In all groups, the plasma level of A  ^  
androstenedione was highly correlated with plasma levels of dehydro­
epiandrosterone sulphate. Simultaneous studies of plasma dehydro­
epiandrosterone sulphate and A  4 androstenedione levels in women 
with breast disease were also reported by Rose et al, 1977. These
60
included sixty-nine women with primary breast cancer (twenty-four 
before and forty-five one month after mastectomy) and forty-nine 
with advanced breast disease. The results were compared with 
similar estimations in a group of sixty-two healthy women. Plasma 
dehydroepiandrosterone sulphate levels were negatively correlated 
with age, and in all three breast cancer groups, significantly 
reduced levels were found, compared with age-com parable controls. 
No significant difference was found in plasma A   ^ androstenedione 
levels between the cancer patients and controls. Contrary findings 
have also been reported. England et al (1981) found the mean 
levels of plasma dehydroepiandrosterone sulphate to be lower in ten 
normal women, compared with twenty-nine patients with breast disease 
(twenty benign disease and nine early cancers) but not significantly 
so. No significant difference in plasma dehydroepiandrosterone 
sulphate concentrations between postmenopausal patients with Stage 1 
or 2 breast cancer and normal postmenopausal women were reported by 
Bird et al, 1981. These workers also found no significant 
differences in plasma levels of testosterone A 5 androstene3B 17B 
diol, A 4 androstenedione and dehydroepiandrosterone between these 
patients and the control group. It was, however, found that the 
mean plasma 5 CXdihydrotestosterone levels were lower for the 
patients with breast cancer. In another report (Zumoff et al, 
1981) comparing eleven women with primary breast cancer (aged 31-78 
years) and thirty-seven normal women, (aged 21-75 years) a marked 
and progressive decline of plasma dehydroepiandrosterone (DHA) and 
the dehydroepiandrosterone sulphate levels varied with age only in 
the normal women; in the cancer group the concentrations of both
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steroids rose as age increased. Premenopausal patients with cancer 
had .s u„b n o r m a l  p l a s m a  d e h y d r o e p i a n d r o s t e r o n e  and 
dehydroepiandrosterone sulphate levels, postmenopausal patients had 
supranormal levels. When the ratio of dehydroepiandrosterone to 
androsterone was calculated it was found to be normal in the 
premenopausal patients but significantly elevated in the 
postmenopausal patients. The authors suggested that subnormal 
plasma adrenal androgen levels in the premenopausal patients was due 
to diminished production while the elevated plasma levels in the 
postmenopausal patients was due to slowed metabolic removal.
In summary, plasma dehydroepiandrosterone and plasma dehydro­
epiandrosterone sulphate tend to be decreased in breast cancer 
within a race but there are contrary findings. Menstrual status may 
affect the concentrations. The report that C-19 steroids such as 
dehydroepiandrosterone sulphate inhibits breast cancer in mice lends 
possible clinical relevance.
Sebaceous glands are stimulated by endogenous androgen with testo­
sterone, A 4 androstenedione and dehydroepiandrosterone as the 
likely agents (Pochi et al 1963). There is some biological 
evidence that patients with breast cancer have increased 
androgenicity and various studies have suggested that there is 
increased sebum excretion in patients with breast cancer (Krant et 
al, 1968; Burton et al, 1970; Wang et al, 1972). These findings 
suggested the possibility that postmenopausal women with advancing 
breast cancer were, in general, in an androgen stimulated internal
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environment and, as a group, were different in this regard from 
healthy postmenopausal women. However, Wang et al (1972) did not 
find that high amounts of plasma oxosteroids were associated with 
the higher level of sebum production in women with breast cancer.
Work also has been carried out in relation to plasma testosterone 
Wang et al (1966). He compared the levels of plasma testosterone in 
fourteen patients with benign breast disease, in twenty-four 
patients with early breast cancer and nineteen normal women. No 
difference in the plasma testosterone levels was found between the 
three groups. In 1974, Horn and Gordon also studied plasma 
testosterone levels in thirteen postmenopausal women. No 
difference in the plasma testosterone levels was found between these 
two groups. Jones et al (1977) measured plasma testosterone levels 
in forty-four women with breast cancer and those in sixty-five women 
with benign breast disease. Again no difference was found in the 
plasma testosterone levels between the two groups.
iii Progesterone and Breast Cancel?
Progesterone is mainly secreted by the corpus luteum. It is a 
hormone whose relationship to breast cancer has only recently 
received attention.
Wang and others (1974) measured plasma progesterone levels in the 
luteal phase in three hundred and forty-one control premenopausal 
women, twenty-five patients with early and twelve with advanced 
breast cancer. Assay was by competitive protein binding. The
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plasma progesterone levels in the group of patients with early 
breast cancer was similar to those in the control group. In the 
study all subjects with progesterone levels greater than 3 ng/ml of 
plasma were considered to have ovulated. There was no evidence of 
an increased incidence of ovulatory failure in patients with early 
cancer. There was however, a significant increase in the incidence 
of ovulatory failure in the advanced cases. The mean plasma 
progesterone level of the patients with advanced disease who had 
ovulated was not significantly lower than both the control group and 
the patients with early breast cancer. Four obese normal women 
with irregular menstrual cycles for six cycles were studied by 
Sherman and Korenman (1974) who found that progesterone levels 
during the luteal phase were far below those observed in ten women 
with normal cycles. These workers suggested that altered hormonal 
environment of the mammary gland consequent to persistent 
oestrogenic stimulation, in the absence of an adequate 
progestational phase, i.e. nluteal phase deficiency", could provide 
a hormonal setting in the breast favourable to the development of 
carcinoma.
Plasma levels of progesterone in ten postmenopausal women with early 
breast cancer were compared with the levels in a control group of 
fifteen postmenopausal women with early cancer at other sites by 
Smethurst et al (1975). The mean plasma progesterone was signi­
ficantly raised in the breast cancer patients compared to the 
control group.
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Plasma progesterone levels were compared in fifty-three normal 
British (high risk group) and fifty-four Japanese (low risk group) 
(premenopausal, menopausal and postmenopausal) women - no 
significant differences between the two groups were found (Bulbrook 
et al 1976). In the following year Malarkey et al (1977) also 
reported that the serum progesterone levels, determined pre- 
operatively in sixteen women with benign breast disease and 
seventeen patients with breast cancer were similar to those found in 
twenty-five age- and weightmatched control women. These patients 
and controls were in the luteal phase of the cycle or were 
postmenopausal.
iv Gonadotrophins and Breast Cancer
Direct attempts to correlate measurements of gonadotrophins and 
pituitary function with the development of breast tumours or with 
the clinical course of the disease have been relatively 
unsuccessful. This was probably due to the lack of accurate
methods for measuring the pituitary hormones in the plasma until 
recently. Even allowing for this, very few associations have been 
demonstrated between pituitary function and tumour growth or 
response to therapy.
Many of the early estimations or urinary gonadotrophins used 
bioassay techniques. Compared with later radioimmunoassay methods 
these methods were relatively insensitive and therefore much of the 
early work may have to be reassessed. In 1958, Loraine used 
bioassay to measure gonadotrophins in post-menopausal patients with
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breast cancer. Urine was collected for eight days, but the 
variability between samples in some patients represented a twofold 
difference in the gonadotrophin levels. Despite this he noted that 
patients who failed to respond to stilboestrol therapy, had a 
significantly higher mean urinary gonadotrophin excretion than the 
patients who obtained a remission. Urinary gonadotrophins were 
later estimated in forty-one patients with advanced breast cancer 
prior to adrenalectomy or hypophysectomy (Hayward et al, 1961). 
The difference between the levels in responsive and unresponsive 
patients was not significant, but high gonadotrophin levels tended 
to be present in those who subsequently responded. The evidence 
for alterations in urinary gonadotrophin excretion in breast cancer 
patients and on the correlation of measurements with response to 
hormone therapy are few and conflicting. With the development of a 
radioimmonoassay for plasma LH and FSH by Midgley (1966; 1967) more 
accurate studies could be performed, and considerable basic 
knowledge on the secretion of LH and FSH has become available. 
This is regulated by complex interactions between releasing hormones 
from the hypothalamus and ovarian hormones (Schalley et al, 1971)* 
Episodic pulsatile patterns of gonadotrophins have been shown to 
occur in pre- and postmenopausal women (Yen et al, 1972). A 
periodicity of 1-2 hours was seen during the early follicular phase 
and mid-cycle surge while a four hourly periodicity was seen in the 
mid and late luteal phase. The frequency of pulses of LH and FSH 
in the postmenopausal subjects was the same as in the follicular and 
mid-cycle women - every 1-2 hours.
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Little, however, is known about the relationship, if any, of plasma 
gonadotrophins to breast cancer. A study in which plasma LH and 
FSH levels in post-menopausal women with early breast cancer, 
advanced breast cancer and normal controls was carried out and it 
was found that the values in the cancer patients did not differ from 
the controls (Wang et al 1976). Malarkey and his colleagues (1977) 
measured serially gonadotrophins in the serum over a twenty-four 
hour period in sixteen women with benign breast disease, seventeen 
women with breast cancer and twenty-five age- and weight-matched 
controls; no differences were detected. Others have reported 
similar findings.
No significant difference in the plasma LH or FSH levels in ninety- 
eight postmenopausal women with early breast cancer compared with 
the levels in thirty-four postmenopausal, control women were 
detected by Bird et al (1981). Only a marginal difference in 
plasma gonadotrophin values between normal British and Japanese 
women, who have different risks of developing breast cancer was 
reported by Kumaoka et al (1976). In the premenopausal group, 
plasma LH in Japanese women was marginally higher than in British 
subjects while in the postmenopausal group plasma LH was 
significantly higher in British women.
In summary, plasma gonadotrophin concentrations seem to be within 
normal limits in patients with breast cancer. A complicating 
factor in women with advanced breast cancer is the report that in 
postmenopausal women, illness may depress LH and FSH levels and
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obscure the true result (Warren et al, 1977)*
v. Prolactin and Breast Cancer
Although some hormones and drugs can act directly on the pituitary 
to influence prolactin secretion, prolactin in contrast to other 
pituitary hormones is largely under control of an inhibitory factor 
(PIF) from the hypothalamus. Talwalker et al (1963) found that the 
hypothalamus contained a factor which inhibited synthesis and 
release of prolactin by the rat anterior pituitary in vitro: this 
factor was not any of the recognised hormones in the hypothalamus 
and it was subsequently termed PIF.
The measurement of human prolactin was delayed by difficulties in 
distinguishing prolaction activity from that of growth hormone. 
Purified growth hormone had been found to have considerable 
prolactin activity, and there had been doubts whether in man the two 
hormones were separate entities. However, evidence of the 
existence of two distinct hormones was forthcoming and human 
prolactin was isolated and purified (Lewis, 1971). These advnaces 
led to the development of homologous radioimmunoassay of the hormone 
(Hwang et al, 1971).
As early as 1971 > Turkington et al, raised the question regarding 
the importance of prolactin in the growth of human breast cancer. 
Their work indicated that evidence of regression of advanced disease 
could occur despite increase in prolactin levels. He and his 
colleagues had measured serum prolactin by a bioassay method in
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eleven patients who had undergone pituitary stalk section for 
treatment of metastatic mammary carcinoma. In eight out of the 
eleven, there was remission of the disease but five of these eight 
patients had elevated prolactin levels. Thus increased prolactin 
levels in these patients did not prevent regression of the disease. 
Evidence is also available from epidemiological studies that early 
pregnancies, which would involve an earlier but considerable 
increase in prolactin secretion (Hwang et al, 1971) reduce lifelong 
risk of breast cancer (MacMahon, 1973).
Comparisons of serum prolactin in normal women and women with breast 
cancer have not provided evidence of an important relationship. 
Such evidence if conflicting. For example, Murray and his 
colleagues (1972) compared plasma prolactin levels in twenty-four 
women with metastatic breast cancer and twenty-three postmenopausal 
patients hospitalised for other reasons. The prolactin levels of 
the cancer group were statistically higher than the controls. In 
contrast Wilson et al (1974) compared plasma prolactin levels in 
forty-nine patients with breast cancer against thirty-nine hospital 
controls and found no difference in the prolactin levels between the 
two groups. A similar finding was also reported by Kwa et al 
(1974) who compared one hundred and fifteen patients with breast 
.cancer with one hundred and fifteen matched controls and found no 
difference in the plasma prolactin levels in the two groups. A 
further study was carried out by Franks et al (1974) who measured 
the plasma prolactin levels in one hundred and thirteen patients 
with a breast lump prior to surgery. They found no difference in
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the prolactin levels between patients with breast cancer and those 
with benign breast lumps. Racial comparisons have also been 
carried out. In a study by Kumaoka and his colleagues (1976) no 
differences were found between the plasma levels of prolactin in 
normal British women (high risk breast cancer) and comparable 
Japanese women (low risk breast cancer), irrespective of whether 
they were adolescent, premenopausal, menopausal, postmenopausal. 
However, women with a family history of breast cancer were reported 
to have an increased prolactin level in the evening (Kwa et al, 
1976). Nocturnal estimates of plasma prolactin were performed by 
Malarkey et al (1977) in twenty-five control women, sixteen women 
with benign breast disease and twenty-three women with breast cancer 
before breast surgery, who showed that the nocturnal plasma 
prolactin concentration was significantly decreased in twelve of the 
postmenopausal breast cancer patients but significantly increased in 
five premenopausal women with breast cancer, as compared to the 
control women. Plasma prolactin levels throughout the mentrual 
cycle were studied by Cole et al (1977) in eleven patients who had 
undergone mastectomy for primary breast cancer and in thirty-two 
normal women at various stages of the menstrual cycle. The cancer 
patients had higher plasma prolactin levels, but this was believed 
to be an acute effect. There was little difference in prolactin 
levels between patients with primary cancer who had had a mastectomy 
more than three months previously, and normal women.
Increased nocturnal plasma prolactin levels were also reported by 
Tarquini et al (1978) in nulliparous premenopausal normal women (at
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high risk) in comparison with parous premenopausal women. In 
addition, five of seven nulliparous premenopausal women with breast 
cancer, had elevated nocturnal prolactin levels compared to five of 
thirteen parous women, also with breast cancer. It was concluded 
that premenopausal nulliparous women with benign or malignant breast 
disease generally exhibited a significant peak of plasma prolactin 
in the early evening but that this was rarely seen in parous 
patients.
In summary, the results of estimates of plasma prolactin in patients 
with breast cancer are variable and depend greatly on the form of 
the study carried out. In the majority of studies plasma prolactin 
has been shown to be within normal limits. It would seem apparent 
that a single sample is inadequate for assessing the role (if any) 
of prolactin in breast cancer and that further work should involve 
multiple sampling.
vi. The Thvroid Hormone and Breast Cancer
In 1896 Beatson described the use of thyroid extract as an adjuvant 
to oophorectomy in the treatment of advanced breast cancer. Its 
use since then has been only occasional and its value never proven. 
It is not known whether thyroid hormones have a role in the 
pathogenesis of breast cancer. It was past belief that there was 
prevalence of goitre or evidence of other thyroid disease in 
patients with breast cancer. Thus (Bogardus and Finley 1961) 
reported that forty-two out of seventy-nine patients with breast 
cancer had an abnormality of the thyroid gland on physical
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examination, while in another report a high incidence of breast 
cancer was found in ninety-two female patients with thyroid cancer 
(Chalstrey and Benjamin, 1966).
It has been reported that iodine deficiency enhances the response of 
rat breast tissues to sex hormone injections. Oestrogen and testo­
sterone administration to iodine deficient hypothyroid rats results 
in lesions which mimic human cystic disease of the breast and 
suggests another physiologic factor which may act to modify breast 
sex steroid interaction (Eskin et al, 1967)* Further more rates of 
morbiditiy and mortality due to breast cancer are reported to be 
higher in areas of iodine inadequacy than in regions where iodine is 
available (Eskin, 1970). Studies have also shown that abnormal 
breast tissue (dysplasia or neoplasia) has increased radio iodine 
uptake compared to histologically normal breast tissue from the same 
patient (Eskin et al, 197*0«
The effect of an intravenous injection of thyrotropin releasing 
hormone (TRH) on plasma TSH was measured in fifty women with early 
and fifty women with advanced cancer of the breast (Mittra and 
Hayward, 19710» The results were compared with those obtained in a 
group of fifty age-matched women in hospital awaiting surgery for a 
variety of reasons. The results suggested that the mean basal 
level of TSH in both cancer groups was significantly higher than in 
the controls and that more cancer patients had TSH levels above the 
normal range. After TRH stimulation, the mean response to TSH was 
significantly higher in the breast cancer groups than in normal
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women. Approximately three times as many cancer patients as 
controls had an exaggerated response of TSH to TRH indicating a 
relative primary thyroid deficiency. From these results it was 
suggested that breast cancer patients as a group had a level of 
thyroid function which was lower than that found in control women in 
hospital with conditions unrelated to breast.
A hypothesis was put forward that a suboptimal level of circulating 
thyroid hormones may abnormally sensitise mammary epithelial cells 
to prolactin stimulation, thus leading to eventual neoplasia. It 
was shown by Rose and his colleagues (1978) that plasma TSH was 
negatively correlated with plasma T^ in early breast cancer and that 
reductions in plasma Tg might explain increased plasma TSH levels. 
Tg has been shown to be the important hormone in the regulation of 
pituitary TSH release (Belchetz et al 1978). Rose suggested that 
these considerations might support the view that patients with early 
breast cancer with elevated plasma TSH and reduced Tg levels had a 
degree of impaired thyroid function and suggests that this 
abnormality might preceed the disease and could be a factor in brest 
cancer risk. Later MacFarlane et al (1980) however studied a large 
number of consecutive patients with breast cancer, a group of women 
with benign breast disease, and a group of normal women by plasma 
TSH, Tg and T^ levels. No increase in the incidence of thyroid 
dysfunction was found in patients with breast cancer compared to 
patients with benign breast disease or controls. Comparisons of 
plasma TSH in British and Japanese women were reported by Kumaoka et 
al (1976). Plasma TSH was higher in the British women but not
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significantly so.
Thyroid hormones are known to affect enzyme systems concerned with 
oestrogen and androgen metabolism. Fishman et al (1962) reported 
that, when levels of thyroid hormones are raised there is a fall in 
the conversion of oestradiol-17B to oestriol while the conversion to 
2 methoxyoestrone is increased. The metabolism of testosterone to 
androsterone is also reported to be stimulated by thyroid hormones.
The androsterone-aetiocholanolone excretion rate was worked out by 
Schorted and his colleagues in 1966 who found that this ws increased 
in 7 6 $ of patients with myxoedema and decreased in 5 9 .1$ of patients 
with thyrotoxicosis. It is known that in patients with thyro­
toxicosis and after administration of thyroid hormone, there is a 
rise in the level of sex hormone binding globulin (SHBG) (Ruder et 
al 1971). Because of the different affinities of this binding 
protein for testosterone and oestradiol-17B, a rise in its level 
results in a greater fall in the plasma level of unbound 
testosterone, than of unbound oestradiol-17B. SHBG is an important 
determinant of the ratio of unbound testosterone and oestradiol-17B. 
Increased SHBG will have a feminizing influence, and decreased SHGB 
levels a masculinizing influence. In thyrotoxicosis, SHBG 
increases considerably with resulting changes in oestradiol-17B and 
testosterone metabolism (Burke and Anderson, 1972).
In summary plasma TSH, T3 and T4 seem to be within normal limits in 
patients with breast cancer. The importance of thyroid hormone and
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these various factors in the development of breast cancer still 
remain known.
vii. Growth Hormone and Breast Cancer
Patients with breast cancer frequently have abnormalities in 
carbohydrate metabolism. Thus it was reported by Glicksman et al 
(1 9 5 6 ) that 3 5 $ of patients with breast cancer had a diabetic-type 
glucose tolerance curve in contrast to only 1 0 $ of subjects with 
benign breast disese. An accurate method for the estimation of GH 
by a radioimmunoassay technique became available in 1962 (Hunter and 
Greenwood) and with its availability, more precise measurements 
could be made in patients with breast cancer. However, plasma 
growth hormone levels are influenced by many psychological factors 
e.g. stress, exercise, fasting (Greenwood and Landon, 1966), and 
measurements can only be meaningful under strictly controlled 
conditions.
A standard stimulus provided the most appropriate condition for 
studying growth hormone and Greenwood et al (1968) used the insulin 
hypoglycaemia test. Growth hormone measurements have therefore 
been used in breast cancer mainly either after a glucose load or 
after insulin hypoglycaemia.
Stimulation of growth hormone levels has been used mainly as a test 
of pituitary function (see Study 3) and studies to determine 
differences between women with breast cancer and normal women are 
few. In one study 24 hour growth hormone levels in sixteen women
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with benign disease, seventeen with breast cancer and twenty-five 
age- and weight-matched controls were measured by Malarkey et al, 
1977. The serum GH concentrations and the pattern of GH secretions 
were similar in all the groups evaluated.
Defects in studies
There appears to be no consensus of opinion that there is a 
difference of either urinary or plasma oestrogens between women with 
breast cancer and normal women. More consistent results were 
reported on C-19 steroids, both in urine and plasma. However the 
abnormality of urinary 11-deoxy-17-oxo steroids reported in patients 
with advanced breast cancer may be a non-specific effect of illness. 
So also may the r e d u c e d  c o n c e n t r a t i o n  of p l a s m a  
dehydoepiandrosterone sulphate be due to secondary effects. The 
results of measuring C-19 steroids in the plasma of patients with 
early breast cancer are more equivocal. Part of the confusion may 
be caused by poor matching of breast cancer patients and control 
women. The need to study well-matched groups is obvious. The 
type of plasma sampling, for the various hormones, used also seems 
to vary from study to study. The types of control women used have 
also been variable. Sometimes, single blood sampling has been 
carried out and sometimes multiple samples over long periods of 
time. Although progesterone, growth hormone, thyroid stimulating 
hormone, prolactin and gonadotrophins all appear to be within normal 
limits, the need for multiple sampling over a period of time is 
required if one is to take into account the cyclical variation of 
these hormones. This is particularly important in the case of
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gonadotrophins and prolactin.
Plasma Hormone Levels in Women with Breast Cancer
2. Objective of Study
a) The object of this present study was to study precisely a small 
group of very well matched breast cancer patients and controls - not 
only matched for age, but for parity and years past the menopause.
b) To use a precise multiple plasma sampling regime, and a well 
recognised radioimmunoassay (see method section). Sequential 
samples of blood were taken at 15 minute intervals for 8 hours from 
individual patients with breast cancer and the levels of plasma LH, 
FSH, oestradiol-17B, testosterone, prolactin and cortisol were 
compared with the levels in control postmenopausal women carefully 
matched for age, parity and last menstrual period.
3. Methods in Patient Sampling
Postmenopausal women were specifically chosen for the study because 
it was felt a more accurate and detailed comparison could possibly 
be made between the women with breast cancer and the control women 
only if the age, parity and years past the menopause were accurate. 
It seemed that a truly accurate hormonal status could not be 
achieved in premenopausal women due to the variability of the 
menstrual cycle in some women with variability of the day of 
ovulation and also the possibility of early pregnancy in the control 
pre-menopausal women. The study therefore was carried out only on
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postmenopausal women.
a) Women with Breast Cancer
All patients studied had presented with histologically proven 
cancer, diagnosed initially either at the Breast Clinic of the 
Department of Clinic Surgery, or at the Combined Breast Clinic in 
the Radiotherapy Department of the Royal Infirmary, Edinburgh. The 
patients were classified as having either primary or advanced 
disease. Primary disease was considered to be present when 
detectable tumour was limited to one breast and its lymph nodes with 
no evidence of local or distant metastatic disease. This, 
therefore, was amenable to surgery which involved removing the 
breast and examining the lymph glands in the axillary tail later. 
If these glands proved histologically to contain tumour then the 
patient was treated with radiotherapy six weeks after mastectomy. 
Advanced breast disease existed when tumour cells had spread beyond 
the breast and axilla to a distant site. The histology of this was 
proven by biopsy in as many cases as possible. This disease was 
out of the scope of local surgery and required treatment either by 
local radiotherapy to the primary lesion or systemic therapy either 
by hormone manipulation or chemotherapy. The patients were further 
subdivided according to menstrual status as follows:-
1. Premenopausal : patients menstruating regularly
2. Menopausal : patients with irregular periods
or within 5 years of the last 
menstrual period.
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3. Postmenpausal : patients beyond 5 years of their
last menstruation.
A detailed clinical history was taken from all new patients on their 
arrival at either of the above clinics. This included noting the 
duration of disease, previous treatment and time which had elapsed 
since that treatment.
In an effort to detect invasion of the other breast or skeletal 
metastases, all patients were given standardised mammography and 
thermography of both breasts and a full skeletal survey of x-rays. 
All patients wherever possible, had pathological confirmation of 
their disease either at the time of mastectomy or by biopsy of 
assessible tumour in advanced disease.
b) Control Women
The controls were all normal women attending the Regional Blood 
Transfusion Centre as blood donors. All were volunteers with no 
previous history of breast disease, thyroid or any other endocrine 
disorders. None were taking drugs.
Design of Study
Six patients with early or advanced breast cancer were studied and 
paired with six control women matched for age, parity and last 
menstrual period. The details of the two groups are shown in table 
VII.
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TABLE V I I
Controls
Control Age Years since Menopause Parity
1 69 2 1 1 + 0
' 2 62 15 0 + 0
3 55 9 0 + 0
4 55 1 2 2 + 0
5 73 2 1 0 + 0
6 61 1 0 2 + 0
Cancer Patients
Cancer
Patient Age
Years since 
Menopause Parity
1 73 2 2 3+0
2 65 17 0 + 0
3 53 7 0 + 0
4 56 9 5+0
5 76 25 0 + 0
6 56 1 0 2 + 0
Details of patients with breast cancer and their 
matched controls
The cancer group consisted of two patients with early breast cancer, 
two with advanced local disease and two with disseminated disease. 
Four patients were tested as hospital in-patients, and two attended 
as out-patients. The control women were all out-patients. The 
blood samples were taken as described for multiple blood samplings, 
every 15 minutes for 8 hours, the plasma was assayed for LH,FSH, 
oestradiol-17B, testosterone, prolactin and hydrocortisone 
(cortisol).
The mean concentration of each hormone for the six patients during 
the 15 minute period was calculated and compared graphically with 
the mean of the six controls.
4. Results of Study
The results are shown in Fig. 9*
In the graphs, means were calculated for a period of time by the 
clock. Some points on the graph at either end did therefore 
represent the means of five or even four patients. For this 
calculation, only samples of those 15 minute periods by the clock 
for which there were both test and control samples were included. 
' Results are shown in table VIII.
The mean concentrations of oestradiol-17B, LH, FSH, and cortisol did 
not differ between the six patients with breast cancer and their 
matched controls. However, prolactin and testosterone did differ.
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Plasma hormone concentrations in patients with breast cancer and 
in controls.
TABLE V I I I
PLASMA HORMONES
L
U
cancer
.H.
/L
control
F.
U
cancer
S.H.
/L
control
TESTOS 
n m 
cancer
TERONE
ol/L
control
OESTRA 
p m 
cancer
0 IO L 17/3 
ol/L 
control
PROL
m
cancer
IVCTIN
J/L
control
COR1 
n m 
cancer
risoL
ol/L
control
1 28.8 26.2 120.5 154.5 1.52 1.36 83.8 69.5 90 90 424 358
2 42.2 34.9 174.0 193.9 0.60 0.53 60.7 44.5 160 180 319 328
3 53.9 35.0 219.2 84.9 0.97 0.60 51.8 65.4 180 100 375 333
4 35.3 42.5 170.5 135.5 0.75 0.44 54.4 50.0 400 140 369 369
5 28.3 41.4 147.1 185.9 1.33 0.36 77.2 36.4 220 150 361 380
6 45.9 53.4 176.2 152.5 1.26 0.52 66.2 51.8 200 120 264 377
mean
difference 0.17 16.72 0.44 12.7 78 5.5
P
(Wilcoxon's 
test)
N S NS C 0.05 < 0.1 N S N S
NS : not statistically significant p > 0 .1
Comparison of sample means for each patient compared with 
those of each time matched control.
The difference in prolactin concentrations was sharply accentuated 
by the levels in one patient (number 4 in table VII) who was 
subsequently found to have been taking Thyroxine 0.1 mg./day and 
spironolactone plus hydroflumethiazide 2 5  mg three times a day, 
before the test; accordingly the prolactin concentration for this 
patient was excluded and the date from the group were re-calculated. 
This is shown in Fig. 10. In table VIII the p. value for 
prolactin has been calculated without patient No. 4.
A significant difference (at the 5$ level) was observed in the 
plasma testosterone concentrations which were higher in every woman 
with breast cancer than in the matched control. Five patients had 
also higher plasma oestradiol-17B levels, but this only reached 
significance at the 10$ level. Both plasma testosterone and 
oestradiol-17B levels however, were within the normal range for 
post-menopausal women although the cancer group had higher values 
within this normal range.
A statistical analysis of the sequential samples in both patients 
and controls was carried out to determine if there was a detectable 
fluctuating pattern in hormone concentration during the eight hour 
period. These values were obtained from each woman separately and 
the amalgamated results are presented. In a relatively short series 
of observations, the results of statistical tests from an individual 
woman are not likely to demonstrate significant differences from 
randomness values unless the pattern is obvious. However, an 
overall test of randomness within the group of subjects may be based
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Fig. 10
Plasma prolactin concentrations in five patients with breast 
cancer and in five control women.
on the sum of the number of turning points. These amalgamated 
results are presented separately for patients with breast cancer and 
their controls as well as for all subjects studied. (Table IX). LH 
showed no significant pattern while the results for prolactin, FSH 
and cortisol showed fewer turning points than would be expected by 
random variation indicating changes in these variables during the 
observation period of eight hours. Cortisol concentrations showed a 
pronounced fall 2 hours or more after starting the test, usually 
followed later by a rise. The pattern for prolactin was not 
consistent for all women and generally showed only undulations from 
sample to sample. 0estradiol-17B and testosterone levels both showed 
significantly more turning points than would be expected by random 
fluctuations.
A Moore-Wallis test was also used and showed that the pattern was 
significantly different from random in prolactin and oestradiol-17B 
but in neither of these cases did examination of the plots show any 
evidence of a pulsatile pattern. (Table X). If anything, there 
was a morning fall in prolactin and the oestradiol-17B fall was in 
the evening. The results of this test also showed that neither LH 
or FSH showed a pulsatile pattern or trend in either the patients 
with breast cancer or the control women.
5. Discussion 
Plasma testosterone
The mean value found in normal postmenopausal women was 0.63 nmol/1 
- range 0 .1 7-1 *9 1 nmol/ 1  and it is in keeping with those reported by
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TABLE X.
Moores Wallis Test
Cancers
n (up) Exp (ups) var (t) Z
LH 80 83 14o 8 -0.78
Pr 64 78 13o9 *-3.75
E 2
84 8 6 15.3 -0.71
FSH 92 91 16.2 0.25
Controls
n (up) Exp (ups) var (t) Z
LH 59 59 0 0
Pr 48 54 1 0 o0 -1.89+
' E 2 59 66.5 1 2 , 1 -2.16 sig 5% 
level
FSH 64 69.5 1 2 o6 -1.55
* significantly fewer upwards than downwards trend
f not quite significant at the 5% level, but in the 
same direction as above
Pattern of sequential sampling in patients and controls 
and significance of differences - using the Moore- 
Wallis Test
This table compares the number of ups on the graph with 
the number of expected ups (Figure p 71)
other workers (Wang et al, 1975; Chakravarti et al, 1976). Plasma 
testosterone levels showed significantly more turning points over 
the sampling time, than would be expected by random fluctuations. 
There was, however, no definite pulsatile pattern, either in the 
women with breast cancer or in the control women. At no time did 
these fluctuations vary outwith the normal range. A zig-zag 
serial pattern of change was present which might be explained either 
due to technical reasons or due to biological reasons. The number 
of samples which could be included in. a single run of testosterone 
assay was limited, and for this reason alternate samples from all 
individuals were taken for each run. Alternatively, these 
fluctuations of plasma testosterone levels agree with the findings 
of Rosenfield and Helke (1974) who, in a study of premenopausal 
women, reported small random fluctuations in testosterone levels 
superimposed upon a diurnal rhythm, which was greater than could be 
accounted for by the imprecision of the method. In another study 
(Tyler et al, 1975) plasma testosterone was measured at 4 hourly 
intervals for 24 hours in nine premenopausal women and the results
showed considerable individual variation in both concentrations and
v\
the pattern of the serial samples.
Although the plasma testosterone levels in breast cancer patients 
were within normal limits, each of the six women with breast cancer 
had significantly higher plasma testosterone values than her matched 
control at each time. Others have also reported that plasma testo­
sterone levels are within normal limits in patients with breast 
cancer (Horn and Gordon, 1974; Wang et al, 1975; Jones et al,
83
1977; Malarkey et al, 1977). No differences, however, were 
observed in these previous studies between the women with early or 
late breast cancer and normal controls. The failure of these 
workers to produce similar findings to this present study may be 
explained by the non-use of sequential plasma sampling by some and 
the use of group comparison rather than matched pairs. As C19 
steroid hormones have been shown to vary with the number of years 
past the menopause (Chakravarti et al, 1976) it is important that 
patients should be matched at least for age and years past the 
menopause. The significance of the high normal circulating plasma 
testosterone levels shown in this study must remain in doubt until 
larger numbers have been studied. It is impossible to assess the 
real importance of testosterone in breast cancer until different 
risk groups are compared and to determine whether small differences 
in plasma testosterone could cause the disease in patients already 
predisposed, or whether these differences are just casually related 
to the disease.
It may be important that testosterone can be metabolised by human 
breast cancer to form oestradiol-17B. The possibility exists that 
higher testosterone levels might result in higher oestrogen 
concentrations within the tumour (Miller and Forrest, 197*0.
A certain amount of biological evidence exists that women with 
breast cancer are more androgenic than normal women. Some workers 
have suggested that ovarian interstitial tissue is a gland of 
internal secretion concerned with the formation of androgens (Rice
and Savard, 1966). Evidence for this is supported by a study from 
Grattarola (1973) who found the excretion level of testosterone to 
be significantly increased in patients with endometrial hyperplasia 
and in patients with breast cancer who had an atypical endometrial 
pattern. Breast cancer patients with anovulation and endometrial 
hyperplasia also presented with higher urinary testosterone levels 
than the women with endometrial hyperplasia but no breast cancer. 
In a later report, Grattarola and his colleagues found increased 
urinary testosterone values in patients with advanced breast cancer 
with metastases present, but not in patients who were clinically 
cured. They concluded that increased androgenic activity was the 
hormonal factor involved in the development of breast cancer 
(Grattarola, 1975). Other workers have reported that women with 
breast cancer in Britain secrete sebum at a higher rate that normal 
women (Krant et al, 1968; Burton et al, 1970). As sebum secretion 
may be increased by androgens, this would indirectly add support to 
the possibility of raised plasma testosterone levels in women with 
breast cancer.
There is, however, evidence that low excretion of plasma dehydro- 
epiandrosterone sulphate (DHAS) and dehydroepiandrosterone (DHA) and 
urinary aetiocholanolone may be associated with an increased risk 
and the presence of breast cancer (Buibrook et al, 1967a). On the 
other hand, there is also evidence of a converse effect. Young 
Japanese women who have a low risk of breast cancer have been 
reported to have lower urinary excretion of androgen metabolites 
than their Western counterparts (Bulbrook et al, 1967b). It may be
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important to note that plasma DHAS and DHA are almost exclusively 
adrenal in origin, whereas an increase in testosterone excretion is 
more likely to be associated with ovarian abnormality.
Since this study, further studies on multiple plasma testosterone 
concentrations have been reported.
The mean 24 hour serum testosterone levels (by radioimmunoassay) was 
measured in sixteen women with benign breast disease, seventeen 
patients with breast cancer and in twenty-five age- and weight- 
matched control women. Mean 24 hour testosterone levels were found 
to be significantly elevated in women with breast cancer in the 
luteal phase of their cycles but were normal in postmenopausal 
breast cancer women (Malarkey et al, 1977)9 while in another report 
(Adami et al, 1979) significantly higher mean plasma testosterone 
levels were found to be present in one hundred and twenty-two 
postmenopausal patients with newly diagnosed breast cancer as 
compared to the values in one hundred and twenty-two age-matched 
control women.
A further study by Jones et al (1981) reported that plasma testo­
sterone levels (total and apparent free) were measured in one 
hundred and forty-seven women - age range between 14 and 9 0  years 
(mean 53 years). Forty-five of these women were normal controls 
and the remainder were classified into groups, those with 
histologically confirmed benign (twenty) or malignant breast tumours 
(seventy-one) and those with non-metastatic cancer at other sites
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(eleven). In the malignant breast group forty-three were 
classified as early and twenty-eight as advanced breast disease. 
The women were then further categorized as in the present study into 
menopausal status and years past the menopause. No significant 
difference was found in the plasma testosterone levels between any 
of the clinical groups. It would seem that although there may be 
some abnormality in plasma androgens in breast cancer, particularly 
in patients with advanced disease, the levels of the plasma 
androgens, such as testosterone, compared and expressed as a group 
are apparently variable depending on the format of the study.
0estradiol-17B
The mean value for plasma oestradiol-17B concentrations in the 
normal postmenopausal women was 5 3  pmol / 1  - range 15-110 pmol/1 . 
This is in agreement with other workers (Baird and Guevara, 1969; 
Vermeulen and Verdonck, 1978; Bird et al, 1981). With regard to 
variation throughout the day, plasma oestradiol-17B concentration in 
both groups of women studied, was found to have more turning points 
than would be expected by random fluctuations. Graphically, the 
plots showed no evidence of a pulsatile pattern, but the levels of 
plasma oestradiol-17B tended to fall in the evenings. These 
findings agree with a study by Alford et al (1973) who found that 
plasma oestradiol-17B levels showed wide fluctuations throughout the 
day in two premenopausal women, a consistent pulsatile pattern not 
being observed.
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Plasma oestradiol-17B levels in postmenopausal women with breast 
cancer were higher, though within normal limits, than in the control 
women. A significant difference was not proved. These findings 
are in agreement with previous reports of normal values in patients 
with breast cancer (Wang and Swain 197^> England et al, 197^5 
Malarkey et al, 1977).
Since the work was completed, it has also been reported by Adams et 
al (1 9 7 9 ) that plasma oestrone (also A 4 androstenedione and testo 
sterone) were significantly higher in postmenopausal patients with 
newly-diagnosed breast cancer compared to the levels found in age 
matched normal women. In the control group of women, plasma 
oestrone levels were shown to be significantly correlated with 
plasma A 4  androstenedione and testosterone, but in the cancer 
group plasma oestrone was only slightly correlated to testosterone 
and was not correlated to androstenedione. These workers
concluded that an incresed availability of A 4 androstenedione and 
testosterone led to increased androgenic stimulation, decreased 
availability of sex-hormones binding globulin and an increased 
plasma oestrone level. There is also a report by Drafta et al 
(1980) that levels of plasma oestradiol-17B were subnormal in 
premenopausal patients with breast cancer in the late cycle, as 
compared to control women, while in postmenopausal patients, plasma 
oestradiol-17B was significantly higher in the breast cancer group. 
Bird and his colleagues (1981), however, found no significant 
difference in plasma oestradiol-1 7 B or oestrone levels between 
postmenopausal patients with breast cancer (Stage 1 and 2) and
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normal postmenopausal women.
In another report, Moore and his colleagues (1982) studied total and 
non-protein-bound-oestradiol-17B in pre and postmenopausal patients 
with Stage 2 breast cancer and in normal control women. They 
reported that in premenopausal women with breast cancer, total serum 
oestradiol-17B levels were normal, but non-protein-bound-oestradiol- 
17B levels were raised. In the postmenopausal group with breast 
cancer, both total and non-protein-bound-oestradiol-17B levels were 
significantly elevated. In these patients, the sex-hormone-binding 
globulin (SHBG) was lower and there was a highly significant 
correlation between non-protein-bound-oestradiol-17B and SHBG, but, 
for a given SHBG binding capacity, the cancer patients had more non- 
protein-bound-oestradiol-17B than controls. These workers 
suggested that the breast in women with breast cancer may be exposed 
to elevated levels of biologically active oestradiol-17B (ie. 
unbound).
Prolactin
The mean plasma prolactin value for the control women was 140 mu/1 
range 5 0 - 7 8 0  mu/1 , which is in agreement with the findings of other 
workers (Kumaoka et al, 1976; Malarkey et al, 1977)* No pulsatile 
pattern of plasma prolactin was found - only undulations in both 
groups of women over the test period. The prolactin concentrations 
were found to be lowest in the morning which agrees with previous 
work in which prolactin was reported to be lowest at 1 2  noon 
(Vanhaelst et al, 1973; Parker et al, 1975). The variation in
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plasma prolactin levels did not correspond with the plasma cortisol 
levels which were highest in the morning and became lower in the 
afternoon. Therefore, it is unlikely that prolactin levels were 
increased by the stress of venepuncture. LfHermite et al (1972) 
have also shown that only rarely does venepuncture cause blood 
release of prolactin.
No differences were found in plasma prolactin levels between 
patients with breast cancer and the matched control women. Other 
workers have also failed to show differences in prolactin levels 
(Franks et al, 1974; Kwa et al, 1974; Wilson et al, 1974). 
Malarkey and his colleagues (1977) reported nocturnal levels of 
prolactin to be diminished in twelve postmenopausal women with 
breast cancer compared to the levels in control women. The daytime 
and mean prolactin levels and patterns of secretion, however, were 
not different between the two groups. More recently, it has been 
reported that significantly higher plasma prolactin values (on a 
single morning sample) are present in postmenopausal women with 
early breast cancer than in postmenopausal control women (Bird et 
al, 1 9 8 1 ).
Plasma Cortisol
The plasma cortisol values were within normal limits, throughout the 
test period (Control mean 358 nmol/1 - range 193-716 nmol/1). 
Levels were highest at the beginning of the test period and then 
declined, reaching a steady state after about two hours. This 
suggests that the patients may have been under stress at the
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beginning of the test period, the cortisol level returning to normal 
after two hours. More likely, the higher values at the start of 
the test and the falling levels throughout the morning were due to 
normal diurnal variation (Hamanaka et al, 1970). Only part of this 
variation was observed in the present study as there were no 
observations between 6 - 8  a.ra. or at 1 2 midnight.
The report by Malarkey et al (1977) or an elevated plasma cortisol 
at 4 pm in breast cancer patients was not substantiated by this 
study.
There was no difference in the mean levels between the cancer and 
control patient.
Plasma Gonadotrophins
The mean value of plasma LH (38.9 u/1 range 15-100 u/1) and plasma 
FSH (151.2 u/1 range 50-300 u/1) described in this study for control 
women agrees with that quoted by other workers for normal post­
menopausal women (Yen et al, 1972; Kumaoka et al, 1976; Wang et 
al, 1976; Malarkey et al, 1977).
Plasma FSH levels in both groups showed small changes during the 
observation period. These probably represent random fluctuation in 
levels detected between samples, there being no consistent evidence 
for a pulsatile pattern of plasma FSH. Plasma LH levels showed no 
fluctutations at all.
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Episodic, pulsatile pattern of plasma gonadotrophins have been 
reported in normal women (Midgely et al, 1971; Yen et al, 1972; 
Wide et al, 1973). In one study, samples were taken hourly from 
seven premenopausal women and it was reported that plasma LH con­
centrations and possibly FSH were maintained as a series of peaks of 
variable magnitude (Midgely et al, 1971). Later Yen and his 
colleagues (1972) reported changes in plasma LH and FSH levels which 
they described as minute to minute fluctuations resembling a 
pulsatile pattern, with a periodicity of 1-2 hours. However, only 
three women were studied and only two were postmenopausal and both 
of these were early postmenopausal. In another study (Wide et al, 
1973) the changes in plasma LH and FSH levels were described as 
episodic. Seventeen women were studied but only seven were post­
menopausal, and the evidence for a pulsatile pattern in these post­
menopausal women is poor.
In this present study plasma FSH did show some fluctuation, while 
plasma LH levels did not fluctuate, which agree with the graphical 
changes displayed by Wide and his colleagues, whose women were also 
older'than those described by Midgely et al (1971) and Yen et al 
(1972). It could be that with increasing age and declining values 
of plasma LH, the pulsatile pattern is lost.
The inability to detect differences in plasma LH and FSH levels 
between patients with breast cancer and the control women agrees 
with previous work by Wang et al (1976) and Malarkey .et al (1977).
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As neither plasma LH nor FSH levels had a pulsatile pattern of 
secretion either in normal postmenopausal women or in postmenopausal 
women with breast cancer, it would seem unnecessary to assay more 
than one blood sample for gonadotrophins. If, however, multiple 
sampling had been omitted in this study, the small but significant 
difference in plasma testosterone between women with breast cancer 
and well matched controls would have passed unnoticed on one single 
sample which would have been within normal limits. A compromise of 
four half-hourly samples over two hours, as will be suggested for 
the regime for the men with gynaecomastic, is probably suitable for 
the women as well.
Since this study was completed, there have been other reports of 
multiple plasma sampling throughout 24 hour and 8 hour time periods. 
In 197T9 Malarkey et al reported studies in which 24 hour serum 
oestradiol-17B levels were measured in sixteen patients with benign 
breast disease, seventeen patients with breast cancer and twenty- 
five age-matched and weight-matched control women. Samples were 
taken every four hours and a radioimmunoassay was used. These
workers found that the serum concentrations and patterns of plasma
\
oestradiol-17B secretion were similar in all three groups.
Further multiple plasma studies on plasma prolactin have been 
reported. Using a multiple sampling regime, Kwa et al (1978) found 
that nulliparous and obese postmenopausal normal women (at risk of 
developing breast cancer) had raised early evening plasma prolactin 
levels compared to a similar group without such risk factors. The
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same group of workers also reported that evening plasma prolactin 
levels in nulliparous premenopausal women with benign and malignant 
breast disease were increased compared to similar parous women.
Plasma prolactin was estimated at four hourly intervals throughout a 
24 hour span from healthy women, women with benign breast disease 
and women with carcinoma of the breast by Tarquini et al (1980). 
These showed considerable variations in prolactin levels throughout 
a day and also differences in circadian mesor of prolactin among the 
groups were significant. This underlined the importance of 
multivariable and multifrequency investigations in breast cancer. 
An increase in 24-hour mean luteal phase plasma prolactin level was 
reported in thirteen young females whose mothers had breast cancer. 
These females were also found to have a partial resistance of 
prolactin to dopamine suppression (Levin and Malarkey, 1981).
Conclusion
In this study, plasma LH, FSH, testosterone, oestradiol-17B, 
prolactin and cortisol concentrations were all within normal limits 
in these patients with breast cancer, but, within the normal range, 
the plasma testosterone concentrations in each cancer patient were 
significantly higher than in each matched control.
.Study Z. - Effect of Endocrine Treatment j_ Relationship 
of Hormonal Changes
A. Hypophvsectomy - 90 Yttrium implantation and pituitary function 
tests
The pituitary stalk has two elements. One is vascular and is 
concerned with the control of the anterior part of the anterior 
lobe. The other is neural and connects with the posterior lobe in 
continuity with the hypothalamus.
The secretion of hormones produced in the anterior lobe is 
controlled by neurohormones secreted by the cells of the 
hypothalamus and carried down the pituitary stalk in the vessels of 
the vascular connections. This system is called the hypophyseal 
portal system. The active endocrine part of the anterior lobe 
consists of epithelial secretory cells. The human pituitary is a 
confederation of five largely independent functioning units each 
represented by a specific cell type synthesizing and releasing one 
or two pituitary hormones. The older classification of pituitary 
cells into acidophile, basophile and chromophobe types is 
inadequate to explain the independent secretion of six hormones. 
Progress has been made by the application of histochemical 
iramunofluorescent and electron microscopic techniques (Pelletier et 
al, 1978). As a result of these studies, the concept has been 
strengthened that each major hormone is secreted by a distinct cell 
type except both gonadotrophins which are secreted from a single
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cell. Pituitary cells are classified on the basis of the hormone 
secreted. The hormones secreted are growth hormone (GH), 
adrenocorticotrophic hormone (ACTH), thyroid stimulating hormone 
(TSH), gonadotrophins, follicular stimulating hormone (FSH) and 
luteinizing hormone (LH) and prolactin (HPr). Unlike the majority 
of anterior pituitary hormones which are under hypothalamic 
stimulatory control by releasing factors, prolactin is under tonic 
and clonic inhibitory control. This control is exercised by the 
median eminence of the hypothalamus. The neuroinhibitor in the 
case of prolactin (HPr) has been termed prolactin inhibiting factor 
(PIF). The existence of a prolactin releasing factor (PRF) has 
also been postulated. The normal physiological level of prolactin 
is maintained by short (pituitary-hypothalamic-axis) and long 
(systemic-hypothalamic-pituitary) feedback mechanisms. Proof that 
prolactin activity is due to escape from a hypothalmic inhibitory 
factor comes from observations that the addition of a hypothalamic 
extract inhibits the secretion of prolactin into the culture media 
(Pasteels, 1963). The presence of an inhibiting factor has also 
been demonstrated in other studies in which hypersecretion of 
prolactin has been observed in experimental animals after pituitary 
stalk section, following the creation of specific median eminence 
lesions or by transplantation, of the pituitary gland to other sites 
(Meites and Nicoll, 1966). In man, pituitary stalk section leads 
to an increase in the concentration of prolactin in the plasma 
(Newsome et al 1971).
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There is no direct evidence of the existence of a factor which 
stimulates prolactin secretion in mammals but such a factor probably 
plays a part in the maintenance of normal prolactin levels by means 
of the short (internal) feedback control. Although PRF has not 
been isolated, injections of pure thyrotropin releasing hormone 
(TRH) in humans causes an elevation of plasma prolactin levels and 
of thyroid stimulating hormone (TSH).
In the early 1950s only the estimation of urinary gonadotrophins was 
available for the direct assessment of pituitary function. Studies 
of pituitary function in patients with breast cancer was therefore 
limited to this particular group of hormones. The measure of 
gonadotrophin function most frequently used was the increase in 
mouse uterine weight, following the injection of an extract of urine 
which estimated both FSH and LH (Klinefelter et al 1953)* The 
development of a method using adsorption on to kaolin with elution 
followed by acetone precipitation (Loraine & Brown, 1956) allowed 
large volumes of low-titre urine to be extracted, which gave 
consistent and reliable results. The estimation of urinary 
gonadotrophins was used as a direct measure of pituitary function 
following attempted ablation of the pituitary gland. In eleven out 
of twelve patients studied at the Mayo Clinic, gonadotrophin 
secretion fell to zero within three to ten days of surgical 
hypophysectomy (Blackburn et al, 1956). Paradoxically, Lipsett & 
Pearson (1956) recorded significant gonadotrophin excretion in two 
patients after surgical removal of the pituitary, despite subsequent 
autopsy evidence that this was complete. However, the method of
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assay used (Klinefelter et al, 1953) lacked precision.
During the 1960*s the development of radioimmune-assays allowed a 
method to become available for the estimation of growth hormone (GH) 
in the blood. Tests evolved in which the release of growth hormone 
was stimulated by hypoglycaemia indirectly by the injection of 
insulin; following which plasma levels of GH were sequentially 
measured. (Greenwood, Landon & Stamp, 1966). These tests were 
used to estimate the completeness of destruction of the pituitary 
e.g. following yttrium implantation. In one such study, reported 
by Stewart et al (1971)» histological assessment of destruction of 
the pituitary gland after yttrium implantation was correlated with 
the results of the insulin test. It was reported that an absent GH 
response to hypoglycaemia was associated with an almost complete 
destruction of the pituitary gland. In a further study the growth 
hormone response to insulin induced hypoglycaemia after yttrium 
implantation was compared with that after transethimoidal 
hypophysectomy. There was no difference between these two 
procedures in terms of the degree of pituitary ablation achieved, 
although persistent small but significant fasting levels of GH which 
did not respond to the hypoglycaemic stimulus was more common after 
yttrium 90 implantation. It was suggested that this probably arose 
from pituitary remnants divorced from hypothalmic control (Roberts 
et al, 1973).
By the 1970*s as a result of the further development of precise 
immunoassay techniques it became possible to estimate most of the
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hormones in the plasma. This included luteinizing hormone (LH), 
follicular stimulating hormone (FSH), thyroid stimulating hormone 
(TSH) and prolactin (HPr). More recently the hypothalamic 
releasing hormones - luteinizing releasing hormone and follicle 
stimulating releasing hormone (LH/FSH - RH) and thyrotropic 
releasing hormone (TRH) have been synthesised and are available for 
clinical use. Direct stimulation of the pituitary with subsequent 
estimation of circulating trophic hormones (LH,TSH, FSH) can now be 
used to assess pituitary reserve. Plasma concentrations of LH and 
FSH thereby increase if functioning gonadotrophic cells are present 
in the pituitary. Similarly TRH administration raises the plasma 
levels of TSH and also prolactin (Bowers et al, 1971) while 
chlorpromazine is also known to raise plasma prolactin 
concentrations (Turkington, 1972,b). Thyroid stimulating hormone 
(TSH) secretion after the administation of synthetic TRH has been 
extensively studied both in normal people and in patients with 
hypothalamic-pituitary disease (Fleischer et al, 1970; Hall et al, 
1972). Similarly LH and FSH response to synthetic LH/FSH-RH have 
been reported in normal people (Besser et al, 1972). These 
releasing hormones have been found to be specific and secretion of 
other pituitary hormones was unchanged after TRH and LH/FSH-RH 
administration (Fleischer et al, 1970). Initially for the 
assessment of pituitary function each provocative test was used 
separately involving the patient in a considerable number of tests, 
A single test, similar to that described by Harsoulis et al, 1973» 
has been developed and evaluated, this with the objective of causing 
ill patients with breast cancer as little upset as possible.
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Results of these tests have been correlated with other estimates of 
pituitary function and also with the clinical response to removal or 
destruction of the pituitary gland.
2. Methods
Hypoglycaemia could be worrying in the pituitary ablated patient and 
the growth hormone test that was used in the present study was the 
insulin infusion test of Carter, Dozois & Kirkpatrick (1972). For 
stimulation of LH, FSH and TSH secretion the releasing hormones LHRH 
and TRH were used. For prolactin stimulation tests using TRH and 
chlorpromazine were carried out. TRH has a direct action on the 
pituitary prolactin secretion, (Lister et al, 1974) while 
ohlorpromazie acts indirectly on the pituitary by the inhibition of 
release of prolactin inhibiting factor. This is brought about by 
blocking dopamine uptake into storage granules in the hypothalamic 
nuclei (Friesen et al, 1972; Leblanc and Yen, 1976)
The patients with breast cancer were assessed for clinical response 
to Y90 six months after treatment, according to the criteria 
suggested by the British Breast Group (1974). Patients were 
grouped as responders, non-responders and those with an equivocal 
response.
Thirteen patients with breast cancer were investigated, nine 
patients before and one month after Y90 implantation, and four post- 
operatively only. In addition three patients with diabetic 
retinopathy were studied. Two of these had tests before and again
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one month after; only one post-operatively. The pituitary 
function tests used were:
a) LHRH test
b) LHRH plus TRH test
c) Insulin infusion test
d) LHRH plus TRH plus insulin infusion test
e) Chi or promazine test.
Test Procedure
The pattern of test undergone by the patients are shown in Table XI. 
Most patients on day one had LHRH alone (Table XI), on day two LHRH 
plus TRH followed afterwards by the insulin test and on day three 
the chlorpromazine test. Other patients (6,7 and 8) had a 
combination of LHRH plus TRH plus insulin on day one and 
chi or promazine on day two.
2. Pituitary Function Tests
a) LHRH Test
The patient was fasted overnight and kept in bed the morning of the 
test. An 18G. teflon cannula was inserted into an arm vein and a 
basal blood sample was withdrawn. A second basal sample was taken 
after 10 minutes and 100 ug. LHRH injected through the cannula. 
Blood was withdrawn at 10,20,30 and 60 minutes, centrifuged and the 
plasma (serum) deep frozen and subsequently assayed in batches for 
LH and FSH as described in the Method Section.
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TABLE XI
Patient Number
LHRH
(a)
LHRH
TRH
(b)
Insulin
(c)
LHRH
TRH
Insulin
(d)
Chlorproma-
zine
(e)
1 OX OX OX - OX
2 OX ox ox - OX
3 ox ox ox — ox
4 ox ox ox - ox
5 ox ox ox - ox
6 -
•
- OX ox
Breast 7 - - - OX ox
8 - - - ox ox
Cancer 9 0 ox ox - ox
10 X X X - X
11 X X X - X
12 X X X - X
13 X X - - X
Diabetic 1 - ox ox - ox
Retinopathy 2 - ox - - ox
3 - X X - X
0 - Test done pre y-90 
X - Test done post y-90
Tests of pituitary function carried out
b) LHRH Plus TRH Test
The patient was fasted overnight and kept in bed the morning of the 
test. An 18G. teflon cannula was inserted into an arm vein and a 
basal blood sample was withdrawn. Following a second basal sample 
100 ug. LHRH plus 200 ug. TRH was injected through the cannula. 
Blood was then withdrawn at 10, 20, 30 and 60 minutes and deep 
frozen and subsequently assayed in batches for LH, FSH, TRH and 
prolactin.
c) Insulin Infusion Test
After the completion of the LHRH plus TRH test, a 21G. butterfly 
needle was inserted into a vein in the dorsum of the hand. Blood 
was withdrawn from a cannula in the other arm. Following two basal 
samples at 15 minute intervals, infusion of insulin was commenced at 
a constant rate to deliver 0.04 u/kg/hour. Blood was withdrawn at 
30, 60, 90 and 120 minutes for GH and blood glucose.
d) LHRH plus TRH plus Insulin Test
Patients were again fasted and as before, a cannula was inserted 
into one arm. Two basal samples of blood were taken. A butterfly 
needle 21G. was inserted into a vein on the dorsum of the other hand 
and through this 100 ug. LHRH and 200 ug. TRH were injected. An 
insulin infusion using a dose of 0.04 u. insulin/kg. body 
weight/hour was immediately commenced through this needle and blood 
was withdrawn from the cannula in the other arm at 10, 20, 30, 40, 
60, 90 and 120 minutes. The basal samples were used for the 
measurement of LH, FSH, prolactin, TSH, GH and blood glucose; those
1 02
at 10, 20, 30, 40 and 60 minutes for LH, FSH, TSH and prolactin, and 
those at 30, 60, 90 and 120 minutes for GH and blood glucose.
e) Chlorpromazine Test
Patients were fasted and as before, a cannula was inserted into an 
arm vein through which basal samples were taken. Chlorpromazine 
(50mg.) was injected intramuscularly into the buttock and blood was 
withdrawn at 30, 60, 90 and 120 minutes and assayed for prolactin.
3. Results
Measurement of Pituitary Function
I. Before Implantation of the Pituitary
The typical response of plasma hormone levels to the stimulation 
used in a patient with breast cancer tested before and one month 
after yttrium implant is shown in Fig. 11. It can be seen that the 
peak circulating concentration of the various hormones occurs at 
different times after injection of the stimulating agent. For each 
hormone the increment in hormone concentration on stimulation has 
been calculated by subtracting the basal value from the observed 
concentration. For each test the average of these increments at 
specified times after injection was calculated. Specified times 
were those when the hormone concentrations were greatest. These 
times are listed in Table I.
The median and range of these increments for each test is given in 
Table XII. The majority of patients showed a large hormonal 
increment to the appropriate releasing hormone.
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pre post Y90
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Fig. 11
Measurement of pituitary function in a patient aged 70 years 
before and after yttrium implant.
TA B LE  X I I
Before y90 Implantation
Test No of patients
Median of
hormonal
increments
Range of 
hormonal 
increments
GH/insulin 10 25 mU/1 7 - 9 3  mU/1
LH/LHRH 6 15 U/l -1 - 73 U/l
LH/LHRH + TRH 10 32 U/l 3.5 - 67.5 U/l
FSH/LHRH 6 20 U/l 3.5 - 95 U/l
FSH/LHRH + TRH 10 26 U/l 4.5 - 83.5 U/l
Prolactin/LHRH + TRH 11 880 mU/1 70 - 1560 mU/1
Prolactin/Chlorpromazine 11 550 mU/1 -350 - 840 mU/1
TSH/TRH 11 10 mU/1 0 - 20.5 mU/1
Median and range of increments of hormone concentration in 
patients before y90 implantation.
The exceptions were one patient (No. 1 in response group), Table 
XIII, who showed very little response to LHRH in either test and low 
prolactin response to chi or promazine. Another two patients had 
negative prolactin response to chiorpromazine (patients No. 2 and 4 
in the non-response group), and a further two a low TSH response to 
TRH (patients No. 3 and 5 in the non-response group).
The mean incremental hormone levels for each test are plotted 
against time in Figure 12. All patients undergoing the tests 
before yttrium 90 implantation are included. For this purpose the 
results for the simultaneous LHRH plus TRH plus insulin test have 
been combined with the results in those patients in whom LHRH plus 
TRH and insulin were given on separate days.
Comparison of Tests of Pituitary Function before yttrium Q0 
implantation
(1) LHRH alone and LHRH Plus TRH.
Five patients underwent both stimulatory tests before Y90 implant. 
Levels of plasma LH and FSH increments in hormone concentrations to 
the two tests were compared using VJilcoxnfs signed rank test. 
There was no significant difference between the mean increments in 
concentrations of LH and FSH for LHRH alone or in combination with 
TRH. Also the two tests produced a very similar ordering of the 
five patients with respect to the increments of the concentration of 
hormones in Spearman1 sp/=0.9 just significant at 5% level.
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TABLE . X I I I
Pre-Implant
Patients GHmU/1
LH
U/l
FSH
U/l
Hpr (TRH) 
mU/1
Hpr (Chlor) 
mU/1
TSH
mU/1
1 7.7 3.5 4.5 990 50 20.5
2 - - - — — -
Responders 3 - - - - - -
4 33 35.5 31.5 420 130 11.5
1
Equivocal
2 16.7 19.5 19.0 1560 61 5
1 16.7 66 83.5 910 550 8.5
2 7.0 32 27.5 380 -350 15
3 37.0 67.5 59.0 1130 690 0
Non- 15.0 38.0 6104 — 50 7Responders
5 39.0 36.5 25 880 170 1.5
6 60.0 - - 580 770 5
7 — — — —
Increments in plasma hormone concentration in individual patients
90wrth advanced breast cancer before Yttrium implantation
MEAN HORMONAL RESPONSE WITH TIME -  PRE-IMPLANT
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Fig. 12
Mean plasma hormone concentration response with time pre-implant 
for G H, L H , F S H , prolactin and T S H .
(2) Prolactin/TRH and prolactin/ohlorpromazine
Eleven patients underwent both of these tests of prolactin 
stimulation. The prolactin response was greater when stimulated by 
TRH than by chi or promazine (sig. at 5% level using Wilcoxon’s signed 
rank test). Results expressed as medians are shown in Table XII. 
Also the two tests produced a quite different ordering of the eleven 
patients, i.e. (Spearman’s p/ = 0.28 which does not differ 
significantly from zero at the 5% levels). Therefore these two 
different tests of prolactin stimulation are not correlated. The 
time course was different too with an early peak of plasma prolactin 
concentration at about 20 minutes after TRH and a late peak at about 
90 minutes after chiorpromazine.
II. After pituitary implantation
In Table XIV are given the median and range of hormonal increments 
for all patients who were tested before and one month after yttrium 
90 implant of the pituitary.
There is an obvious and significant decrease in pituitary function 
in patients tested after implant compared with those tested before 
(p<0.01 on the Mann Whitney rank sum test for increments of all 
hormones). (See Methods page). Some patients showed a complete 
absence of pituitary function on all tests, whereas others still 
gave a response to one or more stimulatory factors. The results 
for the individual patients can be seen in Fig. 11 and Table XV.
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T A B L E . X IV
-7 UAfter Y Implantation
Test No of patients
Median of 
hormonal 
. increments
Range of 
hormonal 
increments
GH/insulin 14 0 mU/l -2 - 13 mU/l
LH/LHRH 9 2 U/l -0.5 - 4 U/l
LH/LHRH + TRH 16 1 U/l - 2 - 9 . 5  U/l
FSH/LHRH 9 0.5 U/l 0 - 13.5 U/l
FSH/LHRH + TRH 16 1 U/l 0 - 13 U/l
Prolactin/LHRH + TRH 16 100 mU/l 0 - 890 mU/l
Prolactin/Chlorpromazine 16 0 mU/l -50 - 190 mU/l
TSH/TRH 14 1.5 mU/l 0 - 5 . 5  mU/L
Median and range of increments of hormone concentration in 
patients after Yttrium implantation
TABLE XV
Post-Implant
Patients GHmU/l
LH
U/l
FSH
U/l
Hpr (TRH) 
mU/l
Hpr (Chlor 
mU/l
TSH
mU/l
1 0 1 1 170 0 2
Responders
? 0 -2 0 0 0 1
3 -1.67 1 1 50 -50 1.5
4 0 -2 0 0 0 0
Equivocal 1
- 2.5 0 150 -10 1.5
2 0 0.5 0 0 0 0
1 -2 0.5 12.5 350 130 5.5
2 0 -0.5 0 0 0 0
Non- 3 3.3 31 13 890 150 0
Responders 4 0 1.5 0.5 10 -20 3.5
5 13 9.5 10 200 80 1.5
6 0 -0.5 0 0 0 0
7 11 5 1.5 150 -40 1.5
Increments in plasma hormone concentrations in individual patients
90
wrth advanced breast cancer after Yttrium implant.
Comparison of tests of Pituitary Function after YQO Implant
(1) LHRH alone and LHRH with TRH
Nine patients underwent both of these tests of gonadotrophin release 
after Y90 implant. No significant difference could be detected 
between the increments of either LH or FSH to each of the two forms 
of stimulation. The two tests produced a very similar ordering of 
the patients with respect to LH and FSH increments (Spearman1 sp/=0.7 
(LH) and 0.8 (FSH), both significantly greater than zero at the 5% 
level).
(2) Prolactin/TRH and prolaotin/chlorpromazine
Sixteen patients underwent tests of both type after implant. As in 
the tests before implantation the prolactin increment after TRH was 
the greater (sig. at level on Wilcoxon’s signed rank test). 
Results are shown in Table XIV. Patients with a low response to 
TRH tended, however, to have a low response to chlorpromazine, 
although the reverse was not true (Spearman’s p/=0.5 significant at 
5% level).
Pituitary Function and Clinical Response
Of the thirteen breast cancer patients, four had objective 
regression of disease at six months, seven had no response and in 
two the clinical response was equivocal (Table XV). An example of 
a patient with a clinical response after hypophysectomy is shown in 
Fig. 13. The results of the pituitary function tests after the 
implant in patients grouped by clinical response are shown in Fig. 
14. The prolactin response is shown in Table XVI*
106
mt1.
V *
m t h s
yr
Fig. 13
Photographs of skin lesions of a patient with advanced breast 
cancer before, 6 months and 1 year after yttrium implant.
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Increment of plasma hormone concentration after yttrium implant 
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TABLE X V I
Pre-Implant
Stimulant
Plasma Prolactin mU/l
Median Range
TRH 610 70 - 1560
Chlorpromazine 170 -350 - 840
Post-Implant
Stimulant
Plasma Prolactin mU/l
Median Range
TRH 95 0 - 890
Chlorpromazine 0 -50 - 190
Mean plasma prolactin concentrations after
stimulation with TRH or Chlorpromazine 
90
before and after Yttrium implantation
Since the administration of TRH with LHRH did not have significantly 
different effects on LH and FSH compared with LHRH alone, the 
results of tests in different patients can be combined. When both 
tests have been performed in one patient an average rate has been 
calculated.
These six patients with an objective or equivocal response showed no 
evidence of pituitary function other than a small increment of 
prolactin when stimulated by TRH (Responders No. 1 and 3 and equi­
vocal responder No. 1 who also had a small TSH increment). (Fig. 14 
and Table XV.
By contrast, only two of the seven patients with no evidence of 
clinical response (non-responders No. 2 and 6) had no hormone 
increments and appeared to have had a complete ablation. Four of 
the patients, Nos. 3> 5 and 7» had considerable increments of all 
hormones, while patient No. 4 had very low increments of LH and TSH 
(Fig. 14 and Table XV).
Because of the small numbers of responders (maximum 4) and the 
limited total number of patients, none of the hormone increments 
could be shown to be significantly different between the non 
responders and the responders plus equivocal responders. 
(Wilcoxon's rank sum test : not significant). However, the results 
quoted above suggest that significantly greater hormone increments 
would be found in the non-responders if these tests were repeated on 
a larger series- of patients.
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4. Discussion
Basal hormone levels after pituitary ablation are often difficult to 
detect even with the most sensitive assay, yet they cannot 
necessarily be regarded as zero. As residual activity may be 
important in continued tumour growth, it is essential to use 
provocative stimulation tests.
Degree of pituitary ablation
Assessing the degree of ablation after Yttrium implantation involves 
measuring the degree of destruction of the pituitary cells. It is 
notable that their resistance to destruction following Yttrium 90 
may vary. Histological studies of pituitaries after implantation 
reveal that surviving pituitary tissue is usually limited to a 
subscapular rim supplied by the capsular vessels. (Forrest et al, 
1959) This variable resistance by some cells may explain why some 
and not other plasma hormones are still present after implantation.
It is necessary to cause as little upset as possible to a patient 
already ill with advanced breast cancer. For this reason the 
various combinations of releasing hormones used in pituitary 
function tests werfc evaluated to allow the simplest combination 
affording the most information about pituitary destruction to be 
used. It was found that the addition of TRH to LHRH given as one 
injection did not affect the plasma, LH or FSH response to LHRH 
alone, either before or after Yttrium implant. The numbers were 
small and the conclusions therefore were tentative but the results 
were consistent with those of Harsoulis and his colleagues (1973).
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A test of pituitary function using LHRH stimulation combined with an 
insulin infusion test for growth hormone was useful. Since TRH 
could be given in combination with LHRH with no extra discomfort to 
the patient, and the addition of TRH stimulated the levels of 
prolactin secretion, the recommended test of pituitary function was 
LHRH plus TRH plus insulin both before and after Yttrium implant. 
A comparison was made between the prolactin response to 
chlorpromazine and TRH stimulation. There was a significant 
difference in plasma prolactin responses, this being significantly 
greater after TRH administration than after stimulation with 
chlorpromazine both before and after Yttrium implant. 
Chlorpromazine tended to produce little prolactin response and this 
apparent suppression of pituitary function was often inconsistent 
with the result of the other stimulation tests including TRH for 
prolactin secretion. The results of the chlorpromazine test was 
therefore ignored in favour of the TRH test for prolactin secretion; 
TRH would appear to be a better stimulant of prolactin than 
chlorpromazine.
The definition of a complete ablation, that following none of the 
stimulation tests was there any evidence of increments of any plasma 
hormones. Incomplete ablation was assumed when the majority if not 
all the tests showed a significant rise in any hormone to any 
stimulation test.
When the patients with advanced breast cancer were grouped by 
clinical response into those with objective regression of disease at
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six months, those with an equivocal response and those with no 
response to Yttrium implantation, a relationship between the degree 
of pituitary destruction and clinical response was observed. An 
absence of measurable pituitary function did not guarantee a 
clinical response but all patients with a response or an equivocal 
response had minimal pituitary function. Gonadotrophins and growth 
hormones were completely suppressed in these patients with a 
response or an equivocal response, but some of these patients did 
show a small prolactin and TSH response stimulation by TRH. These 
results seem to indicate that if a hypophysectomy was incomplete a 
clinical response was less likely to occur due to residual pituitary 
tissue, continuing to secrete hormones. Conversely a complete 
ablation did not guarantee clinical response.
These conclusions were not in agreement with views expressed by 
other workers. (Peck and Olson, 1963; Stoll, 1969; Bates et al, 
1976; Fairney et al, 1976; Wang et al, 1979) who did not find any 
relationship between residual pituitary function and clinical 
response to hypophysectomy. It has been suggested that two factors 
are required for a clinical response (Hawkins et al, 1980) - the 
pituitary destruction must be complete and the breast tissue must be 
hormone sensitive i.e. the tumour must at least be oestrogen 
receptor positive. These other workers removed the pituitary 
surgically and so the general level of destruction may have been 
more complete than by Yttrium implant. The receptor status of the 
groups of patients may also have been different.
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The results of this present study indicate the need for testing 
pituitary function in patients with advanced breast cancer who have 
been treated by Yttrium implantation. If, at one month after 
implantation, residual pituitary tissue is evident from the tests, 
particularly LH, FSH and growth hormone secretion, then it seems 
reasonable to assume that pituitary ablation is incomplete and a 
clinical response will be unlikely to occur. A change of treatment 
then to another regime would therefore be advisable and time-saving.
5* Conclusion
1. The most suitable combination of pituitary function test to use 
in a patient with advanced breast cancer is a combination of LHRH, 
TRH and insulin by infusion.
2. TRH is a better stimulant of prolactin secretion than chlorprom­
azine particularly after Yttrium implantation.
3. The results of these tests suggest that when the ablation of 
the pituitary, as measured by residual hormones on stimulation, is 
incomplete a clinical response is unlikely to occur, while a 
clinical response is more likely if the pituitary destruction is 
complete though not guaranteed.
B. Chemotherapy
The extent to which chemotherapy exerts its action by inhibition of 
the endocrine glands is uncertain.
In 1976 Bonnadonna and his colleagues studied the effects of cyclo­
phosphamide, methotrexate and 5-fluorouracil (CMF) used as adjuvant
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treatment to radical mastectomy. They found that half the premeno­
pausal patients with breast cancer being treated by this regime 
developed amenorrhoea, an effect produced mainly by the cyclo­
phosphamide, and it was suggested that when amenorrhoea did occur in 
these patients the CMF treatment was more likely to be successful 
and the patient more likely to have a clinical response. It was 
suggested by Rubens et al (1977) that the probable action of chemo­
therapy used prophylatically in early breast cancer was on the 
ovary, the effect being similar to that of carrying out a 
prophylactic oophorectomy. Another group of workers studied the 
effect of either L-phenylalanine mustard (L.PAM) or 
cyclophosphamide, methotrexate, 5-florouracil and vincristine (CMFV) 
on pituitary and steroid hormones in pre and postmenopausal patients 
with breast cancer (Rose and Davis, 1977). They suggested that a 
fall in plasma oestrogens (oestradiol-17B and oestrone) was 
accompanied by a rise in plasma LH and FSH, as would be found 
naturally at the menopause. In the postmenopausal woman, only 
plasma A 4 androstenedione levels fell; the other hormones were 
unchanged. These results suggested ovarian suppression by a direct 
effect on the ovaries in the premenopausal group and could also be 
due to suppression of the ovary in the postmenopausal group since 
after the menopause this organ secretes some testosterone and A4 
androstenedione. The same workers studied ovarian and adrenal 
function in premenopausal breast cancer patients .before and at 
intervals during adjuvant therapy with cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF), CMF plus prednisone (CMFP) or 
CMFP plus tamoxifen (Rose and Davis 1980). Amenorrhoea developed
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within 10 months in thirty-four of the thirty-eight patients. In 
the patients receiving CMF there was a reduction in plasma total 
oestrogens and an increase in plasma LH and FSH, again indicating 
that these drugs suppress ovarian function. These authors found 
that the age of the patient was inversely correlated with the time 
to the onset of the drug-induced amenorrhoea, reflecting perhaps an 
increasing ovarian sensitivity to cytotoxic agents as a woman 
approaches her natural menopause.
After adjuvant chemotherapy plasma androstenedione levels in
the premenopausal women who developed amenorrhoea fell to levels 
similar to those of untreated postmenopausal patients. There was 
also a small but significant fall in plasma A 4 androstenedione 
concentrations in postmenopausal patients. However, the plasma 
dehydroepiandrosterone sulphate (DHAS) concentrations were 
unaffected by adjuvant chemotherapy in either group of patients. 
These observations suggested that the altered plasma All 
androstenedione concentrations after adjuvant chemotherapy were due 
to the loss of ovarian secretion whereas the adrenal source of 
both A 4 androstenedione and DHAS remained intact. On the basis 
of plasma LH and oestradiol-17B levels (Schulz et al, 1979) 
suggested that combination chemotherapy led to alteration in the 
hypothalamic-pituitary-ovarian axis in premenopausal and 
perimenopausal women but not in postmenopausal women who continued 
to have physiologically high levels of LH and FSH and low plasma 
prolactin and 17B oestradiol levels under cytotoxic treatment. The 
effect of chemotherapy was on the ovary and the hypothalamic and
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pituitary functions were resistant to the influence of combination 
chemotherapy; the effects on the ovary were more likely to be 
involved in premenopausal and perimenopausal women than in 
postmenopausal women, perimenopausal women being more likely to 
develop amenorrhoea than premenopausal women. In women who 
continued to menstruate during adjuvant chemotherapy, Sherman et al 
(1979) found no major alterations in plasma hormone secretions (LH, 
FSH, oestradiol-17B, progesterone and prolactin). Despite these 
recent reports it was thought at the time this study was originally 
set up that the effects of chemotherapeutic drugs on ovarian hormone 
levels could be secondary to the effects at the pituitary level, and 
so this study has investigated the effect of chemotherapy on 
pituitary function.
2, Methods of Study
Fifteen women with progressive advanced breast cancer were included 
in the study. Following an initial trial of additional hormone 
therapy, they were randomly allocated into three groups, one of 
which was treated by yttrium 90 implantation of the pituitary alone; 
one by chemotherapy alone and the third by yttrium 90 implantation 
plus chemotherapy. All patients had received no therapy one month 
prior to their inclusion in the study.
Chemotherapy was by the cyclophosphamide, methotrexate, 5- 
fluorouracil (CMF) regime in which two doses of 5-fluorouracil (700 
mg/m2) and methotrexate (60 mg/m2) were given intravenously on days 
1 and 8 of a 28 day cycle and cyclophosphamide 11 00mg/m2/day was
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given orally for days 1 - 4  inclusively.
Pituitary function studies were carried out during the week prior to 
the operation or the commencement of chemotherapy and were repeated 
exactly one month later. In the case of those patients treated 
with combined modalities, chemotherapy was started one day following 
yttrium 90 implantation. The pituitary function test used was the 
combination of LHRH plus TRH plus insulin as described in the 
preceding section and the hormones measured were plasma prolactin, 
GH, FSH and LH.
The increments of plasma hormones were calculated by subtracting the 
basal levels from the average of those at specified times after 
injection. The times used for estimating the average peak response 
level as previously defined; 60, 90 and 120 minutes for growth 
hormone, 30 and 60 minutes for LH and FSH and 10, 20 and 30 minutes 
for prolactin.
3. Results
The basal levels and increments in hormone concentrations have been 
plotted for each patient before and after treatment, in Figs. 15 and 
16.
The number of patients in each group is small so that real changes 
in increments of hormone concentrations may not be significant.
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Fig. 15
Basal hormone levels pre and post ^Oyttrium implantation, 
chemotherapy and ^yttrium implantation and chemotherapy.
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Fig. 16
Increments in hormone concentrations in response to LHRH, TRH 
and insulin pre and post 90yttrium implantation, chemotherapy 
and 90yttrium implantation and chemotherapy„
Basal levels of plasma LH and FSH were significantly lowered (P<0.05 
Wilcoxonfs signed rank test) after .yttrium implantation with or 
without chemotherapy. Although the average basal levels of plasma 
prolactin and growth hormone levels were lower after these 
treatments, this barely reached statistical significance (P>0.05<0.1 
Wilcoxonfs signed rank test).
Patients who had an yttrium implant (either with or without chemo­
therapy) had significantly lowered increments for all hormones 
(p<0.05 Wilcoxori's signed rank test). No such reduction of hormone 
increments could be detected in those patients who received chemo­
therapy.
Three of the five patients on chemotherapy alone and one who had an 
yttrium implant, had taken stilboestrol in the month prior to chemo­
therapy, and this is likely to account for the suppression of LH and 
FSH basal levels and the reduced increments after stimulation prior 
to commencing chemotherapy or the performance of yttrium 90 
implantation. The post-treatment values of all patients on chemo­
therapy, however, were not different from the pre-treatment values 
for all patients who were not on drug treatment. Nor did the 
addition of chemotherapy to yttrium implant cause any further 
suppression of the increments of hormonal concentrations (Wilcoxonfs 
Rank Sum Test:NS)
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ll. Disoussion
The present studies of the effects of multiple chemotherapy on 
pituitary function, using a combined stimulation test of LHRH, TRH 
and insulin, showed that chemotherapy (CMF) alone did not produce an 
effect on pituitary function. Furthermore, the administration of 
chemotherapy to patients treated by implantation of Y90 into the 
pituitary did not produce any changes in pituitary function 
additional to those observed by Y90 implantation alone. It should, 
however, be remembered that the number of patients in each group was 
small and it is just possible that the administration of 
stilboestrol prior to the test may have compromised the results. 
However there ws no evidence that this was so.
Although the present studies were carried out in postmenopausal 
women with advanced disease, some support for our conclusions can be 
derived from the work of Samaan et al (1978) who studied fifty-five 
premenopausal women with early breast cancer, of which thirty-eight 
became amenorrhoeic; eleven of these amenorrhoeic women were 
compared with eleven of the women who did not develop amenorrhoea. 
Basal plasma LH, FSH, oestradiol-17B and prolactin were measured 
before and after LHRH and TRH administration. The results showed 
that the amenorrhoea was a result of primary ovarian failure.
On the basis of previous studies of hormone levels, the following 
tentative conclusions can be drawn. In the premenopausal woman, it 
seems likely that chemotherapy has two sites of action: 1.
Directly on the cell division in the tumour. 2. On the ovary. In
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the postmenopausal woman, however, there may be possibly three sites 
of action: 1. The tumour. 2. The ovary. 3« The adrenal.
The reason for including the action on the ovary as a possible site 
in the postmenopausal woman is because a fall in plasma A  4 andro- 
stenedione concentration could be due either to action on the 
adrenal or the ovary. The pituitary seems not to be involved 
except perhaps when prednisone (strictly a hormone rather than a 
cytotoxic drug) acts via the pituitary to alter adrenal function. 
These hypotheses can also be examined in the light of knowledge 
concerning the oestrogen receptor and response to chemotherapy. It 
is well established that oestrogen receptors relate to (1) a 
response to endocrine therapy (Croton et al, 1981) and (2) to 
prognosis (Knight et al, 1977; Cooke et al, 1980). However, the 
relationship to chemotherapy is less clear.
If in the premenopausal women chemotherapy acts by suppressing 
hormones, then one would expect mainly receptor-positive patients to 
benefit, leading to approximately 33$ response rate. This is not 
so. Firstly, in advanced disease, chemotherapy is effective in 
approximately 55-60$ of patients (Taylor et al, 1976; Helman et al, 
1982). Secondly, despite varying evidence it would appear on 
balance that neither oestrogen receptor-positive nor oestrogen 
re cep tor-negative tumours respond preferentially to chemotherapy 
(Hawkins, Roberts and Forrest, 1980). This argues for the effects 
of chemotherapy being at least partially not related to ovarian 
suppression. Despite this, since patients with oestrogen receptor-
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negative tumours are unlikely to benefit from adjuvant endocrine 
treatment, it may well be that patients with early disease, of poor 
prognosis, with oestrogen receptor-negative tumour, should still be 
selected for adjuvant chemotherapy in the absence of any suitable 
alternative (Croton et al, 1981)•
5. Conclusion
A 28-day cycle of chemotherapy in patients with advanced breast 
disease does not produce an effect on pituitary function, nor does 
its addition to the yttrium 90 implantation procedure produce any 
additional effect over and above that seen for yttrium 90 
implantation alone. It is concluded that these chemotherapeutic 
agents, therefore, probably act directly on the tumour, though the 
possibility of some ovarian action cannot be excluded.
C. Treatment with tamoxifen or stilboestrol
Stilboestrol had been used in the treatment of advanced breast 
cancer since the 1930*8, while tamoxifen has been introduced more 
recently. The latter, ICI 46, 474 - the trans-isomer of L-(pB 
dimethylamino ethoxy phenyl 1.2 diphenyl but-l-ene) is a non­
steroidal antioestrogen which has emerged as a hightly effective 
non-toxic drug for the treatment of women with advanced breast 
cancer. Early clinical studies indicated that benefit from 
tamoxifen therapy could occur in 30-40$ of women with advanced 
breast cancer (Cole et al, 1972; Ward, 1973)
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A remission rate of 38$ in postmenopausal women with advanced breast 
cancer has been reported by Lipton et al (1982). A similar 
response rate to tamoxifen of 30$ was found by Smith et al (1982) in 
a controlled randomised trial of women with advanced breast cancer 
who were given either tamoxifen or aminoglutethimide. In another 
series of one hundred and thirteen consecutive selected patients 
with Stage IV breast cancer, tamoxifen induced an objective 
remission in 50$ lasting an average period of sixteen months. 
Tumour regression occurrred in visceral, osseous and soft tissue 
sites with equal frequencies. Patients with oestrogen receptor- 
positive tumours had a significantly higher remission rate (63$) 
than did those in whom oestrogen receptor measurements were not done 
(44$). Women who were more than ten years postmenopausal had a 
significantly higher remission rate 58$ than did those who were less 
than ten years postmenopausal (41$) (Pearson et al, 1982).
More recently, and since the time this study now reported used 
tamoxifen, two controlled trials between tamoxifen and stilboestrol 
were initiated - one at the Mayo Clinic and the other in Edinburgh. 
Both studies showed that the two drugs were equal in efficacy, but 
since tamoxifen was less toxic it appeared to be the preferred agent 
(Stewart et al, 1980; Ingle et al, 1981).
Tamoxifen appears to compete with oestradiol for its cytoplasmic 
receptor, the oestrogen receptor (Furr et al, 1979). The precise 
mechanism by which the anti oestrogens antagonize oestradiol is not 
clear, but they appear to produce a receptor complex that it not
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able to interact properly with the genome specific for the receptor- 
oestrogen complex (Edwards et al, 1979).
Patients with tumours which contained oestrogen receptors and those 
patients who had responded to previous hormonal manipulation tended 
to respond to tamoxifen (60$ and 69$ respectively) (Kiang et al,
1977). On the other hand, patients with receptor negative tumours 
or with a history of failure of response to previous hormonal 
treatments did not respond to tamoxifen therapy. It has also been 
reported from a review of two hundred and thirty five patients that 
54$ of these patients responded to tamoxifen when oestrogen 
receptors were present and only 14$ responded when oestrogen 
receptors were not present. (Hawkins et al, 1980). Since this 
study was started, it has been reported that tamoxifen had no effect 
on plasma oestradiol-17B, testosterone or prolactin levels, but it 
reduced the concentration of plasma FSH (Golder et al, 1976; Willis 
et al, 1977; Wilking et al, 1982; Coombs et al, 1982).
The aim of this present study was to examine (a) the effect of 
therapy on circulating plasma hormone levels, and (b) if the 
clinical response was related to changes in plasma hormone levels.
2. Methods of Study
Thirty-five postmenopausal women with advanced breast cancer were 
studied within the Edinburgh trial. None had been given any 
previous hormone or other systemic therapy for the treatment of 
their disease.
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Studies were carried out at the Combined Breast Clinic of the 
University Department of Clinical Surgery and the Department of 
Radiotherapy at the Royal Infirmary of Edinburgh. This clinic is 
specifically concerned with the conduct of therapeutic trials in 
patients with advanced cancer of the breast.
Following documentation of the state of the disease, patients were 
entered into a double blind crossover trial in which they received 
identical tablets of either tamoxifen (10mg.) or stilboestrol (5 
mg.), one tablet being taken by mouth thrice daily. Prior to 
allocation, the patients were stratified according to the 
distribution of their recurrent or metastatic disease, the 
performance of a previous mastectomy and the recurrence-free 
interval.
Some patients, because of cardiac or respiratory problems, were 
considered to be unsuitable for treatment by stilboestrol. They 
were excluded from the trial but given elective tamoxifen therapy in 
the same dose as in the trial. As their pattern of hormonal 
changes did not differ from that of the patients included in the 
trial, they have been included with the patients given tamoxifen in 
the trial. Patients attended the clinic at monthly intervals when 
their response to therapy was assessed.
Documentation of the response was by the criteria advised by the 
British Breast Group (1974) and patients were classified as 
undergoing objective regression, an equivocal or intermediate
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response, or no response at three and six months.
If no response occurred or when a good response had ended, 
administration of the drug was stopped for one month before the 
patient was started on a second agent. Some patients, therefore, 
received both drugs sequentially.
Before starting a drug, 10 ml. of blood was withdrawn from an arm 
vein. The blood was heparinised, centrifuged and stored as 
described in General Methods Section. Similar samples were taken 
at the same time of day at one, three and six months after starting 
therapy. The plasmas were sent in as batch to the laboratories and 
assayed for FSH, oestradiol-17B, testosterone and prolactin. The 
number of treatments on each drug is shown in Table XVII. Conduct 
of the trial allowed opportunity to study the effect of the drugs on 
plasma hormone levels in all patients receiving the treatment as 
first or second drugs; but analysis of the relationship of these 
hormonal changes to clinical response was restricted to those 
patients receiving the drug on their first treatment.
3. Results
Tables XVIII and XIX give the results of the concentrations of 
plasma hormones in those patients who received tamoxifen or 
stilboestrol. The median increase or decrease is shown for each 
hormone at one, three and six months after commencement of treatment 
with the significance of these changes.
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TABLE X V I I
1st Drug 
No. Patients
2nd Drug 
No. Patients
Total No. 
1st and 2nd 
Drug
Stilboesterol 11 5 16
Tamoxifen 15 3 18
Elective Tamoxifen 9 - 9
Treatment on Stilboesterol or Tamoxifen. Total number of 
treatments on each drug, given to 35 patients. Some patients 
had both drugs sequentially.
TABLE X V I I I
FSH
U/l
0estradiol-17B
pmol/1
Testosterone 
nmol/I
Prolactin
mU/1
Pretreatment 
n
median
range
27
137
55to+261
26 
452 
0to+60 3
25
1.39
0to+2.08
26
200
0to+450
1 Month 
n
median
range
24
-25
-72to+74
24
3.7
-426to+408
24
0
-1.25to+1.32
25
0.00
-420to+600
3 Months 
n
median
range
20.
-33
-188to+54
20
37
-441to+261
20
0
-1.18to+1.53
19
-20
-370to+340
6 Months 
n
median
range
14
-33
-178to+24
14 
3.7 
-99 to +198
14
0
-l.08tol.46
13
-70
-300to+120
Significance
WSRT*
Significant 
decrease 
at 1/12, 
3/12&6/12
NS NS NS
WSRT - Wilcoxon signed rank test 
n - number of patients
Changes in median plasma hormone concentration values and ranges 
on treatment with Tamoxifen as 1st or 2nd drug. Changes all 
refer to pretreatment values.
TABLE X IX
FSH
U/l
0estradiol-17B
pmol/1
Testosterone 
nmol/I
Prolactin
mU/1
Pretreatment
n 16 16 16 16
median 106 110 1.39 120
range lto+208 14to+202 0.24to+3.23 70to+960
1 Month
n 16 16 16 16
median -105 3.7 0 300
range -203to+l -99to+673 -1,60to+2.22 -440to+580
3 Months
n 8 8 8 8
median -104 -18.4 0.03 310
range -203to+2 -48to+44 -0.97to+0.80 -620to+780
6 Months
n 3 3 3 3
median -120 0 -0.24 130
range -69to-145 Oto+99 -0.28to+0.49 -570to+310
Significance
WSRT*
Significant 
decrease 
at 1/12, 
3/12&6/12
NS NS Significant 
increase 
at 1/12
* WSRT - Wilcoxon signed rank test 
n - number of patients
Changes in median plasma hormone concentrations and ranges on 
treatment with stilboestrol as 1st or 2nd drug. Changes all refer 
to pretreatment values.
For clinical reasons, some of these patients were withdrawn from the 
hormone therapy before the six month period, and collection and 
analysis of blood samples was incomplete in others. The results at 
three and six months of drug therapy are therefore based on smaller 
numbers than those at one month, so at a later time, evidence may 
then be insufficient for even a considerable change in hormone level 
to be statistically significant. Patients compared at three and 
six months also over-represent those who responded to treatment, and 
this should be borne in mind when interpreting Tables XVIII and XIX.
Plasma prolactin level rose in eleven out of twenty-five patients 
treated with tamoxifen at one month, and in six out of nineteen 
patients at three months. In contrast, levels of plasma FSH fell 
in nineteen out of twenty-four patients at one month, and seventeen 
out of twenty patients at three months. Administration of 
tamoxifen therefore significantly suppressed the median circulating 
levels of FSH in the plasma at one, three and six months after 
administration. Tamoxifen did not change the plasma concentration 
of oestradiol-17p or testosterone. Stilboestrol was more effective 
than tamoxifen in depressing plasma FSH concentrations. Levels of 
FSH fell in fifteen out of sixteen patients at one month ancl seven 
out of eight at three months. No patient taking stilboestrol had 
plasma FSH levels more than 3 u/1 above the limits of detection of 
the assay when on treatment. In addition, stilboestrol 
significantly increased plasma prolactin concentration (fifteen out 
of sixteen patients at one month, and seven out of eight patients at 
three months) but had no effect on plasma oestradiol-17B or
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testosterone levels.
To relate these hormonal changes with clinical response to therapy, 
patients with a definite clinical response at three months and six 
months were selected and compared with those with no response at 
either time. All those patients with a short-lived or equivocal 
response, and those who were not fully assessed due to intolerance 
or other causes were excluded. The numbers of definite responders 
and non-responders to stilboestrol was insufficient for meaningful 
comparison to be made. Results for tamoxifen are shown in Table 
XX. No relationship was detected between the changes in hormone 
levels and the clinical response to treatment.
4. Discussion
The effect of tamoxifen and stilboestrol on basal plasma hormone 
levels has been studied.
The effect of stilboestrol
Stilboestrol (diethylstilboestrol) failed to have an effect on the 
plasma levels of testosterone or oestradiol 17B and these findings 
are in agreement with those of previous workers (Mahajan et al,
1978). However as was reported by Franchimont and his colleagues 
(1971)> stilboestrol reduced the plasma FSH level. Plasma gonado­
trophins are known to rise naturally at the menopause due to the 
fall in plasma oestrogen levels. Therefore the administration of 
oestrogen might be expected to cause a fall in plasma gonadotrophins 
due to the inhibition of the pituitary feedback mechanism. There
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is ample evidence that this is so in experimental animals. It has 
been reported by Piacsek and Meites (1966) that oestrogen given for 
twenty-one days depressed hypothalamic luteinizing releasing 
hormones (LHRH) content in ovariectomised rats. The pituitaries of 
the ovariectomised rats showed a four-fold rise in LH concentration 
whereas oestrogen by injection prevented this increase. Their 
results also suggested that oophorectomy stimulates the release of 
hypothalamic LHRH more than its synthesis while systemic injections 
of oestrogen can inhibit both release and synthesis of LHRH. 
Oestrogen can act directly on the pituitary to stimulate LH release.
Yen and his colleagues (1974) in a study of five hypogonadal women, 
(three of whom were postmenopausal, one ovariectomised and one had 
gonadal dysgenesis) found oestrogens exert a direct negative feed­
back action on pituitary gonadotrophins. A rapid increase in 
circulating oestradiol-17B concentration induced a marked diminution 
in pituitary responsiveness to LHRH.
In our studies stilboestrol raised the concentration of plasma 
prolactin. This has been reported by other workers. L'Hermite et 
al (1974) showed that prolactin secretion was increased in women 
with breast cancer treated with oestrogen. In animal studies in 
which oestrogen was given to rats, it has been shown that the 
oestrogens decrease hypothalamic prolactin inhibiting factor content 
and increase the release of prolactin (Meites 1972). There is a 
certain amount of evidence that oestrogens have a similar action in 
humans with prolactin.
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The effect of tamoxifen
Tamoxifen was found in this present study to have no effect on 
plasma oestradiol-17B, testosterone or prolactin levels but it 
reduced the concentration of plasma FSH, though to a lesser extent 
than stilboestrol. These findings are in agreement with previous 
reports (Golder et al, 1976; Willis et al, 1977; Coombes et al, 
1982; Wilking et al, 1982). The mode of action of tamoxifen must 
either be a direct effect on hormone synthesis or indirectly via 
oestrogen receptor. The mechanism of action of tamoxifen was 
originally studied mainly in animals. In rats, tamoxifen has been 
reported as a weak and atypical oestrogen with anti-oestrogen 
properties (it inhibits the effect of the response to exogenous 
oestrogen of the vaginal epithelium (cornification) and uterus 
(weight increase), and has little pituitary inhibitory activity. 
In mice, it is more oestrogenic when given in large doses than in 
rats (Harper and Walpole, 1967) > but so far there is no convincing 
evidence that this is so in man. Therefore the mechanism by which 
FSH is suppressed by tamoxifen is still unknown.
Tamoxifen presumably behaves in man similarly to animals. It can 
be inferred from the work of Klopper and Hall (1971) that it has an 
effect on the hypothalamus in the human. In this respect it 
resembles its chemical relative, clomiphene - another substituted 
triphenyl ethylene compound which has been used to induce ovulation. 
Clomiphene has been shown in rats to exhibit a marked depression in 
the uptake of tritiated oestradiol-17B by the anterior hypophysis 
and a small depression of oestrogen uptake by the anterior
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hypothalamus (Kato et al, 1968). This depression of uptake of (3h) 
oestrogen indicates binding of the clomiphene with oestrogen 
receptor proteins as in other tissues. There is reason to believe 
that tamoxifen has a complex mode of action, but it appears to 
operate primarily through the oestrogen receptor system to inhibit 
the biological effect of oestrogen in the tumour cell (Nicholson,
1979). It competes with oestradiol at the cytoplasmic receptor
sites. Tamoxifen receptor complexes are formed and translocated
into the nucleus where it remains for prolonged periods and 
interferes with the regeneration of cytosol oestrogen receptors 
(Jordan et al, 1975; Nicholson et al, 1976; Clark et al, 1977).
In our studies both stilboestrol and tamoxifen lowered plasma FSH 
concentrations both in patients who responded to these agents and in 
those who did not. This is in agreement with other reports (Willis 
et al, 1977; Coombes et al, 1982; Wilking et al, 1982) but is in 
disagreement with the results of the study reported by Golder et al, 
1976 who found that plasma FSH levels in those responding returned 
to pre-treatment levels in the second and third month of treatment. 
By contrast those in the non-res ponding group remained lower than in 
the pre-treatment value. A significant difference between plasma 
FSH levels in responders and non-responders was found during the 
second and third month of treatment by these workers.
The failure of patients to respond to tamoxifen and stilboestrol is 
thus not due to failure of the drugs to reduce plasma FSH levels. 
Changes in circulating hormones may only be indirectly involved.
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5. Conclusion
Tamoxifen decreases plasma FSH levels in post-menopausal women with 
breast cancer at one, three and six months, but has no effect on 
prolactin levels. Stilboestrol has a more profound effect in 
suppressing FSH levels at one, three and six months and also 
increased prolactin levels. Neither drug affects plasma testo­
sterone or 17B-oestradiol levels. These effects were present in 
patients with and without a clinical response to the drug. The 
effects of tamoxifen and stilboestrol may relate to the presence of 
oestrogen receptors and not necessarily to changes in plasma hormone 
levels.
129
Study 3. - Men with Gvnaecomastia
Gvnaeoomastia
The breast in the male remains rudimentary, but in certain 
circumstances there is abnormal breast hyperplasia which is termed 
gynaecomastia.
1. Literature review 
Aetiology of Gvnaecomastia
The first recorded clinical description of gynaecomastia was that of 
Paulus Aeginate - the last of the Byzantine physicians who lived at 
the end of the 6th century AD. He wrote nAs at the season of 
puberty, the breasts of females swell up. so in like manner those of 
males also swell to a certain extent, but in the most part they 
subside again. In some cases, however, having acquired a beginning 
they go on increasing owing to the formation of fat below.”
During and after the Renaissance, gynaecomastia received the passing 
mention afforded to a medical curiosity. An interesting case of 
gynaecomastia with secretion from the nipples was described by 
Charleton in 1669. Later in that century, Diemerbroeck (169*0 used 
knowledge of the occurrence of gynaecomastia in males as an argument 
against the view that lactation in females was due to the expression 
of menstruous blood, retained during pregnancy and the puerperium. 
Little appears to have been written on the subject of gynaecomastia 
for the next one hundred and fifty years. However, in 1848, Von
r
Basedow described a man suffering from a severe degree of
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thyrotoxicosis who showed gynaecomastia. In the first two volumes 
of the Annals of Surgery, three papers reporting cases of 
gynaecomastia were published - one of the patients then described 
was a boy whose mother had acromegaly. At about that time 
gynaecomastia was attributed to diseases, injury or atrophy of the 
testes or its excision (Williams 1894). It was noted that 
testicular atrophy was also seen in some cases of cirrhosis of the 
liver (Corda 1925). In 1926, Sylvestrini drew attention to an 
observation he had made in 1904 that gynaecomastia was sometimes 
seen in patients with cirrhosis of the liver - the triad of 
cirrhosis, testicular atrophy and gynaecomastia is sometimes 
referred to as the Sylvestrini-Cor da syndrome. It was believed by 
Erdheim (1928) that in most cases, gynaecomastia was the primary 
condition, though in some cases the lesion was obviously secondary 
to its condition. A case of bilateral pubertal gynaecomastia was 
described by Richardson (1943) who suggested that the gynaecomastia, 
was due either to excessive production of oestrogens by the testes 
at puberty or due to an abnormally vigorous response on the part of 
the breasts to normal endocrine stimulation.
It is now recognised that there are many causes associated with 
gynaecomastia - a suggested classification as described by 
Hall (1959) is given in Table XXI.
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TABLE XXI
THE CAUSES OF GYNAECOMASTIA (Hall, 1959)
1. Gynaecomastia associated with physiological states.
(a) Neonatal gynaecomastia.
(b) Essential gynaecomastia.
(c) Involutional gynaecomastia.
2. Gynaecomastia due to underlying disease.
A. Diseases of the endocrine glands.
I. Diseases of the testes.
(a) Prepubertal testicular failure.
(b) Klinefelter*s syndrome.
(c) Leprosy.
(d) Mumps.
(e) Orchitis of unknown aetiology.
(f) Tumours: Teratoma.
Chorionepithelioma.
Seminoma.
Interstitial cell tumour.
Sertoli cell tumour.
(g) Radiation.
(h) Undescended testes.
(i) Castration.
(j) Trauma.
(k) Unilateral testicular lesions: Varicocoele;
atrophy of unknown aetiology.
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II. Diseases of the adrenal cortex.
(a) Tumour.
(b) Hyperplasia.
(c) Stress.
III. Diseases of the tyroid gland.
(a) Hyperthyroidism.
(b) Hypothyroidism.
IV. Diseases of the pituitary gland.
(a) Acromegaly.
(b) Chromophobe adenoma.
(c) Hypopituitarism.
V. Disorders of sex.
(a) Hermaphroditism: True
False.
(b) Transvestism.
VI. Miscellaneous.
(a) Following prostatectomy.
(b) Albright*s syndrome.
(c) Diabetes mellitus.
(d) Cushing*s syndrome.
B. Diseases of the liver.
I. Cirrhosis.
II. Hepatitis.
III. Carcinoma.
IV. Haemochromatosis.
C. Diseases of the alimentary canal.
Ulcerative colitis.
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D. Malnutrition and renutrition.
E. Diseases of the central nervous system.
I. Traumatic paraplegia.
II. Friedreichfs ataxia.
III. Syringomyelia.
IV. Dystrophia myotonica.
F. Pulmonary disease.
I. Bronchogenic carcinoma.
II. Tuberculosis.
III. Bronchiectasis.
IV. Empyema.
G. Drugs.
Oestrogens.
Androgens.
Chorionic gonadotrophin.
Adrenocortical hormones.
Digitalis.
Radioactive iodine.
Amphetamine.
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CLASSIFICATION (amended)
From the clinical experience in the study later described it is now 
recognised that there are many causes of gynaecomastia. A simple 
classification is suggested as follows:
I Physiological (associated with physiological states)
1. neonatal gynaecomastia
2. pubertal gynaecomastia
3. gynaecomastia of 'old age1
II Due to:
a) Diseases of the testis:- eg.
1. tumours
2. Klinefelters syndrome
3. castration
4. undescended testes
5. unilateral testicular lesions - varicocoele
b) Diseases of the liver:- eg.
1. cirrhosis
c) Diseases of the pulmonary system:- eg.
1. bronchiectasis
2. bronchogenic carcinoma
d) Diseases of the endocrine system:- eg.
1. pituitary tumours
2. adrenal tumours
3. diabetes mellitus
4. thyrotoxicosis
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e) Malnutrition and renutrition:-
refeeding prisoners of war
III Pharmacological
Gynaecomastia due to the following drugs
oestrogens, reserpine, mariuhana, Salbutamol, 
spironolactone, cimetidine, Paroven, androgens, 
alcohol.
1. Clinical Appearance of Gvnaecomastia
At the time of puberty, 70% of boys show a palpable button-like 
nodule in the chest wall. The altered mammary gland appears as a 
mass or a nodule under the nipple. Occasionally it is attached to 
the nipple, but it is not adherent to other structures. The mass 
may become fairly large and appear as a more or less globular body 
(Karsner 1946). It is usually firm, smooth in outline and may be 
tender. (A typical picture is shown in Fig. 17 of a 21 year old man 
who had had gynaecomastia since the age of 14). During the process 
of growth which can go on for months, or even years, the enlargement 
is usually gradual, although there can be periods of interruption or 
accelerated growth. After it reaches a certain size, growth ceases. 
There are variable degrees of enlargement and projection of the 
nipple with widening of the areolar ; sometimes there is also 
increased pigmentation and prominence of the glands of Montgomery. 
Unilateral gynaecomastia is more frequent but bilateral involvement
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A photograph of a 21 year old man with right sided gynaecomastia 
of 7 years’ duration.
can occur. Menville (1933) reported bilateral disease in 1 2 .8 $ of 
eighty-eight cases, Geschickler (19*11) found it bilateral in 20$ of 
one hundred and eight cases, while Karsner (19*16) found bilateral 
involvement in only *1.6 $ of two hundred and seventy-four cases. 
Such estimates may not be accurate as slight, or even moderate 
enlargement of a second breast may not be noticed by the patient or 
examiner. Mammographically, gynaecomastia is more often bilateral, 
even when clinically appears to be unilateral.
It is evident that gynaecomastia arising in early life may be a 
continuation or augmentation of the pubescent node, but when arising 
in later life, after the node can be assumed to have disappeared, 
the aetiology is presumably different.
2. Pathology of Gvnaecomastia
Gynaecomastia breast tissue histologically and in its gross 
appearance closely resembles the mammary tissue of girls at the time 
of puberty (Goodman 1937). The microscopic appearance is a picture 
of growth of mammary ducts and of periductal stroma; lobule 
formation is absent. Karsner (19*16) pointed out that the 
enlargement of the breast in gynaecomastia is chiefly due to a 
proliferation of connective tissue, and that adipose tissue, 
although present, does not contribute much to the size of the 
breast. Epithelial cell change also occurs. Ducts which are 
normally lined by one or at the most two cells, can in gynaecomastia 
become 5 - 6  cells thick. Budding of the ducts is sometimes seen 
either as narrow branching structures or as spherical projections
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from the duot or its branched prolongations. typical histology of 
gynaecomastia is shown in Fig. 18 (a,b and c).
It was demonstrated by Karnauchow (1954) in twenty patients with 
gynaecomastia that the myo-epithelial cells of the breast in gynae­
comastia also show proliferation. These cells lie within the 
basement membrane of the lactiferous ducts and occasionally 
proliferate to such an extent that they push their way into the 
lumen of the duct. He also found that myo-epithelial cells may 
proliferate alone or with the ordinary ductal epithelium to form 
benign, intraductal papillomatous growths. When regression with 
ductal atrophy occurred in gynaecomastia, the myo-epithelial cells 
persisted after the ordinary epithelial cells had vanished and 
remained as bizarre cell groupings in dense fibrous tissue. Alveoli 
such as are seen in the female breast do not appear in 
gynaecomastia, with one exception; small acini do develop in 
neonatal gynaecomastia, and may produce ’’witches milk". Although 
there are few reports of this, neonatal gynaecomastia in general 
resembles miniature lactating glands in microscopic appearance 
(Dietrich 1927).
3. Hormone levels in men with gynaecomastia
A hormone is a substance produced by an endocrine gland and secreted 
directly into the blood stream where it circulates in extremely low 
concentrations to have an effect at a distant target organ. In the 
past decade considerable progress has been achieved in the 
development of techniques for the assays of plasma hormones with the
1 3 8
a -
b  -
c -
Fig. 18 X  3 8
Typical histology of gynaecomastia. Three different photomicrographs 
from the same breast.
sensitivity and specificity necessary for the measurement of normal 
levels of most blood-borne hormones.
As gynaecomastia is most frequently associated with either puberty 
(at which time there is great hormonal change), diseases of the 
endocrine glands, or hormone administration, it is natural to 
suppose that the underlying cause of breast disorder is hormonal 
imbalance. Even in gynaecomastia associated with other 
aetiological factors such as liver disease, malnutrition or drug 
administration the effect may be via a secondary action on hormone 
metabolism and excretion.
In animals at all stages of development, among the many factors that 
control mammary growth, hormones play a leading role (Lyons et al 
1958). It has been shown that breast development in foetal male 
and female mice is different (Raynaud 1971). The mammary growth 
patterns in both male and female foetuses up to the 14th day are 
similar. After this, sex differences in breast development occur. 
In the male mouse foetus, there is no nipple formation and in the 
adult male mouse, the mammary gland has no connection to the skin 
and no nipples. However, early gonadectomy (by localised 
irradiation of the mouse foetus by X-rays at 13 days) prevents the 
destruction of the primary duct in the foetal male mouse and leaves 
the glands connected to the skin in the adult and the newborns, 
regardless of their genetic sex, have mammary glands similar to 
those mammary glands in females (Raynaud 1971). The effects of 
castration of male foetuses demonstrate that it is the secretion of
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the foetal testis which is responsible for the male pattern of 
development of the mammary gland. In the early stage of mammary 
rudiment development, growth is slow and is uninfluenced by 
pituitary hormones but is affected by ovarian or testicular 
hormones. Later growth is rapid and is affected by pituitary 
hormones but resists ovarian or testicular hormones (Raynaud 1971 > 
Ceriani 1974).
Male rats feminised prenatally by an anti-androgen develop nipples, 
teat ducts, a complete gland system, main milk ducts and mammary 
glands. It seems likely that the androgens of the male foetus 
inhibit the development of the mammary glands and that in the male 
rat foetuses, the anti-androgen prevents endogenous testosterone 
from producing the incomplete organogensis with athelia and without 
adnexa that normally occurs in the male mamma (Neuman et al 1966 
a,b). Hormones are also involved in post-pubertal growth. It has 
been shown in rats and mice, in which hypophysectomy, adrenalectomy 
and oophorectomy has been carried out, that no single hormone has 
been found capable of inducing complete ductal mammogenesis and at 
least five hormones play an important part in mammogenesis and 
lactation. LH and FSH stimulate the ovary to produce oestrogen, 
while corticoids (under the influence of ACTH) are required for 
inducing ductal growth. Prolactin and progesterone are necessary 
as well, for full lobulo-alveolar development (Lyons 1958; Nandi 
1958).
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No similar studies are available in humans. It seems likely that 
hormones must play a part in male breast development, and that men 
may have the potential for full mammary gland development. 
Research has therefore been focussed on determining individual 
hormone values in patients with gynaecomastia.
i) Oestroeens and the male breast
The changes produced by oestrogens in man are almost identical with 
those found in gynaecomastia due to other causes. As early as 19^0, 
Dunn reported gynaecomastia occurring in men taking 5 mg. 
stilboestrol orally daily for two months, while Fitzsimmon ( 1 9 W  
reported twenty-eight cases of gynaecomastia out of thirty-eight men 
who were employed in the manufacture of stilboestrol. In 19^5, 
Moore et al, described the biopsy findings of the enlarged breasts 
of men on stilboestrol for carcinoma of the prostrate. However, no 
hormone measurements were carried out at that time as satisfactory 
assays for plasma hormones were not available.
The most important circulating oestrogens in the male are 
oestradiol-17B and oestrone. The formulae for these compounds are 
shown in Table I. These circulating plasma oestrogens in the male 
arise from testicular secretion, adrenal secretation and peripheral 
conversion of androgens to oestrogens (Van Thiel et al 1975). 
Males are, in fact, capable of greater peripheral aromatization of 
androgens to oestrogens than menstruating females and the conversion 
of ZW androstenedione to oestrone and of testosterone to oestradiol- 
17B is a highly significant source of oestrogens in man (Longscope
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et al 1969). In normal men, approximately 80$ of the oestrogens are 
derived from peripheral metabolism of circulating androgens 
(Kirschner 1972). It has been suggested that in the adult, 
peripheral aromatization of C«jg steroids takes place partially in 
the liver (Smuk and Schwers 1977). Similarly, changes in rates of 
catabolism of oestrogens (eg. in liver disease) might indirectly 
lead to changes in androgen secretion rate and therefore influence 
oestrogen production.
A study of the urinary excretion of oestriol, oestrone and 
oestradiol-17B in pubertal boys with and without gynaecomastia 
concluded that gynaecomastia of puberty was not associated with an 
increased concentration of urinary oestrogens (Jull et al 1964). A 
similar study was carried out at the same time in older men. In 
this group, the results of analysis of urinary oestrogen levels in 
the gynaecomastia group were variable but there was no conclusive 
evidence of increased concentrations of urinary oestrogen in the 
group as a whole.
Normal oestrone levels in patients with gynaecomastia were also 
reported by Hall (1959), though he found high urinary oestrogen 
values in patients with thyrotoxicosis - a condition often 
associated with gynaecomastia; Larsson and Sundborn (1963) 
confirmed the existence of elevated urinary oestrogens in patients 
with thyrotoxicosis and gynaecomastia; others have reported raised 
oestrogen in the urine of gynaecomatic males. For example, Okano et 
al (1 9 6 3 ) found urinary oestrogens increased in five patients with
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gynaecomastia, while in a large series of patients with 
gynaecomastia, Rupp et al (1951) found thirteen out of twenty-eight 
patients with gynaecomastia to have increased urinary oestrogen 
levels.
Therefore, studies of urinary oestrogen levels in gynaecomastia have 
yielded inconsistent results with normal oestrogen values in some 
studies - and elevated values in other.
More recently investigators have turned to study the oestrogens 
circulating in blood. One of the first studies of serum oestrogens 
in gynaecomastia was reported by Goldfine (1971) who described a 
single case of a 14-year old boy who developed spectacular 
gynaecomastia in association with pubescent growth and rapid sex 
maturation. Amongst several hormones which were abnormal the 
plasma oestradiol-17B concentration was elevated.
Plasma oestradiol-17B levels were also studied in sixteen boys with 
pubertal gynaecomastia, by La Franchi et al (1975). They found 
that six of the boys had elevated oestradiol-17B levels. However, 
Bidlingmaier et al (1973) found that in twenty-nine patients with 
pubertal gynaecomastia the plasma oestradiol-17B and oestrone levels 
did not differ from normal, though some individual values were 
slightly above the normal range. In a report by Korenman (1969)> 
using a radioligand binding assay (employing rabbit uterine 
receptors as binding protein) unconjugated oestradiol-17B was 
measured in normal men, in seven men with severe cirrhosis in the
presence or absence of gynaecomastia and in gynaecomastia of non­
cirrhotic aetiology. He found that the levels of circulating 
oestrogens were elevated in cirrhosis and, also, gynaecomastia per 
se was associated with increased mean plasma oestradiol-17B level.
A moderately raised plasma oestrogen concentration in one case of 
gynaecomastia which had developed after mild infective hepatitis was 
found by Anderson et al (1972). It was suggested that increased 
sex hormone binding globulin (SHBG) also associated with liver 
disease, may have caused the rise in oestradiol-1 7 B which is bound 
by the sex hormone binding protein. Elevated SHBG levels had also 
been found in thyrotoxicosis, a condition associated with 
gynaecomastia (Crepy 1967; Chopra and Tulchinsky 197*0. In most 
cases, the gynaecomastia appeared during hyperthyroidism and receded 
when the patient became euthyroid. It was proposed that alterations 
in balance between circulating oestrogen and unbound androgen might 
play a significant role in the genesis of gynaecomastia (Chopra and 
Tulchinsky 1974). It has been demonstrated that thyroid hormone 
alters the metabolism of oestradiol-16-14c-in vivo in human 
subjects, resulting in decreased conversion of oestradiol-17B to 
oestriol and increased conversion to 2-methoxyoestrone (Fishman et 
al 1962).
In another study of gynaecomastia and cirrhosis, Chopra et al (1973) 
measured oestradiol-1 7 B concentrations by radioimmunoassay in a 
group of thirteen patients with chronic hepatic cirrhosis, six of 
whom had gynaecomastia. The serum oestradiol-17B concentration was
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elevated in eight of the thirteen patients. (Only one of these 
eight had gynaecomastia), and the mean value was significantly 
higher than that of normal men. The percentage of oestradiol-17B 
that was dialyzable (percentage unbound oestradiol) in the sera of 
men with cirrhosis averaged 2 0 $ higher than that in the sera from 
normal men. The concentration of unbound oestradiol-17B in serum 
(Percentage unbound x total oestrogen concentration) was elevated in 
eleven of the thirteen patients. However, these differences in 
serum concentration of the total and unbound oestradiol-17B between 
patients with and without gynaecomastia were not statistically 
significant. It was concluded that in some of cirrhotic patients, 
the tissues might be perfused with supra normal concentrations of 
unbound oestradiol-17 B. These workers also found low levels of 
serum testosterone (which is described later) and found the 
oestradiol-17B/testosterone (E2 /T) ratio in the patients with 
gynaecomastia was higher, although not significantly so. They 
concluded that both oestrogens and androgens may be involved in the 
development of gynaecomastia.
Plasma oestrone levels were measured by radioimmunoassay in fifty 
men with chronic alcoholism and varying degrees of alcoholic liver 
disease, seven of whom had gynaecomastia (Van Thiel et al 1975). 
It was found that the plasma oestrone levels in these seven men with 
gynaecomastia was significantly higher than that found in those who 
did not have gynaecomastia. They concluded that chronically 
alcoholic men had an absolute increase in plasma oestrone and this 
may provide an explanation for the development of signs of
feminization, eg. gynaecomastia and spider angiomata, which are 
common in alcoholism.
In summary studies of plasma oestrogens suggest that these may be 
raised or normal in gynaecomastia. The SHBG concentrations are 
elevated and there is often an elevated oestradiol-17B/testosterone 
ratio.
ii) Androgens and Gynaecomastia
In gynaecomastia most of the emphasis on hormonal abnormalities has 
been placed on the oestrogens, but in many studies androgens have 
also been measured. The results of these studies are summarised 
below.
The most active and abundant naturally occurring androgens in the 
male are 5 OC dihydrotestosterone, testosterone, A4 androstenedione 
and dehydroepiandrosterone sulphate. Testosterone and 5 OC dihydro­
testosterone are strongly bound to plasma globulins while A 4 andro­
stenedione and dehydroepiandrosterone sulphate are weakly bound. 
All except 5 OC dihydrotestosterone can be converted to oestrogens in 
the male.
5 CX dihydrotestosterone, testosterone andA4 androstenedione are 
produced mainly by the testes, but some testosterone andA4 andro­
stenedione are also produced by the adrenals while dehydroepiandro­
sterone sulphate is almost exclusively andrenal-derived, ie. 
dehydroepiandrosterone is produced by the adrenal and converted
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peripherally to dehydroepiandrosterone sulphate.
It has been reported that the plasma testosterone levels in a 14- 
year old boy with gynaecomastia and pubescent growth with rapid 
sexual maturation, were consistently above the range observed in 
normal men and other pubertal boys (Goldfine et al 1971). These 
authors concluded that the gynaecomastia in this case was the result 
of elevated levels of plasma testosterone. This hyperleydigism, as 
it is called, was explained on the basis of a failure of the 
negative hypothalamic pituitary feedback system to respond 
appropriately to circulating testosterone and oestradiol-17B.
Plasma testosterone and oestradiol-17B concentrations were measured 
by La Franchi et al (1975) in sixteen pubertal patients with 
gynaecomastia. Eleven of the sixteen had elevated oestradiol- 
17B/testosterone ratios. These authors concluded that these 
increased ratios played a causative role in most cases of pubertal 
gynaecomastia.
24-hour profiles of plasma oestrogens and androgens levels in males 
at puberty (eleven) with gynaecomastia and eight without gynae­
comastia were studied (Large and Anderson 1979) who found that there 
was no difference between the 24 hour plasma testosterone and 
androstenedione profiles of pubertal boys and those boys with gynae­
comastia. The major findings in male puberty was that levels of 
plasma oestradiol-17B and to a lesser extent, of oestrone were high 
relative to testosterone levels for prolonged period of the
afternoon and evening (when testosterone levels were lowest). A 
finding (seen only in the boys with gynaecomastia) was that of 
elevated and markedly fluctuating levels of plasma oestradiol-17B. 
There was an absolute increase in the area under the 24 hour 
oestradiol-17 B. These authors concluded that normal men require 
sustained adult circulating testosterone levels to prevent their 
oestrogens from stimulating breast development.
Earlier, Anderson (1972) had measured plasma oestradiol-17B and 
testosterone concentrations in a patient with mild jaundice 
attributed to infective hepatitis. The patient subsequently 
developed gynaecomastia and Anderson found plasma testosterone 
levels to be high with oestradiol-17B values high or normal, though 
the concentration of unbound testosterone was low. He suggested 
that an increase of hepatic serum hormone binding globulin (SHBG) 
production following the attack of jaundice resulted in a fall in 
unbound testosterone. In turn this would stimulate LH release to 
the plasma and, consequently, increased Leydig cell activity, 
resulting in androgen production until the free testosterone levels 
(monitored by the hypothalamus) returned to normal.
Plasma testosterone levels were measured by radioimmnoassay in 
thirteen patients with cirrhosis, six of whom had gynaecomastia 
(Chopra et al 1973)* It was found that the serum testosterone 
levels were below the normal range in nine out of the thirteen men 
with cirrhosis and that the mean value was significantly lower than 
that found in normal men of comparable age. The percentage of
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serum testosterone which was dialyzable (ie. unbound fraction) in 
cirrhotic men was similar to that in normal men, but the 
concentration of unbound testosterone (total testosterone 
concentration x dialyzable fraction) was below normal in twelve out 
of thirteen patients. The serum concentrations of total and 
unbound testosterone in the six patients with gynaecomastia were not 
significantly different, however, from those patients with cirrhosis 
without gynaecomastia. The authors concluded that it was not the 
oestrogens or androgens on their own which were the main 
abnormality, but it was a ratio of the two which was important. 
Thus, the mean oestradiol-17 B/testosterone ratio in patients with 
cirrhosis was significantly higher than that in the normal men and 
was also further elevated in the presence of gynaecomastia, although 
this difference was not statistically different. They concluded 
that the lack of a clear relationship between an elevated 
oestradiol-17B/testosterone ratio and the occurrence of 
gynaecomastia in cirrhotic patients suggests that the development of 
gynaecomastia in cirrhosis may be related to factors in addition to 
oestrogen androgen imbalance, but these are obscure.
Plasma testosterone levels were also measured in fifteen patients 
with thyrotoxicosis, four of whom had gynaecomastia (Chopra et al 
1974). The mean serum testosterone level was significantly raised 
in those patients with thyrotoxicosis as compared to the mean value 
for normal men, but the oestradiol-17B/testosterone ration did not 
differ from that in normal men. However, the mean ratio of unbound 
oestradiol-17B to unbound testosterone in the hyperthyroid men was
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significantly higher than in normal men. The values of serum 
testosterone, dihydrotestosterone and unbound testosterone in the 
presence of gynaecomastia did not differ from those without 
gynaecomastia. Chopra and his colleagues proposed that it was the 
alteration in the balance between circulating unbound oestrogen and 
unbound androgen which might play a significant role in the genesis 
of gynaecomastia, particularly in hyperthyroidism.
More recently, Aiman et al (1980) reported studies of oestradiol-17B 
and testosterone secretion rates in three cases of gynaecomastia 
after testicular atrophy due to mumps orchitis. At the time of 
study, the ages of the men varied from 63-68 years. The mean 
plasma production rate of testosterone was 2 0 ? of the value found in 
normal elderly men without gynaecomastia, while the mean production 
rates of oestradiol-17B and oestrone were comparable to those of 
normal voung men. Plasma gonadotrophins were elevated due to 
decreased testosterone production. Conclusions were that the 
capacity of Leydig cells to secrete testosterone was impaired after 
mumps, but the capacity to form oestrogen was not similarly 
impaired, since most oestrogen is formed in extraglandular sites. 
Therefore, there was a reduction in the ratio of testosterone to 
oestrogen production rates and gynaecomastia resulted.
In summary, plasma androgen concentrations in gynaecomastia are 
variable while the plasma oestradiol-17B/testosterone ratio is fre­
quently elevated and the balance between circulating unbound 
oestrogen and unbound androgen is important.
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iii) Gonadotrophins and gvnaeoomastia
The above considerations lead to review of the findings related to 
gonadotrophin concentrations in gynaecomastia. Immunoassay 
estimation of gonadotrophins only became available in the early 
1 9 7 0 *s and so the levels of gonadotrophins have been measured in a 
small series of patients with gynaecomastia and the results of 
gonadotrophin estimates in the condition are conflicting.
Normal values for plasma LH and FSH, using a radioimmunoassay, were 
reported by Goldfine (1971) in a 1^-year old boy who developed 
spectacular gynaecomastia associated with pubescent growth and rapid 
sexual maturation. Lee (1973) studied a large number of normal 
children and some with endocrine abnormalities. It was found that 
the plasma LH and FSH concentrations, using a double antibody radio­
immunoassay technique, were within normal limits in six boys with 
gynaecomastia. Normal concentrations of plasma LH and FSH again 
using radioimmunoassay, were reported by La Franchi et al (1975) in 
sixteen boys with pubertal gynaecomastia.
In a report of men with gynaecomastia associated with chronic haemo- 
dialysis, the plasma LH and FSH levels, - measured by radio­
immunoassay - were studied in eight patients on haemodialysis 
without gynaecomastia and compared with seven men with gynaecomastia 
(Swerdloff et al 1970). The presence of gynaecomastia was not 
associated with elevated levels of plasma oestradiol-17B, testo­
sterone or FSH but all patients with gynaecomastia had increased 
plasma LH concentrations.
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In another group of five men with gynaecomastia, which had developed 
during haemodialysis for chronic renal failure plasma LH and FSH 
were measured using a radioimmmonassay. All patients had elevated 
plasma LH levels and four also had elevated plasma FHS levels (Sawin 
et al 1973). Whilst the cause of gynaecomastia was not clear these 
workers thought it was more likely to be related to elevation of 
plasma LH or plasma FSH or both, than to be due to increased plasma 
oestradiol-17B or oestradiol-17B/testosterone ratio.
In another study, however, the plasma LH and FSH concentrations, 
using a radioimmunoassay, were reported to be low in one patient 
with gynaecomastia of two and a half years duration (Smith, 1971).
In another case of gynaecomastia following infective hepatitis 
Anderson (1972) found that the plasma LH levels were persistently 
higher, or at the upper limit of normal for an adult male. He 
thought the elevated levels were associated with a low plasma testo­
sterone level which stimulated the LH production.
In a study by Chopra (1973) it was found that the serum 
concentration of LH was elevated in seven out of thirteen patients 
with cirrhosis, but serum FSH levels were normal. The method of 
estimation was by radioimmunoassay. However, the serum LH levels 
in the six patients with gynaecomastia and cirrhosis were not 
statistically different from the plasma LH levels in seven patients 
who did not have gynaecomastia.
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From these conflicting results, the role of gonadotrophins in 
intitiating gynaecomastia must still be in doubt, although in some 
groups with particular aetiology, for example, gynaecomastia 
commomly associated with renal dialysis, plasma LH and FSH appear 
to be consistently elevated.
iv) Prolactin and gynaecomastia
In a recent comprehensive study, Large et al (1980) carried out 24- 
hour profiles of circulating prolactin levels in eight boys with 
delayed puberty, eleven boys with gynaecomastia and two normal adult 
men. The mean 24-hour plasma prolaction levels in the four boys 
with delayed puberty and in ten boys with gynaecomastia exceeded the 
mean levels for the two adult men. Boys with gynaecomastia had 
higher 24-hour mean levels of plasma prolactin, higher day time 
levels and higher sleep associated levels than did control subjects. 
The levels were not related to the degree of duration of gynaeco­
mastia, but 24-hour mean plasma levels of prolactin and oestradiol- 
17B were positively correlated. The authors believed that 
oestrogen androgen imbalance during the day time was the major cause 
of gynaecomastia, with hyper-prolactinaemia sometimes occurring, as 
a response to relative hyperoestrogenaemia.
Using a bioassay, Turkington (1972) examined the plasma prolactin 
levels in twenty-nine adult patients with gynaecomastia associated 
with a variety of clinical conditions. The results showed that the 
prolactin levels were normal in all the patients. These results 
failed to provide evidence that prolactin was aetiologically related
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to the development of gynaecomastia.
In another study plasma prolactin levels were measured by an immuno­
assay in nineteen patients undergoing chronic haemodialysis (Nagel 
et al, 1973). Of these nineteen patients, eleven had 
gynaecomastia. The plasma prolactin concentration was elevated in 
seven of the patients, but these elevations did not correlate with 
the presence of gynaecomastia:plasma prolactin concentration was 
increased in four of the eight patients without gynaecomastia and 
only in three of the eleven with gynaecomastia.
In contrast, Van Thiel and others (1975) measured the plasma pro­
lactin levels by radioimmunoassay in fifty men with chronic 
alcoholism and varying degrees of alcoholic liver disease. Seven 
patients had gynaecomastia and these seven had plasma prolactin 
levels significantly greater than the values for men without 
gynaecomastia.
In summary, plasma prolactin concentrations have been found to be 
normal or elevated in gynaecomastia. The elevation may be a 
secondary phenomenon to increased oestrogen levels.
Results from all these studies suggest that in gynaecomastia plasma 
hormone results are variable. The plasma oestradiol-17B/testo- 
sterone ratio is frequently elevated. The plasma gonadotrophins 
may be elevated or normal and plasma prolactin may also be elevated 
or normal.
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It must be emphasised that in many of these reported studies the 
number of patients investigated were few. One of the reasons for 
results being variable may be the varied aetiology of gynaecomastia 
and it may well be that more meaningful interpretation of these 
studies may be obtained by categorising the results into different 
aetiologies.
While some conditions associated with gynaecomastia are not directly 
connected with an endocrine abnormality, hormones are probably 
associated with most types of gynaecomastia. Most conditions 
associated with gynaecomastia are diseases of endocrine organs, or 
with the administration of steroid hormones, eg. oestrogens or drugs 
which may resemble or release endogenous hormones. The occurrence 
of gynaecomastia at birth, puberty and old age in many otherwise 
healthy subjects is probably related to some hormone imbalance at 
these times.
With the availability of radioimmunoassays, hormone analysis can now 
be done on small amounts of blood taken sequentially and the concen­
trations of several hormones can be studied simultaneously. This 
is the basis for the present study of plasma hormones in 
gynaecomastia.
2. Methods of Study 
PATIENTS
Between 1972 and 1975, fifty-five patients with gynaecomastia were 
referred for an opinion at the breast clinic and these were all
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studied in a similar way. Four patients were not included in the 
plasma studies, as three of these patients did not have clinical or 
mammographis evidence of breast tissue and one further man had 
Klinefelter1 s syndrome and was excluded. None of the patients 
studied were suspected of having hormone-secreting tumours.
For each patient a standard questionnaire was completed which 
documented the age of onset of the breast swelling, length of 
history of the condition, the breast involved, the presence of 
breast pain or secretion, shaving habits, drug history, number of 
children, sexual function and occupation.
Clinical examination included careful palpation of the testes, the 
abdomen and both breasts. Presence of acne was also sought.
In younger boys a button-like nodule was usually easily detected and 
there was normally no confusion with adipose tissue. This was not 
the case in older men in whom the distinction was more difficult.
All patients aged twenty years and over had mammography carried out. 
Only when this confirmed the presence of breast tissue was a patient 
considered to have gynaecomastia. A mammogram typical of 
gynaecomastia is shown in Fig. 19* All men over twenty years also 
had X-rays of chest, skull and abdomen to exclude tumours of lung, 
brain and adrenals. Younger men did not have these X-rays 
routinely so as to avoid radiation.
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Fig. 19
Mammogram of a patient with gynaecomastia.
Laboratory investigations were performed in all patients. These 
included measurement of haemoglobin, protein-bound iodine or plasma 
thyroxine to exclude hyperthyroidism or hypothyroidism, blood sugar 
concentration, (random sample) - to exclude diabetes mellitus,
i
plasma cortisol concentration and liver function tests including 
measurement of serum bilirubin, SGOT, SGPT, lactic dehydrogenase and 
plasma proteins (to exclude liver disease) to delineate factors in 
gynaecomastia.
Age
The median age of the total group was 26 years - range 14-78 years - 
and in most cases the aetiology of the gynaecomastia was unknown 
(see later). The group was arbitrarily divided into two - young 
and old, 50 years of age being taken to be the dividing age ( 5 0  
years and above being included in the older group). In the young 
group, thirty-six men were studied, median age 25 years, twenty-five 
of whom were at or near puberty, the remainder being over 2 0  years 
of age. There were fifteen men over 50 years, median age 65 years 
- range 54-78 years.
Controls
These comprised twenty-eight normal older men who had no known 
history of endocrine disease and were not taking drugs of any kind. 
They were all ex-patients from a surgical ward who had had minor 
surgery more than one year prior to the study.
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The young controls were seven normal men from the Immunoassay 
Section Hormone Laboratory. All were healthy men with no history 
of endocrine disease and none were taking drugs. The median range 
of ages are shown in Tables XXII and XXIII.
Results
(a) General and histological appearance
In the group of fifty-one patients, fourteen had right sided 
gynaecomastia, twenty-four had left sided and thirteen men had 
bilateral disease. Gynaecomastia was of longer duration in 
patients with bilateral disease (an average of 4 years 3 months) as 
compared with unilateral gynaecomastia ( 1 year 8 months).
Two typical cases are shown in Figures 20 and 21 and the course 
summarised in the legends. Figure 20 shows the typical external 
appearance of gynaecomastia as seen in a 25 year old man who had had 
gynaecomastia for two months. Figure 21 is of a 14 year old boy 
who three years previously had had breast tissue removed - the old 
scar is seen. The swelling had recurred two months prior to this 
picture. In patient Number 1 the swelling subsided and no 
operation was necessary, but patient Number 2 had a mastectomy 
because of breast discomfort.
Thirty-one patients had breast tissue removed by surgery under 
general anaesthesia. This was sent for routine pathology and in 
all cases, gynaecomastia was confirmed histologically on H and E 
paraffin section. Figure 22 is a photomicrograph of breast tissue
158
TABLE X X I I
Gynaecomastia 
under 50 years
n = 36
Controls 
under 50 years
n = 7
Mean + SD or range Mean
+ SD 
or range t p
Median
Age
Median
Age
25 14 - 46 28 2 2 - 4 7
Log LH 
LH
1.62
5.04
+0.62 
2.7-9.4
1.97
7.20
+0.04 
6 .9-7.5
1.63 NS
Log FSH 
FSH
1.29
3.63
+0.5 
2 .2 -6 . 0
1 . 2 0
3.32
+0.63 
1 .8-6 . 2
0.42 NS
Oestradiol 17B 92.0 +30.9 98.3 +27.6 -
Testosterone 2 2 . 0 +8.9 - 10.4-35
NR
-
Prolactin 1 2 0 +60 - 0-600
NR
-
LH - expressed in U/l
FSH - expressed in U/l
Oestradiol 17b - expressed in pmol/1
Testosterone - expressed in nmol/1
Prolactin - expressed in mU/1
NR = normal range
NS = not significant
Mean plasma concentrations _+ SD or range for each hormone from 
a single blood sample in younger men (under 50 years) with or 
without gynaecomastia.
TA B LE X X I I I
Gynaecomastia 
50 years and over
n = 15
Controls 
50 years and over
n = 28
Mean + SD or range Mean
+ SD 
or range t P
Median
Age
Median
Age
65 54 ~ 78 70 6 1 - 8 6
Log LH 
LH
2.69
14.80
+0.61
8.0-27.1
1.84
6.31
+0.58
3.5-11.2 4.61 <0 . 0 0 1
Log FSH 
FSH
2.62
13.74
+0.85
6.2-32.1
2.03
7.61
+0.64
4.0-14.4
2.61 <0 . 0 2
Oestradiol 17B 143.1 +43.4 111.9 +63.7 4.20 <0 . 0 0 1
Testosterone 22.7 +1 0 . 1 2 1 . 6 +7.3 0.33 NS
Prolactin 140 + 2 0 - 0-600
NR
- -
LH - expressed in U/l
FSH - expressed in U/l
Oestradiol 17B - expressed in pmol/1
Testosterone - expressed in nmol/1
Prolactin expressed in mU/1
NR = normal range
NS = not significant
Mean plasma concentrations hh SD or range for each hormone from a 
single blood sample in older men (50 years and over) with and 
without gynaecomastia.
Fige 20
Patient No, 1
A photograph of a 25 year old man with right sided gynaecomastia 
of 2 months' duration.
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Fig. 22
Photomicrograph of breast tissue removed from patient in 
Fig. 21.
removed at surgery from patient Number 2. This shows the typical 
picture of gynaecomastia with elongated dilated ducts associated 
with stromal hyperplasia.
Past History
Associated disease was found in ten patients with gynaecomastia and 
in nine patients there was a history of treatment with drugs. The 
details are detailed in Table XXIV.
Routine Screening Test Results
Liver function tests, including the measurement of serum bilirubin, 
SGPT, SGOT and alkaline phosphatase level and protein bound iodine 
or plasma thyroxine were normal in all patients. No case of 
diabetes mellitus was found. None of the patients were anaemic and 
none had abnormal changes in diurnal plasma cortisol levels. All 
X-rays of chest, skull and abdomen were normal.
Plasma Hormones in Single Samples
The first twenty-seven from the total of fifty-one men had only one 
single sample of blood taken at 9*30 am for estimation of plasma 
LH, FSH, oestradiol-17B, testosterone and prolactin. The following 
twenty-four consecutive patients who were not selected in any 
different way from the first twenty-seven patients, had multiple 
blood samples taken, including one at 9.30 am. The latter patients 
with multiple blood samples form the basis of the studies described 
in more detail below.
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TABLE X X IV
Associated Conditions Number of Patients
Seminoma of Testis 2
Tuberculosis of Testis 1
Hypospadias 1
Dystrophica Myotonica 1
Bilateral undescended Testes
History of alcohol ingestion 1
Congestive cardiac failure 3
History of drug intake 9
Clinical conditions associated with the 
patients who had gynaecomastia.
Single Samples
To allow comparison of plasma hormone concentrations on all the 
total group of fifty-one men, the value for the 9 . 3 0  am sample has 
been used. The results are presented in Table XXII and XXIII along 
with similar samples in thirty-five normal men. These have been 
divided into two groups - younger ( < 5 0  years) and older (50 years or 
more). In the younger men no significant change was detected in 
any plasma hormone concentration between men with gynaecomastia and 
normals. In the older men with gynaecomastia the gonadotrophin and 
oestradiol-1 7 B concentrations were elevated as compared with the 
corresponding control group. This elevation was highly 
significant.
Multiple Samples
Study 1; Plasma hormone concentrations over £. hour sampling period 
in men with gynaecomastia and control subjects
Six men with gynaecomastia were studied whose ages and clinical 
background are shown in Table XXV. The control subjects were seven 
healthy normal male volunteers from the Regional Hormone Laboratory 
(now Immunoassay Section, Clinical Chemistry Department, Royal 
Infirmary) aged 22-47 years and two normal older men with no history 
of endocrine disorders or drug history (aged 62-64 years). In this 
group of fifteen men, intensive sampling was carried out to 
determine the pattern of change with time.
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TA B LE XXV
Subject Age in years Possible Aetiology of Gynaecomastia
1 16 Pubertal
2 37 Seminoma testis treated by orchid- 
ectomy and radiotherapy 1 year 
before gynaecomastia
3 55 Drugs: Bendrofluazide and Digoxin 
for 6 months before gynaecomastia
4 70 Drugs: Salbutamol and Prednisol­
one for 3 months, 2 years before 
gynaecomastia
5 71 Unknown
6 73 Bilateral undescended testes
Age and clinical details of the six patients with 
gynaecomastia in Study 1.
Method of Sampling
Both patients and control subjects had their blood withdrawn as 
described in the General Methods Section every 15 minuts for 8 hours 
starting between 9.30 and 10 am. Plasma was prepared as described 
previously and the levels of plasma LH, FSH, oestradiol-17B, testo­
sterone and prolactin were measured.
Results ri. Study JL
The plasma hormone levels showed considerable variation over the 8  
hour period for all the hormones studied in six patients with 
gynaecomastia and nine control men. Plasma FSH had the least 
variation with coefficients of variation for each patient around 
15%• Plasma LH and oestradiol-17B had coefficients of variation
around 2555 over the 8 hour period.
To seek pulsatile patterns of hormone secretion a test described by 
Moore and Wallis (19^3) was used. This consisted of counting the 
number of upward steps in the hormone levels in the patients who 
were studied with gynaecomastia and normal subjects and comparing 
this with the number of upward steps expected in a completely random 
series (see Method Section). Pulsatile secretion should result in 
a fewer upward steps, at the pulses, followed by a larger number of 
downward steps during the decay phase. This analysis was carried 
out in all six patients and nine controls.
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Only the plasma levels of LH in the young controls showed a 
significantly raised number of upward steps compared with a random 
series, and plots of the plasma LH levels with time confirmed the 
existence of a pulsatile pattern in all subjects in this group with 
pulses at intervals ranging from 30 minutes to two hours. This 
pattern of LH was not observed in any other group.
The plots of FSH and oestradiol-17 B levels with time for 
individiual patients and controls were also examined by this 
statistical test and these did not suggest any common pattern of 
variation for any group. An example of these patterns is given in 
Figure 23. This includes one of the young men with gynaecomastia 
as contrast to one of the young controls, and an old man with 
gynaecomastia as compared with a normal old man. This seems to 
illustrate the existence of a pulsatile pattern of LH in the normal 
young man, but not in the other groups.
To test whether any of these hormones measured varied one with 
another, rank correlations (Kendall1 s) were compared for the sets of 
hormones measured at 15 minute intervals for each patient. Pooled 
tests for each group showed only one correlation that was signficant 
at the 5$ level, namely a value of 0 . 3 7 for the correlation between 
LH and FSH, in the young controls (Table XXVI).
Conclusion
This study of sequential sampling indicated that there was no 
obvious pulsatile variation in the levels of the hormones studied
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Example of plasma LH and FSH and oestradiol 173 profiles from 
2 patients with gynaecomastia and 2 controls one from each age 
group.
TABLE X X V I
Young 
Gynae c omas t i a Controls Gynaecomastia Controls
LH - FSH 0.03 0.37* 0.04 -0 . 1 0
E2 - LH 0 . 0 1 0.07 0.09
E2 - FSH 0.04 0 . 1 0 0.16 -
*p<0 . 0 1  on a combined test i.e. that correlation is zero for 
all the subjects.
Pooled correlation for each group of patients with gynaecomastia 
and control subjects for daily variations in hormone levels
i.e. average rank correlation (Kendall’s t).
(other than LH in normal young men) over an 8 hour period. For 
this reason it was considered justifiable to restrict sampling to a 
2 hour period, during which, 4 half-hour samples were taken and to 
use this method for studying a larger series of patients.
STUDY 2.
Comparison of mean plasma hormone concentrations of JL half hourly: 
samples in patients with gynaecomastia and normal males
A total of twenty-four male patients were studied, including the six 
subjects investigated in Study 1 and a further eighteen men. Of 
these twenty-four patients, eight had right sided gynaecomastia, 
twelve left sided and four bilateral gynaecomastia. The apparent 
duration of gynaecomastia was one year or less in eighteen out of 
twenty-four patients and more than two years in only three patients, 
two of whom were in the bilateral group.
Seventeen patients under the age of 50 years were classified as 
"young men" and formed a group with a median age 2 1 years (range 15- 
46). The remaining seven had a median age of 6 8 years (range 55- 
71); Table XXVII. Four of the seventeen young men with gynaeco­
mastia were married with children. The remainder were unmarried. 
All, except two had testes which were normal in size and 
consistency. These two men had a history of seminoma of testis 
treated by orchidectomy and radiotherapy before the development of
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TABLE X X V I I
Numbers Median age in years
Range in 
years
Young
Controls 7
28 22 - 47
Young
Gynaecomastias 17
2 1 15 - 46
Old
Controls
28 70 61 - 8 6
Old
Gynaecomas tias 7 6 8 55 - 71
Study 2
Numbers studied and median age of patients with 
gynaecomastia and control subjects who had multiple 
plasma hormone sampling.
gynaecomastia.
Buccal smears in all the younger patients were negative for the Barr 
antibody. Klinefelterfs syndrome was therefore excluded.
Two patients had received drugs (one man had had a short course of 
stilboestrol seventeen years before the onset of gynaecomastia and 
also reserpine five years before; the other patient had been 
smoking marihuana for one year until one month prior to onset of 
gynaecomastia).
Five of the seven older men with gynaecomastia were married with 
children, one married with no children and one was unmarried. In 
this group, one patient had congestive cardiac failure, one an 
undescended testis of long standing and three others were on drugs. 
One had been taking salbutamol and prednisolone, one bendrofluazide 
and digoxin and the third man spironolactone, methyl dopa and 
Distalgesic (all drugs were continued till one day prior to the 
studies). The various clinical conditions and drugs are shown in 
Tables XXVIII and XXIX.
Controls comprised seven normal young and twenty eight older men. 
The young controls were seven normal men from the Immunoassay 
Section, Clinical Chemistry. All were healthy men with no history 
of endocrine disease and none were taking drugs. • The older 
controls comprised of twenty-eight normal older men (described 
previously) who had no known history of endocrine disease and were
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TABLE X X V I I I
Associated Condition No. under 50 No. over 50
Seminoma Testis 2 0
Undescended Testis 0 1
Cardiac Failure 0 1
History of drugs 2 3
Unknown aetiology 13 2
Clinical conditions associated with 24 patients with 
gynaecomastia who had plasma hormone studies.
TABLE X X IX
Number of Patients Drugs Involved . Age
salbutamol, prednisolone . . 70
bendrofluazide, digoxin 55
1 reserpine, stilboestrol 46
1
spironolactone, methyl dopa, 
"Distalgesic". 62
marihuana 2 0
Pharmacological agents taken by this group of 24 patients with 
gynaecomastia who had intensive plasma studies.
not taking drugs of any kind. They were all ex-patients from a 
surgical ward who had had minor surgery more than one year prior to 
the study. The median range of ages are shown in Table XXVII.
Method of Sampling
All men had blood withdrawn at 30 minute intervals for two hours in 
the morning. The appropriate samples from the subjects in Study 1 
were also included. The procedure for obtaining blood and the 
method of assay for plasma LH, FSH, oestradiol-17B, testosterone and 
prolactin were as described in the General Method Section.
Results ^  Study 2.
The hormone levels between different groups of patients were 
compared using the mean concentrations from the four half-hourly 
morning samples. The median starting time of sampling for the 
patients with gynaecomastia with four half-hourly samples was 1 0 am. 
(range 9 am - 11.25 am). For those with the longer series of 15 
minute samples, (Study 1 patients) the equivalent samples were used 
to represent each patient in order to ensure that valid comparisons 
were made. Since serum levels of gonadotrophins have been shown to 
have a log-normal distribution (Wide et al 1973; Hunter et al
1974), logarithms of LH and FSH values were used in the statistical 
analysis. However, the distributions of the arithmetic values for 
testosterone and oestradiol-17B appeared to be symmetrical and log- 
transformation was not used. To allow for correlations between 
various hormone levels, multi-variate statistical tests (Hotellings 
T2 test) were used instead of individual t tests for each hormone
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(described previously in Statitistical Methods Section).
Mean Plasma Hormone Levels using four half hourly samples - 
Expression of results
The results are expressed in three ways.
1. Scatterplots of the mean values of plasma LH, FSH for each 
patient for the two groups of patients and their controls are 
produced in Figures 24 and 25, and for oestradiol-17B tests in 
Figure 26. The two patients with seminomas had markedly increased 
plasma levels of LH and FSH compared with the rest of the young 
patients with gynaecomastia (Fig, 24), and were therefore excluded 
from all further analysis of plasma hormone levels. Therefore the 
results in Table XXX include only twenty-two men (fifteen under 50 
years). Those patients with a drug history in either the young or 
older group did not have levels different from the other patients 
with gynaecomastia in their respective age groups and so were 
included.
2. In Table XXX the mean values of the four hormones for each group 
of patients are shown. The means of LH and FSH are geometric 
means. For testosterone and oestradiol-17B arithmetic mean values 
and standard deviations are given.
3. The correlation coefficients between the mean hormone levels 
for pairs of hormones in each group of patients and controls have 
been calculated and are given in Table XXXI.
166
L.H. 
U / 1
2 0 0 -1
100 -
5 0 -
20-
x-^ x
1 0
i
2- 5
 1--
5 0
F S H  U / l
X young normals
•  young gynaecomastics
© bilateral gynaecomastia
■  mean of normals
□  mean of gynaecomastics
S seminoma
0 drugs
100 200
— I
5 0 0
Fig. 24
Plasma LH and FSH concentrations for all patients and controls 
under 50 years. Ellipses show 95% confidence regions for the 
estimated, means-controIs (upper ellipse) and patients with gynae­
comastia (lower ellipse). The two seminoma patients are excluded 
from the calculations of the mean for the gynaecomastic group. 
Note log. scales for both LH and FSH.
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Fig. 25
Plasma LH and FSH concentrations for all patients with gynae­
comastia and controls over 50 years. Upper ellipse shows 95% 
confidence region for the estimated mean of patients with gynae 
comastia. Lower ellipse gives 95% confidence region for the 
controls. Note log. scale on both axis.
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Plasma oestradiol 173 and testosterone concentrations for all 
patients with gynaecomastia over 50 years. Smaller ellipse gives 
9 5 % confidence region for the estimated mean of the controls; 
larger ellipse the 95% confidence region for the estimated mean 
of the patients with gynaecomastia.
TABLE XXX
Gynaecomastia 
under 50
Controls 
under 50
Gynaecomastia 
over 50
Controls 
over 50
N 15 7 7 28
LH Mean* 3.82 6.98 14.54 5.98 '
u/l + 1 sd 2.32-6.30 4.97-9.78 8.98-23.40 3.62-9.37
FSH Mean* 3.12 3.00 15.07 7.58
u/l + 1 sd 2.36-4.13 2.38-3.78 5.96-38.30 3.84-14.97
E 2
Mean 96 1 0 1 142 1 0 1
pmol/ 1 sd (31) (26) (48) (24)
T Mean 23.0 t 21.9 21.5
nmol/ 1 sd (9.4) f (12.7) (7.4)
* For LH and FSH these means are calculated from the logarithms 
of the raw data, and are thus the geometrical means of the LH 
and FSH values; the range gives the raw values equivalent of 
+ 1 standard deviation of the log values, other means are arithmetic. 
- No testosterone values are available for normal young controls.
Mean plasma hormone concentrations from four morning samples, in 
patients with gynaecomastia and in control subjects.
TABLE XXXI
Gynaecomastia 
under 50
Controls 
under 50
Gynaecomastia 
over 50
Controls 
over 50
N 15 7 7 28
LH/FSH 0.81* 0o87* 0.72* 0.67*
lh/e2 0o 25 -0o 71* 0o 17 -0 . 1 0
LH/Test 0o 15 t -0.14 0.29
fsh/e2 0 o 18 -0,82* -0.35 -0.14
FSH/Test t t -0.37 0.25
^2 /Test 0.58* t 0.81* 0.43*
* p < 0o05 that correlation is zero 
t No testosterone values available on young controls 
Note: LH and FSH values are on a log0 scale
Correlations between the mean plasma hormone concentrations in 
men with and without gynaecomastiaQ
In considering these results, change in absolute levels of gonado­
trophins will be considered first; oestrogen and testosterone 
second and thirdly correlations between them.
(i) Plasma LH and FSH Mean Level_s_
In Fig. 24 the distribution of LH and FSH for the controls and 
patients with gynaecomastia under 50 years is shown. The ellipses 
give the 9 5 # confidence intervals on a one-dimensional plot, and 
their elongation is a consequence of the correlation between the two 
hormones. The separation of the ellipses indicates a significant 
difference between the mean values of the two groups and the 
appropriate test of significance confirms this (Hotellingsfs T2 test 
p<0.01). The young patients with gynaecomastia had lower plasma LH 
values than the controls, but similar plasma FSH values and thus 
exhibit a lower LH/FSH ratio.
The equivalent plot for the older groups is shown in Figure 25. 
Again the patients with gynaecomastia differ from the controls but 
now the pattern is different. The men with gynaecomastia have 
raised values of both LH and FSH and the ratio LH/FSH is similar in 
the two groups (Hotellingsfs T2 p<0.01). The mean levels of LH and 
FSH given in Table XXX reflect these changes. However there is also 
evidence that the plasma FSH levels but not the LH levels are raised 
in the normal older controls compared with the younger controls (p 
value <0.01 studentfs t test). The scatter of FSH but not LH is 
also greater for the older men (p<0.01 variance ratio (F) test).
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(ii) Plasma 0estradiol-17B and testosterone mean levels 
Figure 26 shows the scatter of testosterone and oestradiol-17B 
values for the two older groups. Here there was a significant 
difference in the group means (p<0 .0 1 ), the patients with 
gynaecomastia having raised plasma oestradiol-17B but similar 
testosterone levels, ie. a raised E2 /T ratio, as compared with old 
controls. This is also shown by the mean value in Table XXX. 
From the standard deviations in Table XXX it can be seen that the 
scatter of both oestradiol-17B and testosterone is greater for this 
group with gynaecomastia than for the controls (p<0 . 0 1  on a 
likelihood ratio test).
Due to technical reasons, no plasma testosterone levels were avail­
able for the young controls. However, plasma oestradiol-17B levels 
for the young men with gynaecomastia were not significantly 
different from those for the young controls (trO.611, not sig).
Plasma Prolactin - mean levels
No values for plasma prolactin concentrations were obtained from 
controls. The values for the two groups of patients with gynaeco­
mastia are given in Table XXXII. The known normal range for plasma 
prolactin values in males is 0-600 mU/1 and both groups are within 
this normal range. It would seem therefore that plasma prolactin 
levels are within normal limits in this group of patients with 
gynaecomastia.
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TABLE X.XXII
Plasma Prolactin mU/1
N Mean Variance
Gynaecomastia < 50 28 155 6
Gynaecomastia > 50 7 198 25
Mean plasma prolactin concentrations in patients 
with gynaecomastia.
(iii) Correlations of hormones.
The correlation coefficient between hormones in Table XXXI indicate 
that a significant correlation existed between LH and FSH values in 
all groups, and also between oestradiol-1 7 B and testosterone in 
older men. However, with the exception of plasma FSH and 
oestradiol-17B in the young controls, the levels of steroids within 
a group were not related to these of gonadotrophins.
k. Discussion
Gynaecomastia is a disease of many different aetiologies, as 
described in the earlier suggested classification. Many varied 
conditions e.g. adrenal tumours, cirrhosis of the liver and drugs 
are associated with breast enlargement in men. There may be common 
reasons for gynaecomastia, including abnormal target organ 
sensitivity and or a disordered hormonal profile. There is, 
however, still the possibility that certain forms of gynaecomastia 
may not be associated with hormone abnormalities. Nevertheless, 
gynaecomastia associated with a physiological aetiology, e.g. 
gynaecomastia in puberty or in old age is most likely to be 
associated with hormonal disturbances; it is at these stages in the 
male life at which the biggest changes in hormones occur. The aim 
of this study was to ascertain whether circulating levels of 
hormones in men with gynaecomastia differed from those in normal 
men. Before it was possible to determine if hormonal abnormality 
existed in patients with gynaecomastia, it was necessary to have 
reliable reference values for hormone concentrations in normal men 
without gynaecomastia. There were potentially problems in
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determining base line data because of reported pulsatile 
fluctuations in hormone secretion. Furthermore, it was not a 
simple matter of measuring one hormone, as it was important to 
investigate the relationship and ratios of various hormones.
The present study has confirmed that there was a pulsatile pattern 
of plasma LH in normal young men (Nanken and Troen 1971 > Santen and 
Barden 1973) but no evidence of this was found in normal older men 
or in older men with gynaecomastia, or indeed in the group of young 
men with gynaecomastia. It could be that as the patient grows older 
and the levels of LH and FSH rise (Rubens et al 1974), the pulsatile 
pattern is lost. Possibly both raised plasma gonadotrophin levels 
and absence of pulsatility of LH are consequences of testicular dys­
function. Such subnormal gonadal function might occur in old age but 
has yet to be consistently proven in young men with gynaecomastia.
Because of the known pulsatile variation of plasma LH, a suitable 
sampling procedure was required. The two hour sampling period used 
in this study reduced the considerable within-day variation seen in 
all the hormones. Its success was gauged by calculation of the 
coefficient of variation of the means of all possible sets of 4 
half-hourly samples taken from our 8 hour series. In all cases the 
coefficient of variation was reduced by a factor of about 2 , 
indicating that samples taken over a 2 hour period had a range of 
values similar to those found in the 8 hour series.
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Based on these mean levels, the younger group of patients with 
gynaecomastia showed evidence of abnormality of plasma gonadotrophin 
levels with decreased LH/FSH ratio, while their oestradiol-17B levels 
did not differ significantly from control values.
The older men with gynaecomastia were found to have two-fold higher 
values of both plasma LH and FSH compared to normal old men with a 
similar LH/FSH ratio, and elevated oestradiol-17B levels. Plasma 
testosterone values were within normal limits.
It appears that plasma LH/FSH ratio is reduced in young men with 
gynaecomastia. Therefore, it could be supposed that a lowered 
plasma LH concentration is not stimulating the Leydig cells to 
produce an adequate plasma androgen level, the negative feedback 
mechanism in the pituitary is stimulated, and more FSH is produced 
by the sertoli cells to increase plasma oestrogen concentrations. 
The mechanism of the anti-developmental effect of androgens on the 
breast has not been fully elucidated, but it could be a lower 
androgen value allows unopposed oestrogen to stimulate breast 
development.
The findings of raised plasma gonadotrophin levels in normal older 
men agree with the findings of previous workers (Schalch et al, 
1968; Rubens et al, 197^5 Ryan and Faiman, 1968). Thus the mean 
plasma FSH level was 2.5 fold higher in our twenty-eight older 
controls (median age 7 0 ) as compared with eight young controls 
(median age 2 8 ) and the values more widely spread about their group
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mean; no elevation was observed for LH levels. These changes 
appear to represent a response of the pituitary to decreasing 
testicular function characterised by a falling testosterone and 
rising oestradiol-17B and oestrone levels (Burger et al, 1974; 
Rubens et al, 1974), In the present work too, plasma oestradiol- 
17B concentration was raised but testosterone was unchanged.
In the younger patients with gynaecomastia the oestradiol-17B levels 
did not differ significantly from those in controls of the same age. 
Although no control values were available, the plasma testosterone 
values in young patients with gynaecomastia did not differ from 
either the older controls or the patients over 50 years with 
gynaecomastia.
Of four previous reports on plasma oestradiol-17B levels described 
in the literature, there were two studies (each on a single patient) 
one of which described similar findings (Smith, 1971)» while the 
other reported an elevated oestradiol-17B level. (Goldfine et al, 
1971). A more intensive study on sixteen pubertal boys, reported 
elevated plasma oestradiol-17B levels in six out of sixteen patients 
and a raised oestradiol-17B/testosterone (E2 /T) ratio in eleven (La 
Franchi et al, 1975). Large and Anderson (1978, 1979) found that 
oestradiol-17 B levels rose with advancing puberty, the highest 
values were found in two boys with gynaecomastia and in a boy who 
later developed gynaecomastia. They also found a marked variation 
in the E2/T ratio throughout 24 hours, and suggested that the 
exposure of the male breast at puberty to significant levels of
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oestrogens unopposed by androgens during the daytime, when plasma 
testosterone levels were lowest, might account for transient 
gynaecomastia at puberty.
In the older patients with gynaecomastia studied here, the 
oestradiol-17B levels were elevated while the plasma testosterone 
values were within normal limits. The E2/T ratio was therefore 
raised in these older men with gynaecomastia, in agreement with the 
finding of Chopra et al (1973) who found an elevated E2/T ratio in 
thirteen older men with cirrhosis (mean age *16 years) compared to 
the ratio in normal men, and an even higher ration in men with 
cirrhosis who also had gynaecomastia. This study reported results 
in older men with gynaecomastia in a similar age group to our group 
of men.
In the absence of any significant evidence for gonadotrophins 
directly acting on breast tissue and the fact that oestrogens are 
known to stimulate breast growth (Dunn, 19^0; Fitzsimmons, 1 9 W >  
it may be that gynaecomastia is not due to an abnormality of LH/FSH 
ratios but that these ratios lead to an increase in oestrogens in 
the presence of normal androgen levels and therefore an increased 
E2/T ratio. A rise in plasma oestrogens without a concomitant rise 
in androgens may be the primary cause of breast tissue growth. 
Thus the abnormality in circulating gonadotrophins and oestradiol- 
17B may ultimately be united in a single hypothesis.
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The mechanism whereby raised plasma gonadotrophin levels in the 
older men with gynaecomastia are associated with oestrogen/androgen 
imbalance still remains to be elucidated. However, if the 
elevation of plasma LH and or FSH are a result of primary gonadal 
dysfunction due to old age, then it is possible that in association 
with a plasma LH stimulation of the Leydig cells to maintain a 
normal level of androgen production, there is also a concomitant 
rise of FSH levels which would in turn stimulate the synthesis of 
oestrogen from testosterone by the Sertoli cells.
0estradiol-17B can be shown to be synthesised by Sertoli cells from 
the testes maintained in cell culture. Addition of FSH caused a 
slight but significant increase in oestradiol-17B synthesis while in 
the presence of testosterone, FSH produced a 12-fold increase in 
oestradiol-17B synthesis. The conclusion was that not only do 
Sertoli cells synthesis oestradiol-17B from testosterone, but this 
conversion is markedly stimulated by FSH when added with 
testosterone (Dorrington and Armstrong, 1975). There are, 
however, other possible pathways to oestrogen/androgen imbalance 
which include changed capacity for metabolism of steroids by breast 
tissue or changes in adrenal function.
The mechanism whereby disturbed oestrogen/androgen balance in male 
breast tissue, leads to gynaecomastia is also unknown. Oestrogen 
receptors are probably present in both normal male and female breast 
since the tissues are oestrogen-sensitive, but by present methods 
the level of receptor activity is barely detectable (Leclerq et al,
m
1975). The anti-oestrogenic effects of androgens in breast cancer 
may be mediated via the oestrogen receptor (Davies et al, 1977; 
Nicholson et al, 1978; Zava and McGuire, 1978; Adams et al, 1981). 
At low concentrations androgens may bind only to the androgen 
receptor but at very high concentrations they can also bind to the 
oestrogen receptor and cause translocation of the oestrogen receptor 
to the cell nucleus where the androgen receptor complex is inactive; 
this process may be involved in tumour regression. It may be that 
equally in normal men, normal concentrations of androgens are 
involved in suppressing breast growth by this kind of mechanism 
whilst in gynaecomastia, lowered oestrogen/androgen ratio leads to a 
greater translocation by oestrogen rather than androgen. 
Alternatively, it may be that androgens inhibit oestrogen action in 
the normal male by a different mechanism eg. by affecting nuclear 
type II receptor sites in a manner similar to that described for the 
effects of progesterone and dexamethasone (Clark, Upchurch and 
Markaveich, 1981). Thus it is possible that in the breast tissue 
from pubertal and aging males the elevation of plasma oestradiol-17B 
levels and fluctuations in the E£/T ratio might permit expression 
rather than suppression of oestrogen-induced stromal hypertrophy.
It has been shown (in vitro) that gynaecomastic breast tissue lacks 
the enzyme 3 /3-hydroxy steroid dehydrogenase; (3 p HSD) (Miller et 
alt 197*0. In the testis this enzyme is influenced by both steroid 
and pituitary hormones (Hafiez et al, 1972). If 3 p-hydroxy steroid 
dehydrogenase in breast tissue is also influenced by hormones, an 
imbalance of circulating hormones could diminish the enzymic
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activity in gynaecomastic breast leading to diminished production of 
testosterone or other 3 B-hydroxy androgens and diminished 
suppression of breast growth.
Changes in pituitary hormones other than gonadotrophins e.g. 
prolactin, may also be associated with the aetiology of gynaeco­
mastia. However, in the present limited study, plasma prolactin 
values were within normal limits for both young and older men with 
gynaecomastia. This is in agreement with a previous study by 
Turkington (1972) who, using a bioassay technique, found normal 
plasma prolactin levels in twenty-nine men with gynaecomastia. 
Nagel and his colleagues (1973) however reported variable prolactin 
levels in patients with gynaecomastia on a chronic dialysis 
programme, while Van Thiel et al,(1975) found increased plasma 
prolactin concentrations in chronic alcoholics particularly those 
with gynaecomastia. Large et al (1980) reported higher mean 24- 
hour plasma prolactin levels in boys with gynaecomastia than 
controls. Thus despite our negative findings, a role for prolactin 
in the aetiology of gynaecomastia cannot be dismissed. 
Nevertheless, changes in plasma prolactin could be secondary to 
those in oestrogen and/or gonadotrophin secretion.
Whilst as a group, patients with gynaecomastia may have abnormal 
levels of hormones, many individuals with gynaecomastia appear to 
have normal values. In order that these normal levels may give 
rise to gynaecomastia it is likely that a second factor ie. abnormal 
sensitivity of breast tissue to endocrine stimulation, is present in
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these cases. Certainly some degree of differential sensitivity to 
hormones must exist between each breast. Both breasts are exposed 
to the same circulating hormone levels and one would suppose that if 
these were the only causative factors, then gynaecomastia would 
always be present initially as bilateral disease.
5 . Conclusion
In summary, both alteration in hormone levels, (especially in the 
oestrogen/androgen ratio) and in tissue sensitivity appear to be 
involved in the aetiology of gynaecomastia. In the normal 
situation, the steroids from the testis are under control of the 
pituitary-hypo thalamic system by a negative feedback mechanism. If 
in old age, or other predisposing conditions, the testicular 
activity diminishes the negative feedback mechanism will be 
diminished also, permitting an enhanced release of FSH with or 
without LH to the plasma in an attempt to maintain a normal plasma 
testosterone level. This may lead to an over-stimulation of the 
Sertoli cells (independent of the Leydig cells) which will produce 
more oestradiol-17B, resulting in a raised oestrogen/androgen ratio 
and a greater stimulation at the oestrogen receptor sites. However 
not all people have raised oestrogen/androgen ratios, which could be 
due to, for example inherited or acquired differential sensitivity 
(a) to feedback in the hypothalamus, or (b) of the Sertoli and 
Leydig cells in the testis. Furthermore, not all people with 
raised oestrogen/androgen ratios develop gynaecomastia and this may 
be due to variations in the sensitivity in the breast tissue to 
hormones; the reasons for these variations are also as yet unknown.
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5. Conclusion
1. In young men with gynaecomastia, the concentration of plasma LH 
and consequently the LH/FSH ratio was lower than that in the control 
subjects.
2. In older men with gynaecomastia, both plasma LH and FSH 
concentrations were higher than those in normal controls, but the 
LH/FSH ratio was similar in the two groups.
3. In older men with gynaecomastia, plasma oestradiol-17B levels 
and the oestradiol-17B/testosterone ratio were higher than those in 
the controls.
H. Older controls had higher plasma FSH levels than younger 
controls.
5. A pulsatile pattern of plasma LH was present only in the young 
controls.
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IV
CONCLUSION
IV. CONCLUSION
There can be little doubt that hormones influence breast development 
both in males and females. The aim of this study was to examine in 
more detail plasma hormone levels in women with breast cancer and in 
men with gynaecomastia.
The conclusions of the studies of the women with breast cancer are 
summarised below.
In the intensive sampling regime of plasma hormones over a six 
to eight hour period, plasma LH, FSH, testosterone, oestradiol-17B, 
prolactin and cortisol levels were all within normal limits in six 
postmenopausal patients with breast cancer, when compared with six 
patients without the disease, matched for age, parity and menstrual 
status.
Within the normal range, plasma testosterone levels were 
significantly higher in each breast cancer patient, compared with 
her control.
Plasma oestradiol-17B levels were also higher in five out of six 
women with breast cancer but not significantly so.
No pulsatile pattern of plasma LH levels was detected in any woman 
whether with or without breast cancer.
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In both groups of women there was a fall of plasma cortisol 
concentration two hours after the start of the tests.
Plasma FSH, prolactin, testosterone and oestradiol-17B levels were 
measured in postmenopausal women with advanced breast cancer, before 
and on treatment with stilboestrol or tamoxifen. Tamoxifen 
treatment significantly decreased plasma FSH levels at one, three 
and six months but had no effect on plasma prolactin concentrations, 
or any of the other hormones measured.
Stilboestrol treatment had a more profound effect in suppressing 
plasma FSH levels at one, three and six months but also 
significantly increased the levels of plasma prolactin.
These effects on plasma hormone levels were present in all patients 
and therefore were not related to clinical response to the drug.
When specific pituitary releasing hormones and drugs were used to
devise an optimum test of pituitary function, it was found that TRH 
was a better stimulant of plasma prolactin concentrations than 
chior promaz ine.
LHRH increased plasma LH and FSH levels; the addition of TRH to
LHRH did not change the response of LH and FSH.
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It was concluded that the best test of pituitary function in a woman 
with breast cancer about to undergo yttrium implantation of the 
pituitary was a combination of LHRH, TRH and insulin by infusion.
This test was used in women with advanced breast cancer as a test of 
pituitary reserve before and one month after yttrium implantation.
Of the patients who had residual pituitary hormones on stimulation 
after implantation, none of these had a clinical response. In 
contrast, those women with minimal residual hormones on stimulation 
(and therefore presumably with the nearer complete pituitary 
destruction), were more likely to have a clinical response, although 
this was not guaranteed.
This stimulation test was also used to test the effect of quadruple 
chemotherapy on pituitary function. When three groups of women 
with breast cancer were treated by either yttrium implantation 
alone, chemotherapy alone or a combination of both and tested for 
pituitary reserve before and one month after treatment, chemotherapy 
was found to have no effect on pituitary function.
The conclusion of the studies of the men with gynaecomastia
In a group of young men (under 50 years) with gynaecomastia, plasma 
LH concentrations were lower than those in controls of a similar age 
without the disease. As plasma FSH levels were similar in both 
groups, young patients with gynaecomastia exhibited a lower LH/FSH
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ratio.
Older men with gynaecomastia (over 50 years) had higher values of 
both plasma LH and FSH than controls of a similar age without the 
disease, but the LH/FSH ratio was similar in the two groups.
The pulsatile pattern of plasma LH was present only in the young 
controls, being absent in the young and old men with gynaecomastia.
The pulsatile pattern of plasma LH was also absent in the old 
control group and this group of men had higher plasma FSH levels 
than the younger control group.
Plasma oestradiol-17B levels were elevated in the older men with 
gynaecomastia, as compared with normal, age-matched controls.
Plasma testosterone levels were similar in the two older groups, ie 
old men with gynaecomastia and older controls. Thus, the 
oestradiol-17B testosterone ratio was raised in the older men with 
gynaecomastia in comparison to older controls.
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